Porphyromonas gingivalis antigen constructs
By using antigens derived from Kgp, RgpA, and/or RgpB, targeting the virulence factors of Porphyromonas gingivalis in the form of mRNA or recombinant protein, the problem of low efficacy of existing vaccines is solved, and effective inhibition of gingival protease and control of inflammation are achieved.
Patent Information
- Application Number
- CN202480047860.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2023-12-18
- Filing Date
- 2024-07-19
- Publication Date
- 2026-04-17
AI Technical Summary
Existing Porphyromonas gingivalis vaccines have reduced efficacy and are unable to effectively inhibit the protease activity and adhesion function of gingival proteases, leading to periodontitis and other inflammatory diseases.
It provides antigens derived from Kgp, RgpA, and/or RgpB, which, in the form of mRNA or recombinant protein antigens encoding the relevant antigens, elicit a strong B cell response and target key virulence factors of Porphyromonas gingivalis.
It effectively inhibits the catalytic domain activity and adhesion function of gingival proteases, reduces bacterial colonization and inflammatory response in periodontal tissues, and lowers the risk of periodontitis and other systemic diseases.
Smart Images

Figure FT_1 
Figure FT_2 
Figure FT_3
Abstract
Description
Technical Field
[0001] This invention pertains to the treatment and prevention of Porphyromonas gingivalis (P. gingivalis) infections such as periodontitis. Specifically, this invention relates to antigens and combinations of antigens that can be used for immune responses against Porphyromonas gingivalis, in the form of nucleic acids (e.g., mRNA) encoding antigen proteins or as recombinant protein antigens. Background Technology
[0002] Periodontitis is a chronic inflammatory disease of the supporting tissues of the teeth (Bostanci and Belibasakis, 2012). It affects all age groups, but is more prevalent in older adults. Its main symptoms are bleeding or swollen gums, pain, and sometimes halitosis. It is characterized by the formation of periodontal pockets, which provide support for the colonization of pathogenic bacteria and the formation of subgingival plaque. Severe periodontitis can lead to the destruction of the periodontal ligaments and alveolar bone, ultimately resulting in tooth loss (Kinane et al., 2017). It is estimated that periodontitis affects nearly 50% of the global population, making it one of the most common inflammatory diseases and a leading cause of tooth loss in adults (Mei et al., 2020). In 2022, the WHO estimated that approximately 19% of the global adult population had severe periodontitis, with over 1 billion cases worldwide (WHO Global Oral Health Status Report, 2022).
[0003] *Porphyromonas gingivalis* is a major pathogen of periodontitis (or periodontal disease). It is a Gram-negative, nonmotile anaerobic pathogen that requires vitamin K and iron in the form of heme or hemin to grow and ferments amino acids for energy (Bostanci and Belibasakis, 2012). It is a secondary colonizer in the human oral cavity, attaching to primary colonizers to form colonies and then colonizing dental plaque. *Porphyromonas gingivalis* is primarily found in the deep periodontal pockets characteristic of periodontitis and has been detected in subgingival plaque samples from 85% of patients with chronic periodontitis (How et al., 2016). It is believed to promote further colonization of pathogenic bacteria by remodeling the symbiotic bacterial community in the oral cavity, leading to an imbalance in the microbial biofilm state (or dysbiosis), thereby inducing the progression of periodontitis (Xu et al., 2020). In addition to its key role in periodontitis, Porphyromonas gingivalis is also considered a potential risk factor for the development of a variety of systemic diseases, such as atherosclerosis, cancer, Alzheimer's disease, diabetes and rheumatoid arthritis (Mei et al., 2020).
[0004] The main virulence factors of *Porphyromonas gingivalis* include lipopolysaccharide, pili, capsular proteins, gingival proteases, and outer membrane vesicles (Xu et al., 2020). Gingival proteases belong to the cysteine protease family. They account for 85% of the extracellular proteolytic activity and 99% of the "trypsin-like activity" of *Porphyromonas gingivalis*. They are usually located on the cell surface or outer membrane vesicles of *Porphyromonas gingivalis* strains, except for strain HG66, which also secretes soluble forms of gingival proteases into the extracellular environment (Li and Collyer, 2011).
[0005] Gingival proteases include arginine-specific gingival proteases (RgpA and RgpB) and lysine-specific gingival proteases (Kgp), which cleave polypeptides at the C-terminus following arginine or lysine residues, respectively. These three proteins are encoded by a single locus found in the genomes of all *Porphyromonas gingivalis* strains (Li and Collyer, 2011).
[0006] It is presumed that the primary function of gingival proteases is to digest proteins for nutrition. For example, Kgp is thought to cleave host heme proteins, providing *Porphyromonas gingivalis* with the heme it needs for growth. However, gingival proteases have recently been found to be involved in the pathogenesis of *Porphyromonas gingivalis*. Specifically, gingival proteases are thought to degrade collagen and fibrin / fibrinogen, leading to gingival tissue damage, inhibiting blood clotting, and increasing periodontal bleeding. Kgp and RgpA are also thought to mediate adhesion to host tissues and promote co-aggregation of *Porphyromonas gingivalis* with other oral pathogens and subsequent biofilm formation. Furthermore, gingival proteases have been shown to modulate the host's immune response, thereby suppressing the ability of innate and adaptive immune responses to eliminate bacteria while increasing inflammation (Aleksijevic et al., 2022).
[0007] Current treatments for periodontitis caused by *Porphyromonas gingivalis* include dental debridement (removal of plaque and tartar) via scaling and root planing, and surgery in more severe cases. Adjunctive therapies include prescription antibiotics and antimicrobial agents (Kinane et al., 2017), but these are considered less effective against *Porphyromonas gingivalis* due to its biofilm-forming ability (Aleksijevic et al., 2022). Therefore, an effective vaccine is needed to treat and / or prevent *Porphyromonas gingivalis*-associated disease. It is hypothesized that pre-immunization targeting key virulence factors of *Porphyromonas gingivalis*, such as gingival proteases, could reduce the bacteria's ability to cause periodontitis or migrate to distant tissues and trigger other inflammatory conditions (Mei et al., 2020).
[0008] One candidate vaccine against *Porphyromonas gingivalis* is based on a modified Kgp protein containing portions of the protease catalytic domain and adhesin domain (referred to as Kas2-A1—O'Brien-Simpson et al., 2011 and WO2011014947 A1). However, improved *Porphyromonas gingivalis* vaccines are still needed.
[0009] The purpose of this invention is to provide an antigen capable of eliciting a functional antibody response to inhibit the protease activity of the gingival protease catalytic domain and the hemagglutination and adhesion functions mediated by the gingival protease adhesion domain. Summary of the Invention
[0010] The inventors have discovered that, as described herein, antigens derived from Kgp, RgpA, and / or RgpB can be used for immune responses against *Porphyromonas gingivalis*. Specifically, the inventors have discovered that antigens containing portions of the Kgp, RgpA, or RgpB polypeptides derived from the *Porphyromonas gingivalis* domain elicit a strong B-cell (i.e., antibody) response when delivered by mRNA encoding the relevant antigen.
[0011] Therefore, the present invention provides *Porphyromonas gingivalis* polypeptides and nucleic acids comprising nucleotide sequences encoding such polypeptides. The polypeptide antigens described herein can be delivered via nucleic acids (e.g., mRNA) comprising nucleotide sequences encoding said polypeptides, i.e., delivered in the form of said nucleic acids.
[0012] The present invention also provides compositions comprising (i) a Kgp-based polypeptide or nucleic acid as described herein and (ii) a combination of an RgpA-based polypeptide or nucleic acid as described herein.
[0013] Gingival protease
[0014] As used herein, the term "gingival protease" refers to either *Porphyromonas gingivalis* lysine-specific protease (Kgp) or arginine-specific proteases (RgpA and RgpB). The term "gingival protease" is used to refer to Kgp, RgpA, and RgpB. The terms "Kgp-based" and "RgpA-based" are used herein to refer to polypeptides containing Kgp or RgpA elements, respectively, and the nucleic acids encoding those polypeptides. Polypeptides containing both Kgp and RgpA elements are referred to as "Kgp- and RgpA-based."
[0015] The domain structures of gingival proteases are highly conserved in *Porphyromonas gingivalis* strains. Kgp and RgpA share the same basic modular structure from the N-terminus to the C-terminus of the protein: a signal peptide, an N-terminal propeptide (which is cleaved in the mature protein), a protease catalytic domain (Cat), and a C-terminal hemagglutinin / adhesin region consisting of an unknown functional domain (DUF) (specifically DUF2436), followed by three cleaved adhesion domains, particularly the K1, K2, and K3 adhesin domains. These domains are interleaved with sequences containing adhesion-binding motifs (ABMs, referred to as ABM1, ABM2, and ABM3). In native Kgp and RgpA, the first ABM1 and first ABM2 are located on either side of DUF2436 (i.e., the first ABM1 is located at the N-terminus of DUF2436, between DUF2436 and the Cat domain, while the first ABM2 is located at the C-terminus of DUF2436). The second ABM1 is located at the C-terminus of the first ABM2, followed by ABM3. The second ABM1 and ABM3 are located at the N-terminus of the K1 adhesion domain. The K1 adhesion domain is followed by the K2 adhesion domain, then the second ABM2. Finally, the third ABM1 and the third ABM2 are located on either side of the K3 adhesion domain, and then the protein terminates with a C-terminal domain (Li and Collyer, 2011).
[0016] Figure 1 This illustrates different arrangements of the structural domains of Kgp and RgpA. As a concrete example, Figure 2A and Figure 2B The wild-type sequences of Kgp and RgpA of Porphyromonas gingivalis strain W50 are shown, with each domain highlighted and annotated according to the position of residues within the wild-type sequence.
[0017] The Cat, DUF2436, and K3 domains of Kgp and RgpA exhibit high sequence differences, while the adhesin domains K1, K2, ABM1, ABM2, and ABM3 are highly conserved between RgpA and Kgp. For example, the Cat domain of Kgp and RgpA shares approximately 27% sequence identity, while the DUF2436 domain of Kgp and RgpA shares approximately 53% sequence identity. In contrast, the K1 and K2 adhesin domains of Kgp and RgpA each share more than approximately 99% sequence identity.
[0018] RgpB contains a signal peptide, an N-terminal propeptide, a protease catalytic domain, and a short C-terminal domain. RgpB lacks the adhesin domain DUF2436, the adhesion-binding motif, and the K1-K3 domains. The Cat domain of RgpB shares approximately 90% sequence identity with the Cat domain of RgpA, but only 20%-30% with the Cat domain of Kgp (Li and Collyer, 2011).
[0019] In a first aspect, the present invention provides a nucleic acid comprising a nucleotide sequence encoding a polypeptide, wherein the polypeptide comprises:
[0020] i) At least a portion of the catalytic domain of the Lys-specific protease (Kgp) of Porphyromonas gingivalis;
[0021] ii) At least a portion of the unknown functional domain 2436 (DUF2436) of Porphyromonas gingivalis Kgp;
[0022] iii) At least a portion of the Kgp K1 adhesin domain of Porphyromonas gingivalis;
[0023] iv) The Kgp portion of *Porphyromonas gingivalis* containing adhesin-binding motif 1 (ABM1) and the Kgp portion of *Porphyromonas gingivalis* containing adhesin-binding motif 2 (ABM2);
[0024] v) Containing the Kgp portion of *Porphyromonas second gingivalis* containing ABM1 and the Kgp portion of *Porphyromonas second gingivalis* containing ABM2; and
[0025] vi) The Kgp portion of Porphyromonas gingivalis containing ABM3.
[0026] In a second aspect, the present invention provides a nucleic acid comprising a nucleotide sequence encoding a polypeptide, wherein the polypeptide comprises:
[0027] i) At least a portion of the Arg-specific protease A (RgpA) catalytic domain or the Arg-specific protease B (RgpB) catalytic domain of Porphyromonas gingivalis;
[0028] ii) At least a portion of Porphyromonas gingivalis RgpA DUF2436;
[0029] iii) At least a portion of the adhesin domain of Porphyromonas gingivalis RgpA K1;
[0030] iv) Contains the RgpA portion of *Porphyromonas gingivalis* containing ABM1 and the RgpA portion of *Porphyromonas gingivalis* containing ABM2;
[0031] v) Containing the RgpA portion of *Porphyromonas second gingivalis* containing ABM1 and the RgpA portion of *Porphyromonas second gingivalis* containing ABM2; and
[0032] vi) The RgpA portion of Porphyromonas gingivalis containing ABM3.
[0033] In a third aspect, the present invention provides a polypeptide comprising:
[0034] i) At least a portion of the catalytic domain of the Lys-specific protease (Kgp) of Porphyromonas gingivalis;
[0035] ii) At least a portion of the unknown functional domain 2436 (DUF2436) of Porphyromonas gingivalis Kgp;
[0036] iii) At least a portion of the Kgp K1 adhesin domain of Porphyromonas gingivalis;
[0037] iv) The Kgp portion of *Porphyromonas gingivalis* containing adhesin-binding motif 1 (ABM1) and the Kgp portion of *Porphyromonas gingivalis* containing adhesin-binding motif 2 (ABM2);
[0038] v) Containing the Kgp portion of *Porphyromonas second gingivalis* containing ABM1 and the Kgp portion of *Porphyromonas second gingivalis* containing ABM2; and
[0039] vi) The Kgp portion of Porphyromonas gingivalis containing ABM3.
[0040] In a fourth aspect, the present invention provides a polypeptide comprising:
[0041] i) At least a portion of the Arg-specific protease A (RgpA) catalytic domain or the Arg-specific protease B (RgpB) catalytic domain of Porphyromonas gingivalis;
[0042] ii) At least a portion of Porphyromonas gingivalis RgpA DUF2436;
[0043] iii) At least a portion of the adhesin domain of Porphyromonas gingivalis RgpA K1;
[0044] iv) Contains the RgpA portion of *Porphyromonas gingivalis* containing ABM1 and the RgpA portion of *Porphyromonas gingivalis* containing ABM2;
[0045] v) Containing the RgpA portion of *Porphyromonas second gingivalis* containing ABM1 and the RgpA portion of *Porphyromonas second gingivalis* containing ABM2; and
[0046] vi) The RgpA portion of Porphyromonas gingivalis containing ABM3.
[0047] In another aspect, the present invention provides a composition comprising any of the nucleic acids of the present invention, preferably wherein the composition is an immunogenic composition.
[0048] In another aspect, the present invention provides a composition comprising the first and second nucleic acids of the present invention, preferably wherein the composition is an immunogenic composition.
[0049] In another aspect, the present invention provides a composition comprising any of the polypeptides of the present invention, preferably wherein the composition is an immunogenic composition.
[0050] In another aspect, the present invention provides a composition comprising the first polypeptide and the second polypeptide of the present invention, preferably wherein the composition is an immunogenic composition.
[0051] In another aspect, the present invention provides a vaccine comprising any one of the nucleic acids, any one of the polypeptides, or any one of the compositions of the present invention.
[0052] The modular nature of gingival proteases means that the nucleic acids and peptides of the present invention can be combined with domains derived from different gingival proteases. Therefore, the nucleic acids and peptides of the present invention can include, for example, any catalytic domain and any DUF2436 domain described herein. As another example, any portion of a gingival protease containing ABM1, as described herein, can be combined with any DUF2436 domain described herein.
[0053] Porphyromonas gingivalis strain
[0054] The nucleic acids and peptides of this invention can be derived from any *Porphyromonas gingivalis* strain. The modular structure of the gingival protease means that one domain of the nucleic acid or peptide can be derived from one *Porphyromonas gingivalis* strain, while another domain can be derived from a different *Porphyromonas gingivalis* strain. In another embodiment, all domains of the nucleic acid or peptide are derived from the same *Porphyromonas gingivalis* strain.
[0055] Table 1 shows examples of *Porphyromonas gingivalis* strains and their corresponding GenBank sequences. For example, by comparing the sequences with the corresponding domains or portions of Kgp or RgpA in *Porphyromonas gingivalis* strain W50 disclosed herein and shown in Figure 2, those skilled in the art can identify different domains of Kgp, RgpA, or RgpB in *Porphyromonas gingivalis* strains, or Kgp, RgpA, or RgpB portions containing, for example, ABM. An example of the wild-type Kgp sequence of *Porphyromonas gingivalis* strain W50 is provided in SEQ ID NO: 157, and the corresponding nucleic acid encoding this sequence is provided in SEQ ID NO: 160. An example of the wild-type RgpA sequence of *Porphyromonas gingivalis* strain W50 is provided in SEQ ID NO: 158, and the corresponding nucleic acid encoding this sequence is provided in SEQ ID NO: 161. An example of the wild-type RgpB sequence of Porphyromonas gingivalis strain W50 is provided in SEQ ID NO:159, and the corresponding nucleic acid encoding the sequence is provided in SEQ ID NO:162.
[0056] Table 1: Examples of *Porphyromonas gingivalis* strains
[0057]
[0058] The nucleic acids and polypeptides of the present invention may be derived from *Porphyromonas gingivalis* and contain several domains that may correspond to domains in naturally occurring Kgp, RgpA, or RgpB sequences. However, the nucleic acids do not encode polypeptides as naturally occurring full-length Kgp, RgpA, or RgpB polypeptides (or mature polypeptides). Similarly, the polypeptides of the present invention are not naturally occurring full-length Kgp, RgpA, or RgpB polypeptides (or mature polypeptides).
[0059] In other words, the nucleic acid of the present invention can encode a polypeptide modified relative to a naturally occurring full-length Kgp, RgpA, or RgpB polypeptide. Similarly, the polypeptide of the present invention is modified relative to a naturally occurring full-length Kgp, RgpA, or RgpB polypeptide. The modified polypeptide can be a variant of a naturally occurring polypeptide having an altered amino acid sequence due to, for example, amino acid substitution, deletion, or insertion. The modified polypeptide can be a truncated or fragmented naturally occurring polypeptide.
[0060] In any of the embodiments disclosed herein, the polypeptide may be a polypeptide modified according to the invention as described elsewhere herein. In any of the embodiments disclosed herein, the nucleic acid may encode a polypeptide modified according to the invention as described elsewhere herein.
[0061] The polypeptides of the present invention can also be in the form of recombinant polypeptides. Therefore, in any of the embodiments described herein, the polypeptide is a recombinant polypeptide.
[0062] Adhesin-binding motif (ABM)
[0063] Adhesin-binding motifs (ABMs) are sequences found in natural gingival proteases, and these sequences are presumed to contribute to the adhesive function of gingival proteases. Three distinct gingival proteases ABMs have been described: ABM1, ABM2, and ABM3 (Li and Collyer, 2011). ABM1 was first described based on the identification of conserved sequences (Slakeski et al., 1998). ABM2 and ABM3 were described based on sequences bound by certain antibodies (O'Brien-simpson et al., 2005).
[0064] The nucleic acids and polypeptides of the present invention comprise: a first Kgp or RgpA portion comprising ABM1, a first Kgp or RgpA portion comprising ABM2, a second Kgp or RgpA portion comprising ABM1, and a second Kgp or RgpA portion comprising ABM2.
[0065] The ABM1-containing portion of gingival protease
[0066] In some embodiments, the first Kgp portion containing ABM1 is derived from *Porphyromonas gingivalis* strain W50. In *Porphyromonas gingivalis* strain W50, the first Kgp portion containing ABM1 has the sequence SEQ ID NO: 106. Therefore, in some embodiments, the first Kgp portion containing ABM1 contains the sequence SEQ ID NO: 106 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it.
[0067] In some embodiments, the first RgpA portion containing ABM1 is derived from *Porphyromonas gingivalis* strain W50. In *Porphyromonas gingivalis* strain W50, the first RgpA portion containing ABM1 has the sequence SEQ ID NO: 114. Therefore, in some embodiments, the first RgpA portion containing ABM1 contains the sequence SEQ ID NO: 114 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it.
[0068] In some embodiments, the second Kgp portion containing ABM1 is derived from *Porphyromonas gingivalis* strain W50. In *Porphyromonas gingivalis* strain W50, the second Kgp portion containing ABM1 has the sequence of SEQ ID NO: 110. Therefore, in some embodiments, the second Kgp portion containing ABM1 contains the sequence of SEQ ID NO: 110 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it.
[0069] In some embodiments, the second RgpA portion containing ABM1 is derived from *Porphyromonas gingivalis* strain W50. In *Porphyromonas gingivalis* strain W50, the second RgpA portion containing ABM1 has the sequence SEQ ID NO: 102. Therefore, in some embodiments, the second RgpA portion containing ABM1 contains the sequence SEQ ID NO: 102 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it.
[0070] Table 2 provides examples of partial sequences of gingival proteases (e.g., Kgp or RgpA) containing the ABM1 sequence, as well as the common sequence of ABM1. The common sequence of ABM1 is SEQ ID NO: 120.
[0071] Table 2: Partial Kgp and RgpA sequences containing ABM1. The common sequences of ABM1 in each sequence are underlined.
[0072]
[0073] In some embodiments, the first Kgp portion containing ABM1 contains a sequence of SEQ ID NO: 120 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it.
[0074] In some embodiments, the first Kgp portion containing ABM1 contains a sequence of SEQ ID NO: 106 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it.
[0075] In some embodiments, the first Kgp portion containing ABM1 contains a sequence of SEQ ID NO: 107 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it.
[0076] In some embodiments, the first Kgp portion containing ABM1 contains a sequence of SEQ ID NO: 89 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it.
[0077] In some embodiments, the first Kgp portion containing ABM1 contains a sequence of SEQ ID NO: 108 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it.
[0078] In some embodiments, the first Kgp portion containing ABM1 contains a sequence of SEQ ID NO: 109 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it.
[0079] In some embodiments, the first Kgp portion containing ABM1 comprises a sequence from a Kgp that binds to a Cat domain at the N-terminus and to DUF2436 at the C-terminus, or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with a Kgp that binds to a Cat domain at the N-terminus and to DUF2436 at the C-terminus.
[0080] In some embodiments, the second Kgp portion containing ABM1 contains a sequence of SEQ ID NO: 120 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it.
[0081] In some embodiments, the second Kgp portion containing ABM1 contains a sequence of SEQ ID NO: 110 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it.
[0082] In some embodiments, the second Kgp portion containing ABM1 contains a sequence of SEQ ID NO: 111 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it.
[0083] In some embodiments, the second Kgp portion containing ABM1 contains a sequence of SEQ ID NO: 92 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it.
[0084] In some embodiments, the second Kgp portion containing ABM1 contains a sequence of SEQ ID NO: 112 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it.
[0085] In some embodiments, the second Kgp portion containing ABM1 contains a sequence of SEQ ID NO: 113 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it.
[0086] In some embodiments, the second Kgp portion containing ABM1 includes a sequence from a Kgp that binds to the ABM2 sequence at the N-terminus and the ABM3 sequence at the C-terminus, or a sequence that has at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with a Kgp that binds to the ABM2 sequence at the N-terminus and the ABM3 sequence at the C-terminus.
[0087] In some embodiments, the first RgpA portion containing ABM1 contains a sequence of SEQ ID NO: 120 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it.
[0088] In some embodiments, the first RgpA portion containing ABM1 contains a sequence of SEQ ID NO: 114 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it.
[0089] In some embodiments, the first RgpA portion containing ABM1 contains a sequence of SEQ ID NO: 99 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it.
[0090] In some embodiments, the first RgpA portion containing ABM1 contains a sequence of SEQ ID NO: 115 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it.
[0091] In some embodiments, the first RgpA portion containing ABM1 contains a sequence of SEQ ID NO: 116 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it.
[0092] In some embodiments, the first RgpA portion including ABM1 includes a sequence from an RgpA that binds to a Cat domain at the N-terminus and to DUF2436 at the C-terminus, or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with an RgpA that binds to a Cat domain at the N-terminus and to DUF2436 at the C-terminus.
[0093] In some embodiments, the second RgpA portion containing ABM1 contains a sequence of SEQ ID NO: 120 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it.
[0094] In some embodiments, the second RgpA portion containing ABM1 contains a sequence of SEQ ID NO: 102 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it.
[0095] In some embodiments, the second RgpA portion containing ABM1 contains a sequence of SEQ ID NO: 117 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it.
[0096] In some embodiments, the second RgpA portion containing ABM1 contains a sequence of SEQ ID NO: 118 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it.
[0097] In some embodiments, the second RgpA portion containing ABM1 contains a sequence of SEQ ID NO: 119 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it.
[0098] In some embodiments, the second RgpA portion containing ABM1 includes a sequence from an RgpA that binds to the ABM2 sequence at the N-terminus and to the ABM3 sequence at the C-terminus, or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with the RgpA that binds to the ABM2 sequence at the N-terminus and to the ABM3 sequence at the C-terminus.
[0099] In the wild-type Kgp sequence from *Porphyromonas gingivalis* strain W50, the first Kgp portion containing ABM1 is located between the Cat domain and DUF2436, and is 35 amino acids in length, and contains the sequence of SEQ ID NO: 106. This sequence contains ABM1 of SEQ ID NO: 120. Therefore, in some embodiments, the length of the first Kgp portion containing ABM1 is between 10 and 35 amino acids, and contains the sequence of SEQ ID NO: 120.
[0100] In some embodiments, the length of the first Kgp portion comprising ABM1 is between 15 and 30 amino acids, and includes the sequence of SEQ ID NO: 120. In some embodiments, the length of the first Kgp portion comprising ABM1 is between 20 and 25 amino acids, and includes the sequence of SEQ ID NO: 120.
[0101] In some embodiments, the first Kgp portion containing ABM1 is 10 amino acids long and contains the sequence of SEQ ID NO: 120. In some embodiments, the first Kgp portion containing ABM1 is 15 amino acids long and contains the sequence of SEQ ID NO: 120. In some embodiments, the first Kgp portion containing ABM1 is 20 amino acids long and contains the sequence of SEQ ID NO: 120. In some embodiments, the first Kgp portion containing ABM1 is 25 amino acids long and contains the sequence of SEQ ID NO: 120. In some embodiments, the first Kgp portion containing ABM1 is 30 amino acids long and contains the sequence of SEQ ID NO: 120. In some embodiments, the first Kgp portion containing ABM1 is 35 amino acids long and contains the sequence of SEQ ID NO: 120.
[0102] In some embodiments, the length of the first Kgp portion comprising ABM1 is 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34 or 35 amino acids, and comprises the sequence of SEQ ID NO: 120.
[0103] In the wild-type Kgp sequence from *Porphyromonas gingivalis* strain W50, the second Kgp moiety containing ABM1 is located between the DUF and K1 adhesin domains. The ABM2 sequence is located at the N-terminus of the second moiety containing ABM1, while the ABM3 sequence is located at the C-terminus of the second moiety containing ABM1. In this context, the second Kgp moiety containing ABM1 is 26 amino acids long and contains the sequence of SEQ ID NO: 110. This sequence contains ABM1 of SEQ ID NO: 120. Therefore, in some embodiments, the second Kgp moiety containing ABM1 is between 10 and 26 amino acids long and contains the sequence of SEQ ID NO: 120.
[0104] In some embodiments, the second Kgp portion comprising ABM1 is between 10 and 25 amino acids in length and contains the sequence of SEQ ID NO: 120. In some embodiments, the second Kgp portion comprising ABM1 is between 15 and 20 amino acids in length and contains the sequence of SEQ ID NO: 120.
[0105] In some embodiments, the second Kgp portion containing ABM1 is 10 amino acids long and contains the sequence of SEQ ID NO: 120. In some embodiments, the second Kgp portion containing ABM1 is 15 amino acids long and contains the sequence of SEQ ID NO: 120. In some embodiments, the second Kgp portion containing ABM1 is 20 amino acids long and contains the sequence of SEQ ID NO: 120. In some embodiments, the second Kgp portion containing ABM1 is 25 amino acids long and contains the sequence of SEQ ID NO: 120. In some embodiments, the second Kgp portion containing ABM1 is 26 amino acids long and contains the sequence of SEQ ID NO: 120.
[0106] In some embodiments, the second Kgp portion comprising ABM1 has a length of 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, or 26 amino acids and contains the sequence of SEQ ID NO: 120.
[0107] In the wild-type RgpA sequence from *Porphyromonas gingivalis* strain W50, the first RgpA portion containing ABM1 is located between the Cat domain and the DUF domain, and is 32 amino acids in length, and contains the sequence of SEQ ID NO: 114. This sequence contains ABM1 of SEQ ID NO: 120. Therefore, in some embodiments, the length of the first RgpA portion containing ABM1 is between 10 and 32 amino acids, and contains the sequence of SEQ ID NO: 120.
[0108] In some embodiments, the length of the first RgpA portion comprising ABM1 is between 15 and 30 amino acids, and includes the sequence of SEQ ID NO: 120. In some embodiments, the length of the first RgpA portion comprising ABM1 is between 20 and 25 amino acids, and includes the sequence of SEQ ID NO: 120.
[0109] In some embodiments, the first RgpA portion comprising ABM1 is 10 amino acids long and contains the sequence of SEQ ID NO: 120. In some embodiments, the first RgpA portion comprising ABM1 is 15 amino acids long and contains the sequence of SEQ ID NO: 120. In some embodiments, the first RgpA portion comprising ABM1 is 20 amino acids long and contains the sequence of SEQ ID NO: 120. In some embodiments, the first RgpA portion comprising ABM1 is 25 amino acids long and contains the sequence of SEQ ID NO: 120. In some embodiments, the first RgpA portion comprising ABM1 is 30 amino acids long and contains the sequence of SEQ ID NO: 120. In some embodiments, the first RgpA portion comprising ABM1 is 32 amino acids long and contains the sequence of SEQ ID NO: 120.
[0110] In some embodiments, the length of the first RgpA portion comprising ABM1 is 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, or 32 amino acids, and comprises SEQ ID NO: 120.
[0111] In the wild-type RgpA sequence from *Porphyromonas gingivalis* strain W50, the second RgpA moiety containing ABM1 is located between the DUF and K1 adhesin domains. The ABM2 sequence is located at the N-terminus of the second moiety containing ABM1, while the ABM3 sequence is located at the C-terminus of the second moiety containing ABM1. In this context, the second RgpA moiety containing ABM1 is 27 amino acids long and contains the sequence of SEQ ID NO: 119. This sequence contains ABM1 of SEQ ID NO: 120. Therefore, in some embodiments, the second RgpA moiety containing ABM1 is between 10 and 27 amino acids long and contains the sequence of SEQ ID NO: 120.
[0112] In some embodiments, the second RgpA portion comprising ABM1 is between 10 and 25 amino acids in length and contains the sequence of SEQ ID NO: 120. In some embodiments, the second RgpA portion comprising ABM1 is between 15 and 20 amino acids in length and contains the sequence of SEQ ID NO: 120.
[0113] In some embodiments, the second RgpA portion containing ABM1 is 10 amino acids long and contains the sequence of SEQ ID NO: 120. In some embodiments, the second RgpA portion containing ABM1 is 15 amino acids long and contains the sequence of SEQ ID NO: 120. In some embodiments, the second RgpA portion containing ABM1 is 20 amino acids long and contains the sequence of SEQ ID NO: 120. In some embodiments, the second RgpA portion containing ABM1 is 25 amino acids long and contains the sequence of SEQ ID NO: 120. In some embodiments, the second RgpA portion containing ABM1 is 27 amino acids long and contains the sequence of SEQ ID NO: 120.
[0114] In some embodiments, the second RgpA portion comprising ABM1 has a length of 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, or 27 amino acids and comprises the sequence of SEQ ID NO: 120.
[0115] The ABM2-containing portion of gingival protease
[0116] In some embodiments, the first Kgp portion containing ABM2 is derived from *Porphyromonas gingivalis* strain W50. In *Porphyromonas gingivalis* strain W50, the first Kgp portion containing ABM2 has the sequence SEQ ID NO: 121. Therefore, in some embodiments, the first Kgp portion containing ABM2 contains the sequence SEQ ID NO: 121 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it.
[0117] In some embodiments, the first RgpA portion comprising ABM2 is derived from *Porphyromonas gingivalis* strain W50. In *Porphyromonas gingivalis* strain W50, the first RgpA portion comprising ABM2 has the sequence SEQ ID NO: 101. Therefore, in some embodiments, the first RgpA portion comprising ABM2 comprises the sequence SEQ ID NO: 101 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it.
[0118] In some embodiments, the second Kgp portion containing ABM2 is derived from *Porphyromonas gingivalis* strain W50. In *Porphyromonas gingivalis* strain W50, the second Kgp portion containing ABM2 has the sequence SEQ ID NO: 124. Therefore, in some embodiments, the second Kgp portion containing ABM2 contains the sequence SEQ ID NO: 124 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it.
[0119] In some embodiments, the second RgpA portion comprising ABM2 is derived from *Porphyromonas gingivalis* strain W50. In *Porphyromonas gingivalis* strain W50, the second RgpA portion comprising ABM2 has the sequence SEQ ID NO: 126. Therefore, in some embodiments, the second RgpA portion comprising ABM21 comprises the sequence SEQ ID NO: 126 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it.
[0120] Table 3 provides examples of partial sequences of gingival proteases (e.g., Kgp or RgpA) containing the ABM2 sequence, as well as the common sequence of ABM2. The common sequence of ABM2 is SEQ ID NO: 130.
[0121] Table 3: Partial Kgp and RgpA sequences containing ABM2. The common sequences of ABM2 in each sequence are underlined.
[0122]
[0123] In some embodiments, the first Kgp portion containing ABM2 contains a sequence of SEQ ID NO: 130 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it.
[0124] In some embodiments, the first Kgp portion containing ABM2 contains a sequence of SEQ ID NO: 121 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it.
[0125] In some embodiments, the first Kgp portion containing ABM2 contains a sequence of SEQ ID NO: 122 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it.
[0126] In some embodiments, the first Kgp portion containing ABM2 contains a sequence of SEQ ID NO: 91 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it.
[0127] In some embodiments, the first Kgp portion containing ABM2 contains a sequence of SEQ ID NO: 123 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it.
[0128] In some embodiments, the first Kgp portion containing ABM2 includes a sequence from a Kgp that binds to DUF2436 at the N-terminus and to the ABM1 sequence at the C-terminus, or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with a Kgp that binds to DUF2436 at the N-terminus and to the ABM1 sequence at the C-terminus.
[0129] In some embodiments, the second Kgp portion containing ABM2 contains a sequence of SEQ ID NO: 130 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it.
[0130] In some embodiments, the second Kgp portion containing ABM2 contains a sequence of SEQ ID NO: 124 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it.
[0131] In some embodiments, the second Kgp portion containing ABM2 contains a sequence of SEQ ID NO: 125 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it.
[0132] In some embodiments, the second Kgp portion containing ABM2 contains a sequence of SEQ ID NO: 95 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it.
[0133] In some embodiments, the second Kgp portion containing ABM2 includes a sequence from a Kgp that binds to the Kgp K2 adhesin domain at the N-terminus and to the ABM1 sequence at the C-terminus, or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with a Kgp that binds to the Kgp K2 adhesin domain at the N-terminus and to the ABM1 sequence at the C-terminus.
[0134] In some embodiments, the first RgpA portion containing ABM2 contains a sequence of SEQ ID NO: 130 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it.
[0135] In some embodiments, the first RgpA portion containing ABM2 contains a sequence of SEQ ID NO: 101 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it.
[0136] In some embodiments, the first RgpA portion containing ABM2 includes a sequence from an RgpA that binds to DUF2436 at the N-terminus and to the ABM1 sequence at the C-terminus, or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with an RgpA that binds to DUF2436 at the N-terminus and to the ABM1 sequence at the C-terminus.
[0137] In some embodiments, the second RgpA portion containing ABM2 contains a sequence of SEQ ID NO: 130 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it.
[0138] In some embodiments, the second RgpA portion containing ABM2 contains a sequence of SEQ ID NO: 105 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it.
[0139] In some embodiments, the second RgpA portion containing ABM2 contains a sequence of SEQ ID NO: 126 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it.
[0140] In some embodiments, the second RgpA portion containing ABM2 contains a sequence of SEQ ID NO: 127 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it.
[0141] In some embodiments, the second RgpA portion containing ABM2 contains a sequence of SEQ ID NO: 128 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it.
[0142] In some embodiments, the second RgpA portion containing ABM2 contains a sequence of SEQ ID NO: 129 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it.
[0143] In some embodiments, the second RgpA portion containing ABM2 comprises a sequence from an RgpA that binds to the RgpA K2 adhesin domain at the N-terminus and to the ABM1 sequence at the C-terminus, or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with the RgpA that binds to the RgpA K2 adhesin domain at the N-terminus and to the ABM1 sequence at the C-terminus.
[0144] In the wild-type Kgp sequence from *Porphyromonas gingivalis* strain W50, the first Kgp portion containing ABM2 is located between DUF2436 and the K1 adhesin domain. DUF2436 is located at the N-terminus of the first portion containing ABM2. The ABM1 and ABM3 sequences are located at the C-terminus of the first portion containing ABM2. In this context, the first Kgp portion containing ABM2 is 65 amino acids long and contains the sequence of SEQ ID NO: 91. This sequence contains ABM2 of SEQ ID NO: 130. Therefore, in some embodiments, the first Kgp portion containing ABM2 is between 14 and 65 amino acids long and contains the sequence of SEQ ID NO: 130.
[0145] In some embodiments, the length of the first Kgp portion containing ABM2 is between 20 and 60 amino acids, and it contains the sequence of SEQ ID NO: 130. In some embodiments, the length of the first Kgp portion containing ABM2 is between 25 and 55 amino acids, and it contains the sequence of SEQ ID NO: 130. In some embodiments, the length of the first Kgp portion containing ABM2 is between 30 and 50 amino acids, and it contains the sequence of SEQ ID NO: 130. In some embodiments, the length of the first Kgp portion containing ABM2 is between 35 and 45 amino acids, and it contains the sequence of SEQ ID NO: 130. In some embodiments, the length of the first Kgp portion containing ABM2 is between 35 and 40 amino acids, and it contains the sequence of SEQ ID NO: 130.
[0146] In some embodiments, the first Kgp portion containing ABM2 is 14 amino acids long and contains the sequence of SEQ ID NO: 130. In some embodiments, the first Kgp portion containing ABM2 is 20 amino acids long and contains the sequence of SEQ ID NO: 130. In some embodiments, the first Kgp portion containing ABM2 is 25 amino acids long and contains the sequence of SEQ ID NO: 130. In some embodiments, the first Kgp portion containing ABM2 is 30 amino acids long and contains the sequence of SEQ ID NO: 130. In some embodiments, the first Kgp portion containing ABM2 is 35 amino acids long and contains the sequence of SEQ ID NO: 130. In some embodiments, the first Kgp portion containing ABM2 is 40 amino acids long and contains the sequence of SEQ ID NO: 130. In some embodiments, the first Kgp portion containing ABM2 is 45 amino acids long and contains the sequence of SEQ ID NO: 130. In some embodiments, the first Kgp portion comprising ABM2 is 50 amino acids long and contains the sequence of SEQ ID NO: 130. In some embodiments, the first Kgp portion comprising ABM2 is 55 amino acids long and contains the sequence of SEQ ID NO: 130. In some embodiments, the first Kgp portion comprising ABM2 is 60 amino acids long and contains the sequence of SEQ ID NO: 130. In some embodiments, the first Kgp portion comprising ABM2 is 65 amino acids long and contains the sequence of SEQ ID NO: 130.
[0147] In some embodiments, the length of the first Kgp portion comprising ABM2 is 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, or 65 amino acids, and comprises the sequence of SEQ ID NO: 130.
[0148] In the wild-type Kgp sequence from *Porphyromonas gingivalis* strain W50, the second Kgp moiety containing ABM2 is located between the K2 and K3 adhesin domains. The second Kgp moiety containing ABM2 is 56 amino acids long and contains the sequence of SEQ ID NO: 124. This sequence contains ABM2 of SEQ ID NO: 130. Therefore, in some embodiments, the second Kgp moiety containing ABM2 is between 14 and 56 amino acids long and contains the sequence of SEQ ID NO: 130.
[0149] In some embodiments, the second Kgp portion containing ABM2 is between 20 and 50 amino acids in length and contains the sequence of SEQ ID NO: 130. In some embodiments, the second Kgp portion containing ABM2 is between 25 and 45 amino acids in length and contains the sequence of SEQ ID NO: 130. In some embodiments, the second Kgp portion containing ABM2 is between 30 and 40 amino acids in length and contains the sequence of SEQ ID NO: 130. In some embodiments, the second Kgp portion containing ABM2 is between 35 and 40 amino acids in length and contains the sequence of SEQ ID NO: 130.
[0150] In some embodiments, the second Kgp portion containing ABM2 is 14 amino acids long and contains the sequence of SEQ ID NO: 130. In some embodiments, the second Kgp portion containing ABM2 is 20 amino acids long and contains the sequence of SEQ ID NO: 130. In some embodiments, the second Kgp portion containing ABM2 is 25 amino acids long and contains the sequence of SEQ ID NO: 130. In some embodiments, the second Kgp portion containing ABM2 is 30 amino acids long and contains the sequence of SEQ ID NO: 130. In some embodiments, the second Kgp portion containing ABM2 is 35 amino acids long and contains the sequence of SEQ ID NO: 130. In some embodiments, the second Kgp portion containing ABM2 is 40 amino acids long and contains the sequence of SEQ ID NO: 130. In some embodiments, the second Kgp portion containing ABM2 is 45 amino acids long and contains the sequence of SEQ ID NO: 130. In some embodiments, the second Kgp portion comprising ABM2 is 50 amino acids long and contains the sequence of SEQ ID NO: 130. In some embodiments, the second Kgp portion comprising ABM2 is 56 amino acids long and contains the sequence of SEQ ID NO: 130.
[0151] In some embodiments, the second Kgp portion comprising ABM2 has a length of 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, or 56 amino acids and comprises the sequence of SEQ ID NO: 130.
[0152] In the wild-type RgpA sequence from *Porphyromonas gingivalis* strain W50, the first RgpA moiety containing ABM2 is located between DUF2436 and the K1 adhesin domain. DUF2436 is located at the N-terminus of the first moiety containing ABM2. The ABM1 and ABM3 sequences are located at the C-terminus of the first moiety containing ABM2. In this context, the first RgpA moiety containing ABM2 is 65 amino acids long and contains the sequence of SEQ ID NO: 101. This sequence contains ABM2 of SEQ ID NO: 130. Therefore, in some embodiments, the first RgpA moiety containing ABM2 is between 14 and 65 amino acids long and contains the sequence of SEQ ID NO: 130.
[0153] In some embodiments, the length of the first RgpA portion comprising ABM2 is between 20 and 60 amino acids, and it includes the sequence of SEQ ID NO: 130. In some embodiments, the length of the first RgpA portion comprising ABM2 is between 25 and 55 amino acids, and it includes the sequence of SEQ ID NO: 130. In some embodiments, the length of the first RgpA portion comprising ABM2 is between 30 and 50 amino acids, and it includes the sequence of SEQ ID NO: 130. In some embodiments, the length of the first RgpA portion comprising ABM2 is between 35 and 45 amino acids, and it includes the sequence of SEQ ID NO: 130. In some embodiments, the length of the first RgpA portion comprising ABM2 is between 35 and 40 amino acids, and it includes the sequence of SEQ ID NO: 130.
[0154] In some embodiments, the first RgpA portion comprising ABM2 is 14 amino acids long and contains the sequence of SEQ ID NO: 130. In some embodiments, the first RgpA portion comprising ABM2 is 20 amino acids long and contains the sequence of SEQ ID NO: 130. In some embodiments, the first RgpA portion comprising ABM2 is 25 amino acids long and contains the sequence of SEQ ID NO: 130. In some embodiments, the first RgpA portion comprising ABM2 is 30 amino acids long and contains the sequence of SEQ ID NO: 130. In some embodiments, the first RgpA portion comprising ABM2 is 35 amino acids long and contains the sequence of SEQ ID NO: 130. In some embodiments, the first RgpA portion comprising ABM2 is 40 amino acids long and contains the sequence of SEQ ID NO: 130. In some embodiments, the first RgpA portion comprising ABM2 is 45 amino acids long and contains the sequence of SEQ ID NO: 130. In some embodiments, the first RgpA portion comprising ABM2 is 50 amino acids long and contains the sequence of SEQ ID NO: 130. In some embodiments, the first RgpA portion comprising ABM2 is 55 amino acids long and contains the sequence of SEQ ID NO: 130. In some embodiments, the first RgpA portion comprising ABM2 is 60 amino acids long and contains the sequence of SEQ ID NO: 130. In some embodiments, the first RgpA portion comprising ABM2 is 65 amino acids long and contains the sequence of SEQ ID NO: 130.
[0155] In some embodiments, the length of the first RgpA portion comprising ABM2 is 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, or 65 amino acids, and comprises the sequence of SEQ ID NO: 130.
[0156] In the wild-type RgpA sequence from *Porphyromonas gingivalis* strain W50, the second RgpA moiety containing ABM2 is located between the K2 and K3 adhesin domains. The second RgpA moiety containing ABM2 is 56 amino acids long and contains the sequence of SEQ ID NO: 126. This sequence contains ABM2 of SEQ ID NO: 130. Therefore, in some embodiments, the length of the second RgpA moiety containing ABM2 is between 14 and 56 amino acids, and it contains the sequence of SEQ ID NO: 130.
[0157] In some embodiments, the second RgpA portion comprising ABM2 is between 20 and 50 amino acids in length and contains the sequence of SEQ ID NO: 130. In some embodiments, the second RgpA portion comprising ABM2 is between 25 and 45 amino acids in length and contains the sequence of SEQ ID NO: 130. In some embodiments, the second RgpA portion comprising ABM2 is between 30 and 40 amino acids in length and contains the sequence of SEQ ID NO: 130. In some embodiments, the second RgpA portion comprising ABM2 is between 35 and 40 amino acids in length and contains the sequence of SEQ ID NO: 130.
[0158] In some embodiments, the second RgpA portion containing ABM2 is 14 amino acids long and contains the sequence of SEQ ID NO: 130. In some embodiments, the second RgpA portion containing ABM2 is 20 amino acids long and contains the sequence of SEQ ID NO: 130. In some embodiments, the second RgpA portion containing ABM2 is 25 amino acids long and contains the sequence of SEQ ID NO: 130. In some embodiments, the second RgpA portion containing ABM2 is 30 amino acids long and contains the sequence of SEQ ID NO: 130. In some embodiments, the second RgpA portion containing ABM2 is 35 amino acids long and contains the sequence of SEQ ID NO: 130. In some embodiments, the second RgpA portion containing ABM2 is 40 amino acids long and contains the sequence of SEQ ID NO: 130. In some embodiments, the second RgpA portion containing ABM2 is 45 amino acids long and contains the sequence of SEQ ID NO: 130. In some embodiments, the second RgpA portion comprising ABM2 is 50 amino acids long and contains the sequence of SEQ ID NO: 130. In some embodiments, the second RgpA portion comprising ABM2 is 56 amino acids long and contains the sequence of SEQ ID NO: 130.
[0159] In some embodiments, the second RgpA portion comprising ABM2 has a length of 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, or 56 amino acids and comprises the sequence of SEQ ID NO: 130.
[0160] Sequences containing ABM1 and ABM2 pairs
[0161] The first Kgp moiety containing ABM1 is located at the N-terminus of DUF2436, while the first Kgp moiety containing ABM2 is located at the C-terminus of DUF2436. The simulated three-dimensional structure of amino acids 229-1732 from the native Kgp of *Porphyromonas gingivalis* strain W50 of Alphafold2 was obtained. Figure 3 As shown (illustrated), the first Kgp portion containing ABM1 and the first Kgp portion containing ABM2 can associate to form a first type III fibronectin-like domain. The type III fibronectin-like domain is a β-sandwich structure consisting of a first β-sheet containing three chains and a second β-sheet containing four chains. The first Kgp portion containing ABM1 forms the N-terminal portion of the first type III fibronectin-like domain and contributes two chains to the three-chain β-sheet. The first Kgp portion containing ABM2 forms the C-terminal portion of the first type III fibronectin-like domain and contributes one chain to the three-chain β-sheet and four chains to the second β-sheet. This type III fibronectin-like domain contains both ABM1 and ABM2 motifs and can play a role in mediating the adhesion function of gingival proteases. Indeed, gingival proteases are known to interact with fibronectin (Li and Collyer, 2011), and the type III fibronectin domain is known to mediate interactions with fibronectin. Furthermore, type III fibronectin-like domains have been found in other bacterial species and are presumed to have similar functions (Konkel et al., 2010). Therefore, it may be advantageous for peptides to present ABM1 and ABM2 motifs in a three-dimensional structure similar to wild-type proteins.
[0162] Therefore, in some embodiments, the first Kgp portion containing ABM1 can form the N-terminal portion of the first type III fibronectin-like domain, for example, a β-sheet containing two chains. In some embodiments, the first Kgp portion containing ABM2 can form the C-terminal portion of the first type III fibronectin-like domain, for example, a β-sheet having four chains and another β-sheet chain. In some embodiments, the first Kgp portion containing ABM1 can form the N-terminal portion of the first type III fibronectin-like domain, for example, a β-sheet containing two chains, while the first Kgp portion containing ABM2 can form the C-terminal portion of the first type III fibronectin-like domain, for example, a β-sheet having four chains and another β-sheet chain. In some such embodiments, the first Kgp portion containing ABM1 and the first Kgp portion containing ABM2 can form a first type III fibronectin-like domain with a β-sandwich structure.
[0163] In some embodiments, the first RgpA portion containing ABM1 can form the N-terminal portion of a first type III fibronectin-like domain, such as a β-sheet containing two chains. In some embodiments, the first RgpA portion containing ABM2 can form the C-terminal portion of a first type III fibronectin-like domain, such as a β-sheet having four chains and another β-sheet chain. In some embodiments, the first RgpA portion containing ABM1 can form the N-terminal portion of a first type III fibronectin-like domain, such as a β-sheet containing two chains, while the first RgpA portion containing ABM2 can form the C-terminal portion of a first type III fibronectin-like domain, such as a β-sheet having four chains and another β-sheet chain. In some such embodiments, the first RgpA portion containing ABM1 and the first RgpA portion containing ABM2 can form a first type III fibronectin-like domain with a β-sandwich structure.
[0164] In some embodiments, the first Kgp portion containing ABM1 and the first Kgp portion containing ABM2 each contain a sequence as shown in Table 4 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with them. In some such embodiments, the first Kgp portion containing ABM1 and the first Kgp portion containing ABM2 are capable of forming a first type III fibronectin-like domain as described in the preceding paragraphs.
[0165] Table 4: Combinations containing the first Kgp portion of ABM1 and the first Kgp portion of ABM2
[0166]
[0167] In some embodiments, the first RgpA portion comprising ABM1 and the first RgpA portion comprising ABM2 each comprise a sequence as shown in Table 5 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with them. In some such embodiments, the first RgpA portion comprising ABM1 and the first RgpA portion comprising ABM2 are capable of forming a first type III fibronectin-like domain as described in the preceding paragraphs.
[0168] Table 5: Combinations containing the first RgpA portion of ABM1 and the first RgpA portion of ABM2
[0169]
[0170] from Figure 3 It is also evident that the second Kgp portion containing ABM1 and the second Kgp portion containing ABM2 associate to form a type III fibronectin-like domain. Specifically, the second Kgp portion containing ABM1 forms the N-terminal portion of the type III fibronectin-like domain and contributes two chains to the β-sheet containing three chains. The second Kgp portion containing ABM2 forms the C-terminal portion of the type III fibronectin-like domain and contributes one chain to the β-sheet containing three chains and four chains to the second β-sheet. The N-terminal portion of the type III fibronectin-like domain associates with the C-terminal portion to form a β-sandwich structure.
[0171] Therefore, in some embodiments, the second Kgp portion containing ABM1 can form the N-terminal portion of the type III fibronectin-like domain, for example, a β-sheet containing two chains. In some embodiments, the second Kgp portion containing ABM2 can form the C-terminal portion of the type III fibronectin-like domain, for example, a β-sheet having four chains and another β-sheet chain. In some embodiments, the second Kgp portion containing ABM1 can form the N-terminal portion of the type III fibronectin-like domain, for example, a β-sheet containing two chains, while the second Kgp portion containing ABM2 can form the C-terminal portion of the type III fibronectin-like domain, for example, a β-sheet having four chains and another β-sheet chain. In some such embodiments, the second Kgp portion containing ABM1 and the second Kgp portion containing ABM2 can form a type III fibronectin-like domain with a β-sandwich structure.
[0172] In some embodiments, the second RgpA portion containing ABM1 can form the N-terminal portion of a type III fibronectin-like domain, such as a β-sheet containing two chains. In some embodiments, the second RgpA portion containing ABM2 can form the C-terminal portion of a type III fibronectin-like domain, such as a β-sheet having four chains and another β-sheet chain. In some embodiments, the second RgpA portion containing ABM1 can form the N-terminal portion of a type III fibronectin-like domain, such as a β-sheet containing two chains, while the second RgpA portion containing ABM2 can form the C-terminal portion of a type III fibronectin-like domain, such as a β-sheet having four chains and another β-sheet chain. In some such embodiments, the second RgpA portion containing ABM1 and the second RgpA portion containing ABM2 can form a type III fibronectin-like domain with a β-sandwich structure.
[0173] In some embodiments, the second Kgp portion containing ABM1 and the second Kgp portion containing ABM2 each contain a sequence as shown in Table 6 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with them. In some such embodiments, the second Kgp portion containing ABM1 and the second Kgp portion containing ABM2 are capable of forming a second type III fibronectin-like domain as described in the preceding paragraphs.
[0174] Table 6: Combinations of the second Kgp portion containing ABM1 and the second Kgp portion containing ABM2
[0175]
[0176] In some embodiments, the second RgpA portion containing ABM1 and the second RgpA portion containing ABM2 each contain a sequence as shown in Table 7 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with them. In some such embodiments, the second RgpA portion containing ABM1 and the second RgpA portion containing ABM2 are capable of forming a second type III fibronectin-like domain as described in the preceding paragraphs.
[0177] Table 7: Combinations of the second RgpA portion containing ABM1 and the second RgpA portion containing ABM2
[0178]
[0179] The nucleic acids and peptides of the present invention that include the combination of the first Kgp portion containing ABM1 and the first Kgp portion containing ABM2 as described in Table 4 may include the second Kgp portion containing ABM1 and the second Kgp portion containing ABM2 as described in Table 6, for example, as shown in Table 8 below. Therefore, in some embodiments, the first Kgp portion containing ABM1 and the first Kgp portion containing ABM2 each contain a sequence as shown in Table 4 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it, while the second Kgp portion containing ABM1 and the second Kgp portion containing ABM2 each contain a sequence as shown in Table 6 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it. For example, the first Kgp portion containing ABM1, the first Kgp portion containing ABM2, the second Kgp portion containing ABM1, and the second Kgp portion containing ABM2 each contain a sequence as shown in Table 8 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it. In some such embodiments, the first Kgp portion containing ABM1 and the first Kgp portion containing ABM2 can form a first type III fibronectin-like domain, while the second Kgp portion containing ABM1 and the second Kgp portion containing ABM2 can form a second type III fibronectin-like domain, as described in the preceding paragraphs.
[0180] Table 8: Combinations of the first Kgp portion containing ABM1 and ABM2 and the second Kgp portion containing ABM1 and ABM2
[0181]
[0182] The nucleic acids and peptides of the present invention that include the combination of the first RgpA portion containing ABM1 and the first RgpA portion containing ABM2 as described in Table 5 may include the second RgpA portion containing ABM1 and the second RgpA portion containing ABM2 as described in Table 7, for example, as shown in Table 9 below. Therefore, in some embodiments, the first RgpA portion containing ABM1 and the second RgpA portion containing ABM2 each contain a sequence as shown in Table 5 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it, while the second RgpA portion containing ABM1 and the second RgpA portion containing ABM2 each contain a sequence as shown in Table 7 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it. For example, the first RgpA portion containing ABM1, the first RgpA portion containing ABM2, the second RgpA portion containing ABM1, and the second RgpA portion containing ABM2 each contain a sequence as shown in Table 9 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it. In some such embodiments, the first RgpA portion containing ABM1 and the first RgpA portion containing ABM2 are capable of forming a first type III fibronectin-like domain, while the second RgpA portion containing ABM1 and the second RgpA portion containing ABM2 are capable of forming a second type III fibronectin-like domain, as described in the preceding paragraphs.
[0183] Table 9: Combinations containing the first RgpA portion of ABM1 and ABM2 and the second RgpA portion of ABM1 and ABM2
[0184]
[0185] In some embodiments, the nucleic acid or polypeptide of the present invention comprises: a first Kgp portion comprising ABM1, a first Kgp portion comprising ABM2, a second Kgp portion comprising ABM1, a second Kgp portion comprising ABM2, a first RgpA portion comprising ABM1, and a first RgpA portion comprising ABM2. In some such embodiments, the first Kgp portion containing ABM1 and the first Kgp portion containing ABM2 each contain sequences as shown in Table 4 (or sequences having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with them), and the second Kgp portion containing ABM1 and the second Kgp portion containing ABM2 each contain sequences as shown in Table 6 (or sequences having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, or 90%) identity with them). The sequences that are at least 70% (e.g., at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identical to ABM1, and the first RgpA portion containing ABM2 each contain sequences as shown in Table 5 (or sequences that are at least 70% (e.g., at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identical to ABM2).
[0186] For example, the first Kgp portion containing ABM1, the second Kgp portion containing ABM2, the second Kgp portion containing ABM1 and the second Kgp portion containing ABM2, the first RgpA portion containing ABM1 and the first RgpA portion containing ABM2 each contain a sequence as shown in Table 10 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it. In some such embodiments, the first Kgp portion containing ABM1 and the first Kgp portion containing ABM2 can form a first type III fibronectin-like domain, the second Kgp portion containing ABM1 and the second Kgp portion containing ABM2 can form a second type III fibronectin-like domain, and the first RgpA portion containing ABM1 and the first RgpA portion containing ABM2 can form a third type III fibronectin-like domain, as described in the preceding paragraphs.
[0187] Table 10: Combinations of the first Kgp portion containing ABM1 and ABM2, the second Kgp portion containing ABM1 and ABM2, and the first RgpA portion containing ABM1 and ABM2.
[0188]
[0189] A technician can determine whether a particular sequence of interest forms a type III fibronectin-like domain by structural modeling in the same manner as the inventors modeled the Kgp structure. For example, the technician can replace the first ABM1 and / or first ABM2 sequences in the first portion of the wild-type Kgp with the sequence of interest. The technician can then use AlphaFold2 to model the structure of the Kgp protein containing the sequence of interest and assess whether the sequence forms a fold homologous to the structure of a type III fibronectin-like domain. Structural homology with a type III fibronectin-like domain can be visually assessed because type III fibronectin-like domains are known to have a conserved β-sandwich fold comprising a β-sheet with three β-chains and a β-sheet with four β-chains. Alternatively, structural homology can be assessed using a protein structure comparison server such as DALI (ekhidna2.biocenter.helsinki.fi / dali / lsinki.fi).
[0190] Technicians can also use functional assays to determine whether a specific sequence of interest forms a type III fibronectin-like domain. The type III fibronectin-like domain is also known to mediate interactions with fibronectin. Therefore, technicians can perform enzyme-linked immunosorbent assays (ELISA) to determine whether a Kgp construct containing a specific sequence of interest supports fibronectin binding activity. In the ELISA, fibronectin is immobilized on the surface of the wells of a polystyrene microplate, and a Kgp construct containing the sequence of interest is added to the wells in a serial dilution. The wells are washed with buffer, and the bound Kgp protein is detected with a high-affinity antibody. A similar approach has been used to test whether the type III fibronectin-like domain of FlpA in Campylobacter jejuni mediates binding with fibronectin (Konkel et al., 2010).
[0191] The ABM3-containing portion of gingival protease
[0192] Wild-type Kgp and RgpA contain the ABM3 motif, such as Figure 1 , Figure 2A and Figure 2B As shown, the ABM3 motif is located at the C-terminus of DUF2436 and the N-terminus of the K1 adhesin domain. The modular nature of Kgp means that the Kgp moiety containing ABM3 can be included in any nucleic acid or polypeptide described herein that contains other Kgp moieties. The same modular structure of RgpA means that the RgpA moiety containing ABM3 can be included in any nucleic acid or polypeptide described herein that contains other RgpA moieties.
[0193] In some embodiments, the nucleic acids and peptides of the present invention comprise a Kgp moiety containing ABM3. In some embodiments, the nucleic acids and peptides of the present invention comprise an RgpA moiety containing ABM3.
[0194] In some embodiments, the first Kgp portion containing ABM3 is derived from *Porphyromonas gingivalis* strain W50. In *Porphyromonas gingivalis* strain W50, the Kgp portion containing ABM3 has the sequence SEQ ID NO: 131. Therefore, in some embodiments, the Kgp portion containing ABM3 contains the sequence SEQ ID NO: 131 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it.
[0195] In some embodiments, the first RgpA portion containing ABM3 is derived from *Porphyromonas gingivalis* strain W50. In *Porphyromonas gingivalis* strain W50, the RgpA portion containing ABM3 has the sequence SEQ ID NO: 135. Therefore, in some embodiments, the RgpA portion containing ABM3 contains the sequence SEQ ID NO: 135 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it.
[0196] Table 11 provides examples of portions of Kgp or RgpA sequences containing the ABM3 sequence, as well as the common sequence of ABM3. The common sequence of ABM3 is SEQ ID NO: 139.
[0197] Table 11: Kgp and RgpA portions containing ABM3 sequences. Common ABM3 sequences in each sequence are underlined.
[0198]
[0199] In some embodiments, the Kgp portion containing ABM3 contains a sequence of SEQ ID NO: 139 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it.
[0200] In some embodiments, the Kgp portion containing ABM3 contains a sequence of SEQ ID NO: 131 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it.
[0201] In some embodiments, the Kgp portion containing ABM3 contains a sequence of SEQ ID NO: 132 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it.
[0202] In some embodiments, the Kgp portion containing ABM3 contains a sequence of SEQ ID NO: 94 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it.
[0203] In some embodiments, the Kgp portion containing ABM3 contains a sequence of SEQ ID NO: 133 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it.
[0204] In some embodiments, the Kgp portion containing ABM3 contains a sequence of SEQ ID NO: 134 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it.
[0205] In some embodiments, the RgpA portion containing ABM3 contains a sequence of SEQ ID NO: 139 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it.
[0206] In some embodiments, the RgpA portion containing ABM3 contains a sequence of SEQ ID NO: 135 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it.
[0207] In some embodiments, the RgpA portion containing ABM3 contains a sequence of SEQ ID NO: 103 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it.
[0208] In some embodiments, the RgpA portion containing ABM3 contains a sequence of SEQ ID NO: 136 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it.
[0209] In some embodiments, the RgpA portion containing ABM3 contains a sequence of SEQ ID NO: 137 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it.
[0210] In some embodiments, the RgpA portion containing ABM3 contains a sequence of SEQ ID NO: 138 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it.
[0211] In the wild-type Kgp sequence of *Porphyromonas gingivalis* strain W50, the Kgp moiety containing ABM3 is located at the C-terminus of DUF2436 and the N-terminus of the K1 adhesin domain. The ABM1 sequence is located at the N-terminus of this ABM3-containing moiety and adjacent to it. In this context, the Kgp moiety containing ABM3 is 30 amino acids long and contains the sequence of SEQ ID NO: 132. This sequence contains ABM3 of SEQ ID NO: 139. Therefore, in some embodiments, the Kgp moiety containing ABM3 is between 15 and 30 amino acids long and contains the sequence of SEQ ID NO: 139.
[0212] In some embodiments, the Kgp portion containing ABM3 is between 17 and 26 amino acids in length and contains the sequence of SEQ ID NO: 139. In some embodiments, the Kgp portion containing ABM3 is between 20 and 25 amino acids in length and contains the sequence of SEQ ID NO: 139.
[0213] In some embodiments, the Kgp portion containing ABM3 is 15 amino acids long and contains the sequence of SEQ ID NO: 139. In some embodiments, the Kgp portion containing ABM3 is 17 amino acids long and contains the sequence of SEQ ID NO: 139. In some embodiments, the Kgp portion containing ABM3 is 20 amino acids long and contains the sequence of SEQ ID NO: 139. In some embodiments, the Kgp portion containing ABM3 is 25 amino acids long and contains the sequence of SEQ ID NO: 139. In some embodiments, the Kgp portion containing ABM3 is 26 amino acids long and contains the sequence of SEQ ID NO: 139. In some embodiments, the first Kgp portion containing ABM3 is 30 amino acids long and contains the sequence of SEQ ID NO: 139.
[0214] In the wild-type RgpA sequence of *Porphyromonas gingivalis* strain W50, the RgpA moiety containing ABM3 is located at the C-terminus of DUF2436 and the N-terminus of the K1 adhesin domain. The ABM1 sequence is located at the N-terminus of the ABM3-containing moiety, while the K1 adhesin domain is located at the C-terminus of the ABM3-containing moiety and adjacent to it. In this context, the RgpA moiety containing ABM3 is 30 amino acids long and contains the sequence of SEQ ID NO: 136. This sequence contains ABM3 of SEQ ID NO: 139. Therefore, in some embodiments, the RgpA moiety containing ABM3 is between 15 and 30 amino acids long and contains the sequence of SEQ ID NO: 139.
[0215] In some embodiments, the RgpA portion containing ABM3 is between 17 and 26 amino acids in length and contains the sequence of SEQ ID NO: 139. In some embodiments, the RgpA portion containing ABM3 is between 20 and 25 amino acids in length and contains the sequence of SEQ ID NO: 139.
[0216] In some embodiments, the RgpA portion containing ABM3 is 15 amino acids long and contains the sequence of SEQ ID NO: 139. In some embodiments, the RgpA portion containing ABM3 is 17 amino acids long and contains the sequence of SEQ ID NO: 139. In some embodiments, the RgpA portion containing ABM3 is 20 amino acids long and contains the sequence of SEQ ID NO: 139. In some embodiments, the RgpA portion containing ABM3 is 25 amino acids long and contains the sequence of SEQ ID NO: 139. In some embodiments, the RgpA portion containing ABM3 is 26 amino acids long and contains the sequence of SEQ ID NO: 139. In some embodiments, the first RgpA portion containing ABM3 is 30 amino acids long and contains the sequence of SEQ ID NO: 139.
[0217] The position of the ABM-containing sequence relative to other gingival protease domains
[0218] The first Kgp or RgpA portion containing ABM1 may differ from its adjacent domains (i.e., the Cat domain and DUF2436), or it may overlap with one or both of its adjacent domains. In some embodiments, the first Kgp or RgpA portion containing ABM1 differs from the Cat domain and DUF2436. In some embodiments, the peptide linker may be located between the Cat domain and the first Kgp or RgpA portion containing ABM1. In some embodiments, the peptide linker may be located between the Cat domain and the first Kgp or RgpA portion containing ABM1, and the peptide linker may be located between the first Kgp or RgpA portion containing ABM1 and DUF2436.
[0219] In some embodiments, the first Kgp or RgpA portion containing ABM1 overlaps with the Cat structural domain. In some such embodiments, the first Kgp or RgpA portion containing ABM1 overlaps with the Cat structural domain and is different from DUF2436.
[0220] The first Kgp or RgpA portion containing ABM2 may differ from its adjacent domains (i.e., DUF2436 and the Kgp or RgpA portion containing ABM1), or it may overlap with one or both of its adjacent domains. In some embodiments, the first Kgp or RgpA portion containing ABM2 differs from DUF2436 and the Kgp or RgpA portion containing ABM1. In some embodiments, the peptide linker may be located between the Cat domain and the first Kgp or RgpA portion containing ABM1. In some embodiments, the peptide linker may be located between the first Kgp or RgpA portion containing ABM1 and DUF2436. In some embodiments, the peptide linker may be located between the Cat domain and the first Kgp or RgpA portion containing ABM1, and the peptide linker may be located between the first Kgp or RgpA portion containing ABM1 and DUF2436.
[0221] The second Kgp or RgpA portion containing ABM1 may differ from its adjacent domains (i.e., the first Kgp or RgpA portion containing ABM2 and the Kgp or RgpA portion containing ABM3), or it may overlap with one or both of its adjacent domains. In some embodiments, the second Kgp or RgpA portion containing ABM1 differs from the first Kgp or RgpA portion containing ABM2 and the first Kgp or RgpA portion containing ABM3. In some embodiments, the peptide linker may be located between the first Kgp or RgpA portion containing ABM2 and the second Kgp or RgpA portion containing ABM1. In some embodiments, the peptide linker may be located between the second Kgp or RgpA portion containing ABM1 and the Kgp or RgpA portion containing ABM3. In some embodiments, the peptide linker may be located between a first Kgp or RgpA portion containing ABM2 and a second Kgp or RgpA portion containing ABM1, and the peptide linker may be located between a second Kgp or RgpA portion containing ABM1 and a Kgp or RgpA portion containing ABM3.
[0222] In some embodiments, the second Kgp or RgpA portion containing ABM1 overlaps with the Kgp or RgpA portion containing ABM3. In some such embodiments, the Kgp or RgpA portion containing ABM1 is different from the first Kgp or RgpA portion containing ABM2 and overlaps with the Kgp or RgpA portion containing ABM3.
[0223] The second Kgp or RgpA portion containing ABM2 may differ from its adjacent domain (i.e., the K2 adhesin domain), or it may overlap with one or both of its adjacent domains. In some embodiments, the second Kgp or RgpA portion containing ABM2 differs from the K2 adhesin domain. In some embodiments, the peptide linker may be located between the second Kgp or RgpA portion containing ABM2 and the K2 adhesin domain.
[0224] The Kgp or RgpA portion containing ABM3 may differ from its adjacent structural domains (i.e., the second Kgp or RgpA portion containing ABM1 and the K1 adhesin domain), or it may overlap with its adjacent structural domains. In some embodiments, the Kgp or RgpA portion containing ABM3 overlaps with the second Kgp or RgpA portion containing ABM1. In some embodiments, the Kgp or RgpA portion containing ABM3 overlaps with the K1 adhesin domain. In some embodiments, the Kgp or RgpA portion containing ABM3 overlaps with the second Kgp or RgpA portion containing ABM1 and the K1 adhesin domain.
[0225] Unknown Functional Domain (DUF)
[0226] The nucleic acids and peptides of this invention comprise at least a portion of an unknown functional domain (DUF), as disclosed herein. The modular nature of gingival proteases allows any DUF disclosed herein to be combined with any other domain disclosed herein. For example, any ABM-containing sequence disclosed above can be combined with any DUF described in subsequent paragraphs.
[0227] Unknown functional domains (DUFs) are protein domains whose functions have not yet been characterized. Therefore, a domain initially designated as a DUF can be subsequently renamed or alternatively grouped with existing domain families that have already been characterized after its function is established. DUFs have been classified in the Pfam database (pfam.xfam.org) and each conserved DUF has been assigned a number (DUF1, DUF2, etc.). This means that when two DUFs exhibit sufficient homology, a DUF found in the first protein can be assigned the same number as a DUF found in the second protein. The Pfam database is currently part of the InterPro database (www.ebi.ac.uk / interpro / ), which classifies proteins, not just DUFs (Paysan-Lafosse et al., 2022).
[0228] DUF has been identified in *Porphyromonas gingivalis* Kgp and RgpA and classified as DUF2436 (Dashper et al., 2017). In the InterPro database, DUF2436 is assigned entry number IPR018832. The nucleic acids and peptides of the present invention comprise at least a portion of DUF2436.
[0229] A technician can determine whether a specific sequence is at least a portion of DUF2436 by comparing it with known DUF2436 sequences. For example, the InterPro database allows searching for specific sequences, thereby allowing the identification of sequences containing at least a portion of DUF2436. DUF2436 is present in many different organisms and proteins, and any DUF2436 can be used in this invention, regardless of whether its specific sequence is present in *Porphyromonas gingivalis*. For example, using DUF2436 from non-gingival protease proteins or non-gingival protease species can cause the remaining *Porphyromonas gingivalis* domain of the polypeptide to fold into a structure sufficiently similar to the three-dimensional structure of wild-type gingival protease.
[0230] Typically, at least a portion of DUF2436 according to the present invention is derived from *Porphyromonas gingivalis* DUF2436. In some embodiments, DUF2436 is derived from *Porphyromonas gingivalis* Kgp. In some embodiments, DUF2436 is derived from *Porphyromonas gingivalis* RgpA.
[0231] In some embodiments, at least a portion of Kgp DUF2436 is derived from *Porphyromonas gingivalis* strain W50. Within *Porphyromonas gingivalis* strain W50, Kgp DUF2436 has the sequence of SEQ ID NO: 168. Therefore, in some embodiments, at least a portion of Kgp DUF2436 comprises at least a portion of SEQ ID NO: 168 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it. For example, at least a portion of Kgp DUF2436 contains a sequence of SEQ ID NO: 168 or a sequence that has at least 70% (e.g., at least 75%, 80%, 85%, 90% or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%) identity with it.
[0232] In some embodiments, at least a portion of RgpA DUF2436 is derived from *Porphyromonas gingivalis* strain W50. In *Porphyromonas gingivalis* strain W50, RgpA DUF2436 has the sequence of SEQ ID NO: 171. Therefore, in some embodiments, at least a portion of RgpA DUF2436 comprises at least a portion of SEQ ID NO: 171 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it. For example, at least a portion of RgpA DUF2436 contains a sequence of SEQ ID NO: 171 or a sequence that has at least 70% (e.g., at least 75%, 80%, 85%, 90% or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%) identity with it.
[0233] Table 12 below provides examples of DUF2436 sequences that can be used according to the present invention.
[0234] Table 12: Examples of DFU2436 sequences
[0235]
[0236] In some embodiments, at least a portion of Kgp DUF2436 comprises at least a portion of SEQ ID NO: 90 or a sequence having at least 70% identity with it (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%). For example, at least a portion of KgpDUF2436 comprises the sequence of SEQ ID NO: 90 or a sequence having at least 70% identity with it (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%).
[0237] In some embodiments, at least a portion of Kgp DUF2436 comprises at least a portion of SEQ ID NO: 169 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it. For example, at least a portion of KgpDUF2436 comprises the sequence of SEQ ID NO: 169 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it.
[0238] In some embodiments, at least a portion of Kgp DUF2436 comprises at least a portion of SEQ ID NO: 170 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it. For example, at least a portion of KgpDUF2436 comprises the sequence of SEQ ID NO: 170 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it.
[0239] In some embodiments, at least a portion of RgpA DUF2436 comprises at least a portion of SEQ ID NO: 100 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it. For example, at least a portion of RgpA DUF2436 comprises the sequence of SEQ ID NO: 100 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it.
[0240] In some embodiments, at least a portion of RgpA DUF2436 comprises at least a portion of SEQ ID NO: 172 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it. For example, at least a portion of RgpA DUF2436 comprises the sequence of SEQ ID NO: 172 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it.
[0241] In some embodiments, at least a portion of RgpA DUF2436 comprises at least a portion of SEQ ID NO: 173 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it. For example, at least a portion of RgpADUF2436 comprises the sequence of SEQ ID NO: 173 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it.
[0242] The inventors have discovered that nucleic acids and peptides comprising full-length DUF2436 may be particularly advantageous in inducing an immune response. Therefore, in some embodiments, the nucleic acids or peptides of the present invention comprise full-length DUF2436.
[0243] A full-length DUF2436 domain refers to the DUF2436 that has not been truncated relative to the corresponding wild-type sequence. Therefore, in some embodiments, at least a portion of DUF2436 is a full-length DUF2436, which has the same length as the corresponding wild-type DUF2436 sequence.
[0244] For example, the DUF2436 present in the Kgp of *Porphyromonas gingivalis* strain W50 is 162 amino acids long. Therefore, in some embodiments, the full-length Kgp DUF2436 is at least 162 amino acids long (e.g., 162 amino acids). The DUF2436 present in the RgpA of *Porphyromonas gingivalis* strain W50 is 163 amino acids long. Therefore, in some embodiments, the full-length RgpA DUF2436 is at least 163 amino acids long (e.g., 163 amino acids).
[0245] In some embodiments, the full-length Kgp DUF2436 has a length of at least 160 amino acids (e.g., 160 amino acids). In some embodiments, the full-length Kgp DUF2436 has a length of at least 161 amino acids (e.g., 161 amino acids). In some embodiments, the full-length Kgp DUF2436 has a length of at least 162 amino acids (e.g., 162 amino acids). In some embodiments, the full-length Kgp DUF2436 has a length of at least 163 amino acids (e.g., 166 amino acids). In some embodiments, the full-length RgpA DUF2436 has a length of 160 amino acids. In some embodiments, the full-length RgpA DUF2436 has a length of at least 161 amino acids (e.g., 161 amino acids). In some embodiments, the full-length RgpA DUF2436 has a length of at least 162 amino acids (e.g., 162 amino acids). In some embodiments, the full-length RgpA DUF2436 has a length of at least 163 amino acids (e.g., a length of 163 amino acids).
[0246] In some embodiments, at least a portion of Kgp DUF2436 is the full-length DUF2436 and includes a sequence of SEQ ID NO:168 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it.
[0247] In some embodiments, at least a portion of Kgp DUF2436 is the full-length DUF2436 and includes a sequence of SEQ ID NO:90 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it.
[0248] In some embodiments, at least a portion of Kgp DUF2436 is the full-length DUF2436 and includes a sequence of SEQ ID NO:169 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it.
[0249] In some embodiments, at least a portion of Kgp DUF2436 is the full-length DUF2436 and contains a sequence of SEQ ID NO:170 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it.
[0250] In some embodiments, at least a portion of RgpA DUF2436 is the full-length DUF2436 and contains a sequence of SEQ ID NO: 171 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it.
[0251] In some embodiments, at least a portion of RgpA DUF2436 is the full-length DUF2436 and contains a sequence of SEQ ID NO: 100 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it.
[0252] In some embodiments, at least a portion of RgpA DUF2436 is the full-length DUF2436 and contains a sequence of SEQ ID NO: 172 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it.
[0253] Truncating DUF2436 can also be performed without significantly altering the properties of the resulting polypeptide. Therefore, in some embodiments, at least a portion of DUF2436 is truncated DUF2436, wherein the truncated DUF2436 is shortened by 1 to 35 amino acids. In some such embodiments, DUF2436 is shortened by 1 to 30 amino acids, 1 to 25 amino acids, 1 to 20 amino acids, 1 to 15 amino acids, 1 to 10 amino acids, or 1 to 5 amino acids. In some embodiments, DUF2436 is shortened by 30 amino acids. In some embodiments, DUF2436 is shortened by 25 amino acids. In some embodiments, DUF2436 is shortened by 20 amino acids. In some embodiments, DUF2436 is shortened by 15 amino acids. In some embodiments, DUF2436 is shortened by 10 amino acids. In some embodiments, DUF2436 is shortened by 5 amino acids.
[0254] Truncating can occur at the N-terminus or C-terminus of DUF. Therefore, in some embodiments, DUF2436 is truncated by 1 to 35 amino acids at the N-terminus. Therefore, in some embodiments, at least a portion of DUF2436 is truncated DUF2436, wherein the truncated DUF2436 is truncated by 1 to 35 amino acids at the N-terminus. In some such embodiments, DUF2436 is truncated by 1 to 30 amino acids at the N-terminus, 1 to 25 amino acids at the N-terminus, 1 to 20 amino acids at the N-terminus, 1 to 15 amino acids at the N-terminus, 1 to 10 amino acids at the N-terminus, or 1 to 5 amino acids at the N-terminus. In some embodiments, DUF2436 is truncated by 30 amino acids at the N-terminus. In some embodiments, DUF2436 is truncated by 25 amino acids at the N-terminus. In some embodiments, DUF2436 is truncated by 20 amino acids at the N-terminus. In some embodiments, DUF2436 is truncated by 15 amino acids at the N-terminus. In some embodiments, DUF2436 is truncated by 10 amino acids at the N-terminus. In some embodiments, DUF2436 is truncated by 5 amino acids at the N-terminus.
[0255] In some embodiments, DUF2436 is truncated by 1 to 35 amino acids at its C-terminus. Therefore, in some embodiments, at least a portion of DUF2436 is truncated DUF2436, wherein the truncated DUF2436 is truncated by 1 to 35 amino acids at its C-terminus. In some such embodiments, DUF2436 is truncated by 1 to 30 amino acids at its C-terminus, 1 to 25 amino acids at its C-terminus, 1 to 20 amino acids at its C-terminus, 1 to 15 amino acids at its C-terminus, 1 to 10 amino acids at its C-terminus, or 1 to 5 amino acids at its C-terminus. In some embodiments, DUF2436 is truncated by 30 amino acids at its C-terminus. In some embodiments, DUF2436 is truncated by 25 amino acids at its C-terminus. In some embodiments, DUF2436 is truncated by 20 amino acids at its C-terminus. In some embodiments, DUF2436 is truncated by 15 amino acids at its C-terminus. In some embodiments, DUF2436 is truncated by 10 amino acids at its C-terminus. In some embodiments, DUF2436 is truncated by 5 amino acids at its C-terminus.
[0256] In some embodiments, the truncated DUF2436 comprises at least a portion of SEQ ID NO: 173 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it.
[0257] Variants of DUF2436 can also be used in this invention. Such variants can remove glycosylation sites, as described elsewhere herein.
[0258] Catalytic domain (Cat domain)
[0259] The nucleic acids and peptides of the present invention comprise at least a portion of a catalytic domain from Kgp and / or at least a portion of a catalytic domain from RgpA or RgpB, as disclosed herein. The modular nature of gingival proteases allows any catalytic domain disclosed herein to be combined with any other domain disclosed herein. For example, any sequence disclosed above comprising ABM and / or DUF can be combined with any catalytic domain described in subsequent paragraphs.
[0260] Kgp, RgpA, and RgpB are lysine- and arginine-specific cysteine proteases belonging to the C25 peptidase family, wherein protease activity is mediated by a catalytic domain located at the N-terminus of the active wild-type protein. The catalytic domain, as defined herein, comprises a C25 peptidase domain and an immunoglobulin fold (C25C) at its C-terminus (Dashper et al., 2017). The nucleic acids and peptides of the present invention comprise at least a portion of the Kgp, RgpA, and / or RgpB catalytic domains to elicit an antibody response that inhibits the protease function of Kgp, RgpA, and / or RgpB. The InterPro database entry for the C25 peptidase domain is IPR001769. The InterPro database entry for the C25C domain is IPR005536.
[0261] In some embodiments, at least a portion of the Kgp catalytic domain according to the present invention originates from Porphyromonas gingivalis Kgp.
[0262] In some embodiments, at least a portion of the RgpA catalytic domain according to the present invention originates from Porphyromonas gingivalis RgpA.
[0263] In some embodiments, at least a portion of the RgpB catalytic domain according to the present invention is derived from Porphyromonas gingivalis RgpB.
[0264] In some embodiments, at least a portion of the Kgp catalytic domain is derived from *Porphyromonas gingivalis* strain W50. In *Porphyromonas gingivalis* strain W50, the Kgp catalytic domain has the sequence of SEQ ID NO: 174. Therefore, in some embodiments, at least a portion of the Kgp catalytic domain comprises at least a portion of SEQ ID NO: 174 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it. For example, at least a portion of the Kgp catalytic domain contains the sequence of SEQ ID NO: 174 or a sequence that has at least 70% (e.g., at least 75%, 80%, 85%, 90% or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%) identity with it.
[0265] In some embodiments, at least a portion of the RgpA catalytic domain is derived from *Porphyromonas gingivalis* strain W50. In *Porphyromonas gingivalis* strain W50, the RgpA catalytic domain has the sequence of SEQ ID NO: 178. Therefore, in some embodiments, at least a portion of the RgpA catalytic domain comprises at least a portion of SEQ ID NO: 178 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it. For example, at least a portion of the RgpA catalytic domain contains the sequence of SEQ ID NO: 178 or a sequence that has at least 70% (e.g., at least 75%, 80%, 85%, 90% or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%) identity with it.
[0266] In some embodiments, at least a portion of the RgpB catalytic domain is derived from *Porphyromonas gingivalis* strain W50. In *Porphyromonas gingivalis* strain W50, the RgpB catalytic domain has the sequence of SEQ ID NO: 251. Therefore, in some embodiments, at least a portion of the RgpB catalytic domain comprises at least a portion of SEQ ID NO: 251 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it. For example, at least a portion of the RgpB catalytic domain contains the sequence of SEQ ID NO: 251 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90% or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%) identity with it.
[0267] Table 13 below provides examples of Kgp, RgpA, and RgpB catalytic domain sequences that can be used according to the present invention.
[0268] Table 13: Examples of Kgp, RgpA, and RgpB catalytic domain sequences
[0269]
[0270] In some embodiments, at least a portion of the Kgp catalytic domain comprises at least a portion of SEQ ID NO: 64 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it. For example, at least a portion of the Kgp catalytic domain comprises the sequence of SEQ ID NO: 64 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it.
[0271] In some embodiments, at least a portion of the Kgp catalytic domain comprises at least a portion of SEQ ID NO: 174 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it. For example, at least a portion of the Kgp catalytic domain comprises the sequence of SEQ ID NO: 174 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it.
[0272] In some embodiments, at least a portion of the Kgp catalytic domain comprises at least a portion of SEQ ID NO: 175 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it. For example, at least a portion of the Kgp catalytic domain comprises the sequence of SEQ ID NO: 175 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it.
[0273] In some embodiments, at least a portion of the Kgp catalytic domain comprises at least a portion of SEQ ID NO: 88 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it. For example, at least a portion of the Kgp catalytic domain comprises the sequence of SEQ ID NO: 88 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it.
[0274] In some embodiments, at least a portion of the Kgp catalytic domain comprises at least a portion of SEQ ID NO: 61 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it. For example, at least a portion of the Kgp catalytic domain comprises the sequence of SEQ ID NO: 61 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it.
[0275] In some embodiments, at least a portion of the Kgp catalytic domain comprises at least a portion of SEQ ID NO: 163 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it. For example, at least a portion of the Kgp catalytic domain comprises the sequence of SEQ ID NO: 163 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it.
[0276] In some embodiments, at least a portion of the Kgp catalytic domain comprises at least a portion of SEQ ID NO: 176 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it. For example, at least a portion of the Kgp catalytic domain comprises the sequence of SEQ ID NO: 176 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it.
[0277] In some embodiments, at least a portion of the Kgp catalytic domain comprises at least a portion of SEQ ID NO: 177 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it. For example, at least a portion of the Kgp catalytic domain comprises the sequence of SEQ ID NO: 177 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it.
[0278] In some embodiments, at least a portion of the RgpA catalytic domain comprises at least a portion of SEQ ID NO: 98 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it. For example, at least a portion of the RgpA catalytic domain comprises the sequence of SEQ ID NO: 98 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it.
[0279] In some embodiments, at least a portion of the RgpA catalytic domain comprises at least a portion of SEQ ID NO: 179 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it. For example, at least a portion of the RgpA catalytic domain comprises the sequence of SEQ ID NO: 179 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it.
[0280] In some embodiments, at least a portion of the RgpA catalytic domain comprises at least a portion of SEQ ID NO: 97 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it. For example, at least a portion of the RgpA catalytic domain comprises the sequence of SEQ ID NO: 97 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it.
[0281] In some embodiments, at least a portion of the RgpA catalytic domain comprises at least a portion of SEQ ID NO: 180 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it. For example, at least a portion of the RgpA catalytic domain comprises the sequence of SEQ ID NO: 180 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it.
[0282] In some embodiments, at least a portion of the RgpA catalytic domain comprises at least a portion of SEQ ID NO: 66 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it. For example, at least a portion of the RgpA catalytic domain comprises the sequence of SEQ ID NO: 66 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it.
[0283] In some embodiments, at least a portion of the RgpA catalytic domain comprises at least a portion of SEQ ID NO: 181 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it. For example, at least a portion of the RgpA catalytic domain comprises the sequence of SEQ ID NO: 181 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it.
[0284] In some embodiments, at least a portion of the RgpB catalytic domain comprises at least a portion of SEQ ID NO: 251 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it. For example, at least a portion of the RgpB catalytic domain comprises the sequence of SEQ ID NO: 251 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it.
[0285] Preferably, the Kgp, RgpA, or RgpB catalytic domain is modified to inactivate its protease function. This ensures that the peptide does not mediate negative effects associated with the function of the Kgp, RgpA, or RgpB protease. The protease function of the catalytic domain can be inactivated in various ways. For example, one or more residues within the active site of the catalytic domain may be mutated. Alternatively or additionally, the catalytic domain may be truncated to form an inactive catalytic domain.
[0286] Some of the catalytic domain sequences in Table 13 are inactivated due to mutations and / or truncation. Specifically, the Kgp catalytic domain of SEQ ID NO: 64 and the RgpA catalytic domain of SEQ ID NO: 98 are inactivated due to mutations. The Kgp catalytic domains of SEQ ID NO: 88 and 163, the RgpA catalytic domains of SEQ ID NO: 97 and 166, and the RgpB catalytic domains of SEQ ID NO: 252 and 253 are inactivated due to truncation.
[0287] In some embodiments, at least a portion of the Kgp catalytic domain contains a mutation that inactivates the protease. In some such embodiments, the mutation that inactivates the protease is a cysteine-to-serine mutation at position 477 (C477S), wherein the mutation position corresponds to position 477 of the wild-type Kgp sequence of SEQ ID NO: 157.
[0288] For example, in the catalytic domains of SEQ ID NO: 64, 174, 176, and 178, position 249 corresponds to position 477 of the wild-type Kgp sequence in SEQ ID NO: 157. Therefore, the mutation that inactivates the protease activity is the cysteine-to-serine mutation (C249S) at position 249 in these catalytic domains.
[0289] In some embodiments, at least a portion of the RgpA catalytic domain contains a mutation that inactivates the protease activity. In some such embodiments, the mutation that inactivates the protease activity is a cysteine-to-serine mutation at position 471 (C471S), wherein the mutation position corresponds to position 471 of the wild-type RgpA sequence of SEQ ID NO: 158.
[0290] For example, in the catalytic domains of SEQ ID NO: 98, 179, and 181, position C248 corresponds to position 471 of the wild-type RgpA sequence in SEQ ID NO: 158. Therefore, the mutation that inactivates the protease activity is the cysteine-to-serine mutation (C248S) at position 248 in these catalytic domains.
[0291] In some embodiments, at least a portion of the RgpB catalytic domain contains a mutation that inactivates the protease activity. In some such embodiments, the mutation that inactivates the protease activity is a cysteine-to-serine mutation at position 473 (C473S), wherein the mutation position corresponds to position 473 of the wild-type RgpB sequence of SEQ ID NO: 159.
[0292] The inventors have discovered that nucleic acids and peptides comprising full-length catalytic domains may be particularly advantageous in initiating immune responses. Therefore, in some embodiments, at least a portion of the Kgp catalytic domain comprises a full-length Kgp catalytic domain. In some embodiments, at least a portion of the RgpA catalytic domain comprises a full-length RgpA catalytic domain. In some embodiments, at least a portion of the RgpB catalytic domain comprises a full-length RgpB catalytic domain.
[0293] Full-length Kgp, RgpA, or RgpB catalytic domains refer to Kgp, RgpA, or RgpB catalytic domains that have not been truncated relative to the corresponding wild-type sequence. Therefore, in some embodiments, at least a portion of the Kgp catalytic domain is a full-length Kgp catalytic domain with the same length as the corresponding wild-type Kgp catalytic domain sequence. In some embodiments, at least a portion of the RgpA catalytic domain is a full-length RgpA catalytic domain with the same length as the corresponding wild-type RgpA catalytic domain sequence. In some embodiments, at least a portion of the RgpB catalytic domain is a full-length RgpB catalytic domain with the same length as the corresponding wild-type RgpB catalytic domain sequence.
[0294] For example, the Kgp catalytic domain in the Kgp of *Porphyromonas gingivalis* strain W50 is 452 amino acids long. Therefore, in some embodiments, the full-length Kgp catalytic domain is at least 452 amino acids long (e.g., 452 amino acids). The catalytic domain in the RgpA of *Porphyromonas gingivalis* strain W50 is 438 amino acids long. Therefore, in some embodiments, the full-length RgpA catalytic domain is at least 438 amino acids long (e.g., 438 amino acids). The catalytic domain in the RgpB of *Porphyromonas gingivalis* strain W50 is 437 amino acids long. Therefore, in some embodiments, the full-length RgpB catalytic domain is at least 437 amino acids long (e.g., 437 amino acids). The length of the Kgp catalytic domain in the Kgp of other *Porphyromonas gingivalis* strains may differ from the length of the Kgp catalytic domain in the Kgp of *Porphyromonas gingivalis* strain W50. Similarly, the length of the RgpA catalytic domain in the RgpA of other *Porphyromonas gingivalis* strains may differ from the length of the RgpA catalytic domain in the RgpA of *Porphyromonas gingivalis* strain W50. The length of the RgpB catalytic domain in the RgpB of other *Porphyromonas gingivalis* strains may also differ from the length of the RgpB catalytic domain in the RgpB of *Porphyromonas gingivalis* strain W50.
[0295] Therefore, in some embodiments, the full-length Kgp catalytic domain is at least 448 amino acids long (e.g., 448 amino acids). In some embodiments, the full-length Kgp catalytic domain is at least 449 amino acids long (e.g., 449 amino acids). In some embodiments, the full-length Kgp catalytic domain is at least 450 amino acids long (e.g., 450 amino acids). In some embodiments, the full-length Kgp catalytic domain is at least 451 amino acids long (e.g., 451 amino acids). In some embodiments, the full-length Kgp catalytic domain is at least 456 amino acids long (e.g., 456 amino acids).
[0296] In some embodiments, the full-length RgpA catalytic domain is at least 434 amino acids long (e.g., 434 amino acids). In some embodiments, the full-length RgpA catalytic domain is at least 435 amino acids long (e.g., 435 amino acids). In some embodiments, the full-length RgpA catalytic domain is at least 436 amino acids long (e.g., 436 amino acids). In some embodiments, the full-length RgpA catalytic domain is at least 437 amino acids long (e.g., 437 amino acids).
[0297] In some embodiments, the full-length RgpB catalytic domain is at least 433 amino acids long (e.g., 433 amino acids). In some embodiments, the full-length RgpB catalytic domain is at least 434 amino acids long (e.g., 434 amino acids). In some embodiments, the full-length RgpB catalytic domain is at least 435 amino acids long (e.g., 435 amino acids). In some embodiments, the full-length RgpB catalytic domain is at least 436 amino acids long (e.g., 436 amino acids).
[0298] Truncating the Kgp, RgpA, or RgpB catalytic domains can also be done without significantly altering the properties of the resulting peptide, for example, the peptide being capable of triggering antibodies that block the catalytic function of Kgp, RgpA, and / or RgpB. Therefore, in some embodiments, at least a portion of the Kgp catalytic domain is a truncated Kgp catalytic domain. In some embodiments, at least a portion of the RgpA catalytic domain is a truncated RgpA catalytic domain. In some embodiments, at least a portion of the RgpB catalytic domain is a truncated RgpB catalytic domain.
[0299] Therefore, in some embodiments, at least a portion of the Kgp, RgpA, or RgpB catalytic domain is a truncated catalytic domain, wherein the truncated Kgp, RgpA, or RgpB catalytic domain is truncated by 1 to 35 amino acids. In some such embodiments, the Kgp catalytic domain is truncated by 1 to 30 amino acids, 1 to 25 amino acids, 1 to 20 amino acids, 1 to 15 amino acids, 1 to 10 amino acids, or 1 to 5 amino acids. In some such embodiments, the RgpA catalytic domain is truncated by 1 to 30 amino acids, 1 to 25 amino acids, 1 to 20 amino acids, 1 to 15 amino acids, 1 to 10 amino acids, or 1 to 5 amino acids. In some such embodiments, the RgpB catalytic domain is truncated by 1 to 30 amino acids, 1 to 25 amino acids, 1 to 20 amino acids, 1 to 15 amino acids, 1 to 10 amino acids, or 1 to 5 amino acids. In some embodiments, the Kgp, RgpA, or RgpB catalytic domain is truncated by 30 amino acids. In some embodiments, the Kgp, RgpA, or RgpB catalytic domain is truncated by 25 amino acids. In some embodiments, the Kgp, RgpA, or RgpB catalytic domain is truncated by 20 amino acids. In some embodiments, the Kgp, RgpA, or RgpB catalytic domain is truncated by 15 amino acids. In some embodiments, the Kgp, RgpA, or RgpB catalytic domain is truncated by 10 amino acids. In some embodiments, the Kgp, RgpA, or RgpB catalytic domain is truncated by 5 amino acids.
[0300] Truncated Kgp, RgpA, or RgpB catalytic domains may be advantageous because the amino acid sequence of the active site can remain identical to the wild type, and thus can trigger antibodies specific to the native Kgp, RgpA, or RgpB active sites. Therefore, in some embodiments, at least a portion of the Kgp catalytic domain is a truncated Kgp catalytic domain, wherein truncation inactivates protease activity. In some embodiments, at least a portion of the RgpA catalytic domain is a truncated RgpA catalytic domain, wherein truncation inactivates protease activity. In some embodiments, at least a portion of the RgpB catalytic domain is a truncated RgpB catalytic domain, wherein truncation inactivates protease activity.
[0301] An example of a truncated Kgp catalytic domain whose protease activity is inactivated is the Lys gingival protease active site peptide (KAS peptide). The KAS peptide is a portion of a Kgp catalytic domain that contains a portion of the active site of the Kgp catalytic domain. Examples of different KAS peptides, particularly the Kas2 peptide and the elongated Kas2 peptide, are listed in Table 13.
[0302] In some embodiments, the truncated Kgp catalytic domain (e.g., a KAS peptide) is at least 36 amino acids long and includes a portion of the Kgp catalytic domain active site. In other embodiments, the truncated Kgp catalytic domain (e.g., an extended KAS2 peptide) is at least 47 amino acids long and includes a portion of the Kgp catalytic domain active site. In some embodiments, the truncated Kgp catalytic domain comprises a KAS peptide, wherein the KAS peptide comprises the Kas2 peptide according to SEQ ID NO: 61 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it. In other embodiments, the KAS peptide comprises the Kas2 peptide according to SEQ ID NO: 163 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90% or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%) identity with it.
[0303] In some embodiments, the truncated Kgp catalytic domain comprises a KAS peptide, wherein the KAS peptide comprises an extended Kas2 peptide according to SEQ ID NO: 175 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it. In other embodiments, the KAS peptide comprises an extended Kas2 peptide according to SEQ ID NO: 88 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it.
[0304] An example of a truncated RgpA or RgpB catalytic domain whose protease activity is inactivated is the Arg gingival protease active site peptide (RAS peptide). A RAS peptide is a portion of an RgpA or RgpB catalytic domain containing a portion of the active site of the RgpA or RgpB catalytic domain. Examples of different RAS peptides, particularly Ras2 peptide and elongated Ras2 peptide, are listed in Table 13.
[0305] In some embodiments, the truncated RgpA or RgpB catalytic domain (e.g., a RAS peptide) is at least 36 amino acids long and includes a portion of the active site of the RgpA or RgpB catalytic domain. In other embodiments, the truncated RgpA or RgpB catalytic domain (e.g., an elongated RAS2 peptide) is at least 47 amino acids long and includes a portion of the active site of the RgpA or RgpB catalytic domain.
[0306] In some embodiments, the truncated RgpA catalytic domain comprises a RAS peptide, wherein the RAS peptide comprises the Ras2 peptide according to SEQ ID NO: 180 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it. In other embodiments, the RAS peptide comprises the Ras2 peptide according to SEQ ID NO: 166 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it.
[0307] In some embodiments, the truncated RgpA catalytic domain comprises a RAS peptide, wherein the RAS peptide comprises an extended Ras2 peptide according to SEQ ID NO: 179 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it. In other embodiments, the RAS peptide comprises an extended Ras2 peptide according to SEQ ID NO: 166 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it.
[0308] In some embodiments, the truncated RgpB catalytic domain comprises a RAS peptide, wherein the RAS peptide comprises the Ras2 peptide according to SEQ ID NO: 253 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it.
[0309] In some embodiments, the truncated RgpB catalytic domain comprises a RAS peptide, wherein the RAS peptide comprises an extended Ras2 peptide according to SEQ ID NO: 252 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it.
[0310] Variants of the Kgp, RgpA, or RgpB catalytic domains can also be used in this invention. Such variants can remove glycosylation sites, as described elsewhere herein.
[0311] As discussed elsewhere in this document, the catalytic domain of Kgp exhibits low sequence conservation compared to the catalytic domains of RgpA and RgpB. Therefore, it may be advantageous for nucleic acids and peptides to contain at least a portion of the catalytic domain of Kgp and at least a portion of the catalytic domain of RgpA or RgpB, as this can trigger an immune response capable of inactivating the catalytic activity of both Kgp and RgpA or RgpB. Alternatively, compositions in which the first nucleic acid or peptide contains at least a portion of the catalytic domain of Kgp and the second nucleic acid or peptide contains at least a portion of the catalytic domain of RgpA or RgpB may be advantageous.
[0312] Therefore, any one of at least a portion of the Kgp catalytic domains defined in the preceding paragraphs may be combined with any one of at least a portion of the RgpA catalytic domains defined in the preceding paragraphs. In other embodiments, at least a portion of the Kgp catalytic domains defined in the preceding paragraphs may be combined with any one of at least a portion of the RgpB catalytic domains defined in the preceding paragraphs.
[0313] In some embodiments, the nucleic acid or polypeptide comprises: (i) at least a portion of a Kgp catalytic domain, wherein at least a portion of the Kgp catalytic domain is a truncated Kgp catalytic domain comprising a KAS peptide, wherein the KAS peptide comprises a Kas2 peptide according to SEQ ID NO: 88 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it; and (ii) at least a portion of an RgpA catalytic domain, wherein at least a portion of the RgpA catalytic domain is a truncated RgpA catalytic domain comprising a RAS peptide, wherein the RAS peptide comprises a Kas2 peptide according to SEQ ID NO: 88. 97% of the Ras2 peptide or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90% or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%) identity with it.
[0314] In some embodiments, the nucleic acid or peptide includes at least a portion of a Kgp catalytic domain and at least a portion of an RgpA or RgpB catalytic domain. Full-length Kgp and full-length RgpA or RgpB catalytic domains may be too long to be combined with other Kgp and RgpA or RgpB domains also present in the nucleic acid or peptide (e.g., DUF2436, a Kgp or RgpA portion containing ABM, and a K1 adhesin domain) in a single nucleic acid or peptide. Using truncated Kgp catalytic domains and / or truncated RgpA or RgpB catalytic domains can be used to avoid any problems where the nucleic acid or peptide becomes too long to be expressed correctly, for example.
[0315] Therefore, in some embodiments, at least a portion of the Kgp catalytic domain is a truncated Kgp catalytic domain, and at least a portion of the RgpA catalytic domain is a truncated RgpA catalytic domain. Any truncated Kgp catalytic domain disclosed herein may be used in combination with any truncated RgpA catalytic domain disclosed herein. For example, in some embodiments, at least a portion of the Kgp catalytic domain is a KAS peptide (e.g., the extended Kas2 peptide of SEQ ID NO: 88 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it), while at least a portion of the RgpA catalytic domain is a RAS peptide (e.g., the extended Ras2 peptide of SEQ ID NO: 97 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it). In other embodiments, at least a portion of the Kgp catalytic domain is a KAS peptide (e.g., an extended Kas2 peptide of SEQ ID NO: 88 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it), while at least a portion of the RgpA catalytic domain is a truncated RgpA catalytic domain. In other embodiments, at least a portion of the Kgp catalytic domain is a truncated Kgp catalytic domain, and at least a portion of the RgpA catalytic domain is a RAS peptide (e.g., the extended Ras2 peptide of SEQ ID NO: 97 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it).
[0316] In other embodiments, at least a portion of the Kgp catalytic domain is a full-length catalytic domain, while at least a portion of the RgpA catalytic domain is a truncated RgpA catalytic domain. For example, in some such embodiments, at least a portion of the Kgp catalytic domain is a full-length catalytic domain, while at least a portion of the RgpA catalytic domain is a RAS peptide (e.g., the extended Ras2 peptide of SEQ ID NO: 97 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it).
[0317] In other embodiments, at least a portion of the Kgp catalytic domain is a truncated Kgp catalytic domain, and at least a portion of the RgpA catalytic domain is a full-length RgpA catalytic domain. For example, in some such embodiments, at least a portion of the Kgp catalytic domain is a KAS peptide (e.g., an extended Kas2 peptide of SEQ ID NO: 88 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it), and at least a portion of the RgpA catalytic domain is an RgpA catalytic domain.
[0318] In some embodiments, at least a portion of the Kgp catalytic domain is a truncated Kgp catalytic domain, and at least a portion of the RgpB catalytic domain is a truncated RgpB catalytic domain. Any truncated Kgp catalytic domain disclosed herein may be used in combination with any truncated RgpB catalytic domain disclosed herein. For example, in some embodiments, at least a portion of the Kgp catalytic domain is a KAS peptide (e.g., the extended Kas2 peptide of SEQ ID NO: 88 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it), while at least a portion of the RgpB catalytic domain is a RAS peptide (e.g., the extended Ras2 peptide of SEQ ID NO: 252 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it). In other embodiments, at least a portion of the Kgp catalytic domain is a KAS peptide (e.g., an extended Kas2 peptide of SEQ ID NO: 88 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it), while at least a portion of the RgpB catalytic domain is a truncated RgpB catalytic domain. In other embodiments, at least a portion of the Kgp catalytic domain is a truncated Kgp catalytic domain, and at least a portion of the RgpB catalytic domain is a RAS peptide (e.g., the extended Ras2 peptide of SEQ ID NO: 252 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, e.g., at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it).
[0319] In other embodiments, at least a portion of the Kgp catalytic domain is a full-length catalytic domain, while at least a portion of the RgpB catalytic domain is a truncated RgpB catalytic domain. For example, in some such embodiments, at least a portion of the Kgp catalytic domain is a full-length catalytic domain, while at least a portion of the RgpB catalytic domain is a RAS peptide (e.g., the extended Ras2 peptide of SEQ ID NO: 252 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it).
[0320] In other embodiments, at least a portion of the Kgp catalytic domain is a truncated Kgp catalytic domain, and at least a portion of the RgpB catalytic domain is a full-length RgpB catalytic domain. For example, in some such embodiments, at least a portion of the Kgp catalytic domain is a KAS peptide (e.g., an extended Kas2 peptide of SEQ ID NO: 88 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it), and at least a portion of the RgpB catalytic domain is a full-length RgpB catalytic domain.
[0321] K1 and K2 adhesin domains
[0322] The nucleic acids and peptides of the present invention comprise at least a portion of a Kgp K1 adhesin domain and / or at least a portion of a RgpA K1 adhesin domain, as disclosed herein. In some embodiments, the nucleic acids and peptides further comprise at least a portion of a Kgp K2 adhesin domain and / or at least a portion of a RgpA K1 adhesin domain.
[0323] The modular nature of gingival proteases allows any K1 adhesin domain disclosed herein to be combined with any other domain disclosed herein. For example, any sequence disclosed above containing an ABM, DUF, or Cat domain can be combined with any K1 adhesin domain described in subsequent paragraphs. Similarly, any K2 adhesin domain disclosed herein can be combined with any other domain disclosed herein. For example, any sequence disclosed above containing an ABM, DUF, or Cat domain can be combined with any K2 adhesin domain described in subsequent paragraphs. Likewise, any K1 adhesin domain disclosed herein can be combined with any other K2 adhesin domain disclosed herein.
[0324] Wild-type Kgp and RgpA contain three adhesin domains, designated K1, K2, and K3. These three domains are structurally homologous and contain conserved sequence motifs, although the percentage of sequence identity between each adhesin is relatively low (e.g., approximately 40% sequence identity between K1 and K2). However, very high sequence identity is observed between the Kgp K1 adhesin domain and the RgpA K1 adhesin domain, and between the Kgp K2 adhesin domain and the RgpA K2 adhesin domain.
[0325] These three domains are members of the cleaved adhesin domain family, designated IPR011628 in the InterPro database. The cleaved adhesin domains of Kgp and RgpA are thought to have multiple functions in *Porphyromonas gingivalis*, including adhesion to and colonization of host tissues, and to promote co-aggregation of *Porphyromonas gingivalis* with other oral pathogens and subsequent biofilm formation (Li and Collyer, 2011; Dashper et al., 2017). For example, the cleaved adhesin domains have been reported to bind to hemoglobin, human serum albumin, and fibrinogen (Li et al., 2011; Ganuelas et al., 2013). These proteins are abundant in blood and are most likely to be targeted by *Porphyromonas gingivalis* during early colonization. Furthermore, it has been demonstrated that the cleaved adhesin domain induces in vitro hemolysis of erythrocytes, thereby enabling Porphyromonas gingivalis to obtain the essential heme from erythrocytes (Li et al., 2011; Ganuelas et al., 2013).
[0326] The nucleic acids and peptides of the present invention contain at least a portion of the Kgp K1 adhesin domain and / or at least a portion of the RgpA K1 adhesin domain to trigger an antibody response that inhibits the adhesion function of Kgp and RgpA.
[0327] At least a portion of the Kgp or RgpA K1 adhesin domain according to the present invention originates from Porphyromonas gingivalis Kgp or RgpA.
[0328] In some embodiments, at least a portion of the Kgp K1 adhesin domain is derived from *Porphyromonas gingivalis* strain W50. In *Porphyromonas gingivalis* strain W50, the Kgp K1 adhesin domain has the sequence of SEQ ID NO: 182. Therefore, in some embodiments, at least a portion of the Kgp K1 adhesin domain comprises at least a portion of SEQ ID NO: 182 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it. For example, at least a portion of the Kgp K1 adhesin domain contains a sequence of SEQ ID NO: 182 or a sequence that has at least 70% (e.g., at least 75%, 80%, 85%, 90% or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%) identity with it.
[0329] In some embodiments, at least a portion of the RgpA K1 adhesin domain is derived from *Porphyromonas gingivalis* strain W50. In *Porphyromonas gingivalis* strain W50, the RgpA K1 adhesin domain has the sequence of SEQ ID NO: 185. Therefore, in some embodiments, at least a portion of the RgpA K1 adhesin domain comprises at least a portion of SEQ ID NO: 185 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it. For example, at least a portion of the RgpAK1 adhesin domain contains a sequence of SEQ ID NO: 185 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it.
[0330] Table 14 provides examples of K1 adhesin domain sequences that can be used according to the present invention.
[0331] Table 14: Examples of K1 adhesin domain sequences
[0332]
[0333] In some embodiments, at least a portion of the Kgp K1 adhesin domain comprises at least a portion of SEQ ID NO: 183 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it. For example, at least a portion of the Kgp K1 adhesin domain comprises the sequence of SEQ ID NO: 183 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it.
[0334] In some embodiments, at least a portion of the Kgp K1 adhesin domain comprises at least a portion of SEQ ID NO: 184 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it. For example, at least a portion of the Kgp K1 adhesin domain comprises the sequence of SEQ ID NO: 184 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it.
[0335] In some embodiments, at least a portion of the RgpA K1 adhesin domain comprises at least a portion of SEQ ID NO: 186 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it. For example, at least a portion of the Kgp K1 adhesin domain comprises the sequence of SEQ ID NO: 186 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it.
[0336] The inventors have discovered that nucleic acids and peptides containing a full-length K1 adhesin domain may be particularly advantageous in inducing an immune response. This may be because peptides containing a full-length K1 adhesin domain can fold into a three-dimensional structure similar to the wild-type three-dimensional structure of the K1 adhesin domain, thereby enabling the construct to induce the production of antibodies that recognize conformational epitopes within the K1 adhesin domain. Therefore, in some embodiments, at least a portion of the K1 adhesin domain comprises a full-length K1 adhesin domain. In some embodiments, at least a portion of the RgpA K1 adhesin domain comprises a full-length RgpA K1 adhesin domain.
[0337] A full-length Kgp or RgpA K1 adhesin domain refers to a Kgp or RgpA K1 adhesin domain that has not been truncated relative to the corresponding wild-type K1 adhesin domain. Therefore, in some embodiments, at least a portion of the Kgp K1 adhesin domain is a full-length Kgp K1 adhesin domain, having the same length as the corresponding wild-type Kgp K1 adhesin domain. In some embodiments, at least a portion of the RgpA K1 adhesin domain is a full-length RgpA K1 adhesin domain, having the same length as the corresponding wild-type RgpA K1 adhesin domain.
[0338] For example, the Kgp K1 adhesin domain in the Kgp of *Porphyromonas gingivalis* strain W50 is 169 amino acids long. Therefore, in some embodiments, the full-length Kgp K1 adhesin domain is at least 169 amino acids long (e.g., 169 amino acids in length). The K1 adhesin domain in the RgpA of *Porphyromonas gingivalis* strain W50 is 170 amino acids long. Therefore, in some embodiments, the full-length RgpA K1 adhesin domain is at least 170 amino acids long (e.g., 170 amino acids in length).
[0339] The length of the Kgp K1 adhesin domain in the Kgp of other *Porphyromonas gingivalis* strains may differ from the length of the Kgp K1 adhesin domain in the Kgp of *Porphyromonas gingivalis* strain W50. Similarly, the length of the RgpA K1 domain in the Kgp of other *Porphyromonas gingivalis* strains may differ from the length of the RgpA K1 domain in the RgpA region of *Porphyromonas gingivalis* strain W50.
[0340] Therefore, in some embodiments, the full-length Kgp K1 adhesin domain is at least 165 amino acids long (e.g., 165 amino acids). In some embodiments, the full-length Kgp K1 adhesin domain is at least 166 amino acids long (e.g., 166 amino acids). In some embodiments, the full-length Kgp K1 adhesin domain is at least 167 amino acids long (e.g., 167 amino acids). In some embodiments, the full-length Kgp K1 adhesin domain is at least 168 amino acids long (e.g., 168 amino acids). In some embodiments, the full-length Kgp K1 adhesin is at least 170 amino acids long (e.g., 170 amino acids).
[0341] In some embodiments, the full-length RgpA K1 adhesin domain is at least 166 amino acids long (e.g., 166 amino acids). In some embodiments, the full-length RgpA K1 adhesin domain is at least 167 amino acids long (e.g., 167 amino acids). In some embodiments, the full-length RgpA K1 adhesin domain is at least 168 amino acids long (e.g., 168 amino acids). In some embodiments, the full-length RgpA K1 adhesin domain is at least 169 amino acids long (e.g., 169 amino acids). Truncation of the Kgp or RgpA K1 adhesin domain can also be performed without significantly altering the properties of the resulting peptide, for example, the resulting peptide can still elicit antibodies that block Kgp and / or RgpA adhesion function. Therefore, in some embodiments, at least a portion of the KgpK1 adhesin domain is a truncated KgpK1 adhesin domain. In some embodiments, at least a portion of the RgpA K1 adhesin domain is a truncated RgpAK1 adhesin domain.
[0342] Therefore, in some embodiments, at least a portion of the Kgp or RgpA K1 adhesin domain is a truncated Kgp or RgpA K1 adhesin domain, wherein the truncated Kgp or RgpA K1 adhesin domain is truncated by 1 to 35 amino acids. In some such embodiments, the Kgp or RgpA K1 adhesin domain is truncated by 1 to 30 amino acids, 1 to 25 amino acids, 1 to 20 amino acids, 1 to 15 amino acids, 1 to 10 amino acids, or 1 to 5 amino acids. In some such embodiments, the KgpK1 adhesin domain is truncated by 1 to 30 amino acids, 1 to 25 amino acids, 1 to 20 amino acids, 1 to 15 amino acids, 1 to 10 amino acids, or 1 to 5 amino acids. In some such embodiments, the RgpA K1 adhesin domain is truncated by 1 to 30 amino acids, 1 to 25 amino acids, 1 to 20 amino acids, 1 to 15 amino acids, 1 to 10 amino acids, or 1 to 5 amino acids. In some embodiments, the Kgp or RgpA K1 adhesin domain is truncated by 30 amino acids. In some embodiments, the Kgp or RgpA K1 adhesin domain is truncated by 25 amino acids. In some embodiments, the Kgp or RgpA K1 adhesin domain is truncated by 20 amino acids. In some embodiments, the Kgp or RgpA K1 adhesin domain is truncated by 15 amino acids. In some embodiments, the Kgp or RgpA K1 adhesin domain is truncated by 10 amino acids. In some embodiments, the Kgp or RgpA K1 adhesin domain is truncated by 5 amino acids.
[0343] In some embodiments, the truncated Kgp K1 adhesin domain contains the sequence GTTTLSESF (SEQ ID NO:191).
[0344] In some embodiments, the truncated RgpA K1 adhesin domain contains the sequence of GTTTLSESF (SEQ ID NO: 192).
[0345] As shown in Figure 2, in the wild-type Kgp and RgpA sequences, the C-terminal portion of ABM3 overlaps with the N-terminal portion of the K1 adhesin domain. Therefore, in some embodiments, the Kgp portion containing ABM3 overlaps with at least a portion of the Kgp K1 adhesin domain (e.g., the eight C-terminal residues of the Kgp portion containing ABM3 are also the eight N-terminal residues of the Kgp K1 adhesin domain). In some embodiments, the RgpA portion containing ABM3 overlaps with at least a portion of the Kgp K1 adhesin domain (e.g., the nine C-terminal residues of the RgpA portion containing ABM3 are also the nine N-terminal residues of the RgpA K1 adhesin domain).
[0346] Table 15 provides examples of sequences that can be used according to the present invention, wherein the Kgp or RgpA portion of ABM3 overlaps with the Kgp or RgpA K1 adhesin domain.
[0347] Table 15: Examples of K1 adhesin domain sequences and ABM3 sequences
[0348]
[0349] Therefore, in some embodiments, the Kgp portion comprising ABM3 and the Kgp K1 adhesin domain together comprise a sequence of SEQ ID NO: 93 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it.
[0350] In some embodiments, the Kgp portion comprising ABM3 and the Kgp K1 adhesin domain together comprise a sequence of SEQ ID NO: 94 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it.
[0351] In some embodiments, the Kgp portion comprising ABM3 and the Kgp K1 adhesin domain together comprise a sequence of SEQ ID NO: 103 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it.
[0352] Variants of the Kgp or RgpA K1 adhesin domain can also be used in this invention. Such variants can remove glycosylation sites, as described elsewhere herein.
[0353] In addition to at least a portion of the Kgp and / or RgpA K1 adhesin domains, the nucleic acids and peptides of the present invention may also contain at least a portion of additional cleaved adhesin domains. Containing at least a portion of the K2 adhesin domain allows the resulting peptide to form a structure more similar to that of wild-type gingival protease, thereby providing additional three-dimensional epitopes that can be used to elicit an immune response. Alternatively or additionally, containing at least a portion of the K2 adhesin domain may mean that the peptide is capable of eliciting antibodies specific to the K2 domain, which are capable of inhibiting the K2-specific function of Kgp and / or RgpA. Therefore, in some embodiments, the nucleic acids and peptides of the present invention may contain at least a portion of the Kgp K2 adhesin domain. In some embodiments, the nucleic acids and peptides of the present invention may contain at least a portion of the RgpA K2 adhesin domain.
[0354] In some embodiments, the Kgp or RgpA K2 adhesin domain is full-length. For example, the Kgp K2 adhesin domain present in the Kgp of *Porphyromonas gingivalis* strain W50 is 172 amino acids long. Therefore, in some embodiments, the full-length Kgp K2 adhesin domain is at least 172 amino acids long (e.g., 172 amino acids in length). For example, the RgpA K2 adhesin domain present in the RgpA of *Porphyromonas gingivalis* strain W50 is 172 amino acids long. Therefore, in some embodiments, the full-length RgpA K2 adhesin domain is at least 172 amino acids long (e.g., 172 amino acids in length).
[0355] The length of the Kgp K2 adhesin domain in the Kgp of other *Porphyromonas gingivalis* strains may differ from the length of the Kgp K2 adhesin domain in the Kgp of *Porphyromonas gingivalis* strain W50. Similarly, the length of the RgpA K2 domain in the Kgp of other *Porphyromonas gingivalis* strains may differ from the length of the RgpA K2 domain in the RgpA region of *Porphyromonas gingivalis* strain W50.
[0356] Therefore, in some embodiments, the full-length Kgp or RgpA K2 adhesin domain is at least 168 amino acids long (e.g., 168 amino acids). In some embodiments, the full-length Kgp or RgpA K2 adhesin domain is at least 169 amino acids long (e.g., 169 amino acids). In some embodiments, the full-length Kgp or RgpA K2 adhesin domain is at least 170 amino acids long (e.g., 170 amino acids). In some embodiments, the full-length Kgp or RgpA K2 adhesin domain is at least 171 amino acids long (e.g., 171 amino acids). In some embodiments, the full-length Kgp or RgpA K2 adhesin domain is at least 171 amino acids long (e.g., 171 amino acids). In some embodiments, the full-length Kgp or RgpA K2 adhesin domain is at least 176 amino acids long (e.g., 176 amino acids). In some embodiments, the length of the full-length Kgp or RgpA K2 adhesin domain is at least 178 amino acids (e.g., 178 amino acids).
[0357] Truncating the Kgp or RgpA K2 adhesin domain can also be done without significantly altering the properties of the resulting peptide; for example, the resulting peptide can still elicit antibodies that block Kgp and / or RgpA adhesion function. Therefore, in some embodiments, at least a portion of the Kgp K2 adhesin domain is a truncated Kgp K2 adhesin domain. In some embodiments, at least a portion of the RgpA K2 adhesin domain is a truncated RgpA K2 adhesin domain.
[0358] Therefore, in some embodiments, at least a portion of the Kgp or RgpA K2 adhesin domain is a truncated Kgp or RgpA K2 adhesin domain, wherein the truncated Kgp or RgpA K2 adhesin domain is truncated by 1 to 35 amino acids. In some such embodiments, the Kgp K2 adhesin domain is truncated by 1 to 30 amino acids, 1 to 25 amino acids, 1 to 20 amino acids, 1 to 15 amino acids, 1 to 10 amino acids, or 1 to 5 amino acids. In some such embodiments, the RgpA K2 adhesin domain is truncated by 1 to 30 amino acids, 1 to 25 amino acids, 1 to 20 amino acids, 1 to 15 amino acids, 1 to 10 amino acids, or 1 to 5 amino acids. In some embodiments, the Kgp or RgpA K2 adhesin domain is truncated by 30 amino acids. In some embodiments, the Kgp or RgpA K2 adhesin domain is truncated by 25 amino acids. In some embodiments, the Kgp or RgpA K2 adhesin domain is truncated by 20 amino acids. In some embodiments, the Kgp or RgpA K2 adhesin domain is truncated by 15 amino acids. In some embodiments, the Kgp or RgpA K2 adhesin domain is truncated by 10 amino acids. In some embodiments, the Kgp or RgpA K2 adhesin domain is truncated by 5 amino acids.
[0359] In some embodiments, at least a portion of the Kgp or RgpA K2 adhesin domain is derived from *Porphyromonas gingivalis* strain W50. In *Porphyromonas gingivalis* strain W50, the Kgp K2 adhesin domain has the sequence of SEQ ID NO: 187. Therefore, in some embodiments, at least a portion of the Kgp K2 adhesin domain comprises at least a portion of SEQ ID NO: 187 or a sequence having at least 70% (e.g., at least 90% or 95%) identity with it. For example, at least a portion of the Kgp K2 adhesin domain comprises the sequence of SEQ ID NO: 187 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it. In *Porphyromonas gingivalis* strain W50, the RgpA K2 adhesin domain has the sequence of SEQ ID NO: 189. Therefore, in some embodiments, at least a portion of the RgpA K2 adhesin domain comprises at least a portion of SEQ ID NO: 189 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it. For example, at least a portion of the RgpA K2 adhesin domain contains a sequence of SEQ ID NO: 189 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90% or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%) identity with it.
[0360] Table 16 provides examples of K2 adherentin domain sequences that can be used according to the present invention.
[0361] Table 16 Examples of K2 adherentin domain sequences.
[0362]
[0363] In some embodiments, at least a portion of the Kgp K2 adhesin domain comprises at least a portion of SEQ ID NO: 96 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it. For example, at least a portion of the Kgp K2 adhesin domain comprises the sequence of SEQ ID NO: 96 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it.
[0364] In some embodiments, at least a portion of the Kgp K2 adhesin domain comprises at least a portion of SEQ ID NO: 188 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it. For example, at least a portion of the Kgp K2 adhesin domain comprises the sequence of SEQ ID NO: 188 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it.
[0365] In some embodiments, at least a portion of the RgpA K2 adhesin domain comprises at least a portion of SEQ ID NO: 104 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it. For example, at least a portion of the RgpA K2 adhesin domain comprises the sequence of SEQ ID NO: 104 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it.
[0366] In some embodiments, at least a portion of the RgpA K2 adhesin domain comprises at least a portion of SEQ ID NO: 190 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it. For example, at least a portion of the RgpA K2 adhesin domain comprises the sequence of SEQ ID NO: 190 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it.
[0367] The inventors have discovered that nucleic acids and peptides containing a full-length K2 adherein domain may be particularly advantageous in inducing an immune response. This may be because peptides containing a full-length K2 adherein domain can fold into a three-dimensional structure similar to the wild-type three-dimensional structure of the K2 adherein domain, thereby enabling the construct to induce the production of antibodies that recognize conformational epitopes within the K2 adherein domain. Therefore, in some embodiments, at least a portion of the K2 adherein domain comprises a full-length K2 adherein domain. In some embodiments, at least a portion of the RgpA K2 adherein domain comprises a full-length RgpA K2 adherein domain.
[0368] A full-length Kgp or RgpA K2 adhesin domain refers to a Kgp or RgpA K2 adhesin domain that has not been truncated relative to the corresponding wild-type K2 adhesin domain. Therefore, in some embodiments, at least a portion of the Kgp K2 adhesin domain is a full-length Kgp K2 adhesin domain, having the same length as the corresponding wild-type Kgp K2 adhesin domain. In some embodiments, at least a portion of the RgpA K2 adhesin domain is a full-length RgpA K2 adhesin domain, having the same length as the corresponding wild-type RgpA K2 adhesin domain.
[0369] For example, the Kgp K2 adhesin domain in the Kgp of *Porphyromonas gingivalis* strain W50 is 172 amino acids long. Therefore, in some embodiments, the full-length Kgp K2 adhesin domain is at least 172 amino acids long (e.g., 172 amino acids in length). The K2 adhesin domain in the RgpA of *Porphyromonas gingivalis* strain W50 is also 172 amino acids long. Therefore, in some embodiments, the full-length RgpA K2 adhesin domain is at least 172 amino acids long (e.g., 172 amino acids in length).
[0370] Variants of the Kgp or RgpA K1 adhesin domain can also be used in this invention. Such variants can remove glycosylation sites, as described elsewhere herein.
[0371] In some embodiments, the nucleic acid or polypeptide comprises at least a portion of a Kgp K1 adhesin domain and at least a portion of a Kgp K2 adhesin domain. In some such embodiments, at least a portion of the Kgp K1 adhesin domain and at least a portion of the Kgp K2 adhesin domain each comprise a sequence as shown in Table 17 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it.
[0372] Table 17: Combinations of K1 and K2 adhesin domain sequences
[0373]
[0374] In some embodiments, the nucleic acid or polypeptide comprises at least a portion of a Kgp K1 adhesin domain, at least a portion of a Kgp K2 adhesin domain, and at least a portion of an RgpA K1 adhesin domain. In some such embodiments, at least a portion of the Kgp K1 adhesin domain and at least a portion of the Kgp K2 adhesin domain each comprise a sequence as shown in Table 17 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with the KgpA K1 adhesin domain, while the RgpA K1 adhesin domain comprises the sequence of SEQ ID NO: 103.
[0375] In some embodiments, the nucleic acid or polypeptide comprises at least a portion of an RgpAK1 adhesin domain and at least a portion of an RgpAK2 adhesin domain. In some embodiments, at least a portion of the RgpAK1 adhesin domain and at least a portion of the RgpAK2 adhesin domain each comprise a sequence as shown in Table 18 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it.
[0376] Table 18: Combinations of RgpA K1 and RgpA K2 adhesin domain sequences
[0377]
[0378] Localization of gingival protease domain and sequence motif
[0379] The domains described in any of the foregoing sections (i.e., the first Kgp portion containing ABM1, the first portion containing ABM2, the second portion containing ABM1, the second portion containing ABM2, at least a portion of DUF2436, at least a portion of the Kgp catalytic domain, and at least a portion of the Kgp K1 adhesin domain) can be combined to generate or encode the polypeptide or nucleic acid of the polypeptide of the present invention.
[0380] The modular nature of Kgp structures means that different gingival protease domains of nucleic acids and peptides can be arranged in any order. However, typically, the order of the gingival protease domains is the same as that in wild-type Kgp and RgpA proteins. Arranging the domains in the same order as wild-type Kgp and RgpA proteins can enhance peptide folding in a manner more closely similar to wild-type Kgp and RgpA, thereby allowing for the preservation of, for example, conformational epitopes.
[0381] from Figure 1 As can be seen, the domain order in wild-type Kgp and RgpA is from N-terminus to C-terminus: propeptide; catalytic domain; first part containing ABM1; DUF2436; first part containing ABM2; second part containing ABM1; part containing ABM3; K1; K2; second part containing ABM2; K3; C-terminal domain. For embodiments containing subsets of these domains, the present domains are located in the same N-terminus to C-terminus order, where any domains are omitted from the wild-type sequence.
[0382] For example, in some embodiments, the polypeptide or nucleic acid encoding the polypeptide of the present invention comprises: i) at least a portion of a Kgp catalytic domain; ii) at least a portion of Kgp DUF2436; iii) at least a portion of a Kgp K1 adhesin domain; iv) a first Kgp portion comprising ABM1 and a first Kgp portion comprising ABM2; v) a second Kgp portion comprising ABM1 and a second Kgp portion comprising ABM2; and vi) a Kgp portion comprising ABM3; wherein these domains are positioned from the N-terminus to the C-terminus of the polypeptide in the following order: Kgp catalytic domain; first Kgp portion comprising ABM1; Kgp DUF2436; first Kgp portion comprising ABM2; second Kgp portion comprising ABM1; Kgp portion comprising ABM3; Kgp K1; and second Kgp portion comprising ABM2.
[0383] In some embodiments, the polypeptide or nucleic acid encoding the polypeptide of the present invention comprises: i) at least a portion of an RgpA catalytic domain; ii) at least a portion of RgpA DUF2436; iii) at least a portion of an RgpA K1 adhesin domain; iv) a first RgpA portion comprising ABM1 and a first RgpA portion comprising ABM2; v) a second RgpA portion comprising ABM1 and a second RgpA portion comprising ABM2; vi) an RgpA portion comprising ABM3; vii) at least a portion of an RgpA K2 adhesin domain; wherein these domains are positioned from the N-terminus to the C-terminus of the polypeptide in the following order: RgpA catalytic domain; first RgpA portion comprising ABM1; RgpA DUF2436; first RgpA portion comprising ABM2; second RgpA portion comprising ABM1; RgpA portion comprising ABM3; RgpA K1; RgpA K2; second RgpA portion comprising ABM2.
[0384] In some embodiments, the polypeptide or nucleic acid encoding the polypeptide of the present invention comprises: i) at least a portion of an RgpA catalytic domain; ii) at least a portion of RgpA DUF2436; iii) at least a portion of an RgpA K1 adhesin domain; iv) a first RgpA portion comprising ABM1 and a first RgpA portion comprising ABM2; v) a second RgpA portion comprising ABM1 and a second RgpA portion comprising ABM2; vi) an RgpA portion comprising ABM3; vii) at least a portion of an RgpA K2 adhesin domain; wherein these domains are positioned from the N-terminus to the C-terminus of the polypeptide in the following order: a first RgpA portion comprising ABM1; RgpA DUF2436; a first RgpA portion comprising ABM2; a second RgpA portion comprising ABM1; an RgpA portion comprising ABM3; RgpA K1; RgpA K2; a second RgpA portion comprising ABM2; and an RgpA catalytic domain.
[0385] In some embodiments, the polypeptide or nucleic acid encoding the polypeptide of the present invention comprises: i) at least a portion of a Kgp catalytic domain; ii) at least a portion of Kgp DUF2436; iii) at least a portion of a Kgp K1 adhesin domain; iv) a first Kgp portion comprising ABM1 and a first Kgp portion comprising ABM2; v) a second Kgp portion comprising ABM1 and a second Kgp portion comprising ABM2; vi) a Kgp portion comprising ABM3; and vii) at least a portion of a RgpA catalytic domain, wherein these domains are positioned from the N-terminus to the C-terminus of the polypeptide in the following order: Kgp catalytic domain; first Kgp portion comprising ABM1; Kgp DUF2436; first Kgp portion comprising ABM2; second Kgp portion comprising ABM1; Kgp portion comprising ABM3; Kgp K1; second Kgp portion comprising ABM2; and RgpA catalytic domain.
[0386] In some embodiments, the polypeptide or nucleic acid encoding the polypeptide of the present invention comprises: i) at least a portion of a Kgp catalytic domain; ii) at least a portion of Kgp DUF2436; iii) at least a portion of a Kgp K1 adhesin domain; iv) a first Kgp portion comprising ABM1 and a first Kgp portion comprising ABM2; v) a second Kgp portion comprising ABM1 and a second Kgp portion comprising ABM2; vi) a Kgp portion comprising ABM3; vii) at least a portion of a Kgp K2 adhesin domain; and viii) at least a portion of a RgpA catalytic domain, wherein these domains are positioned from the N-terminus to the C-terminus of the polypeptide in the following order: Kgp catalytic domain; first Kgp portion comprising ABM1; Kgp DUF2436; first Kgp portion comprising ABM2; second Kgp portion comprising ABM1; Kgp portion comprising ABM3; Kgp K1; Kgp K2; the second Kgp moiety containing ABM2; the RgpA catalytic domain.
[0387] In some embodiments, the polypeptide or nucleic acid encoding the polypeptide of the present invention comprises: i) at least a portion of a Kgp catalytic domain; ii) at least a portion of Kgp DUF2436; iii) at least a portion of a Kgp K1 adhesin domain; iv) a first Kgp portion comprising ABM1 and a first Kgp portion comprising ABM2; v) a second Kgp portion comprising ABM1 and a second Kgp portion comprising ABM2; vi) a Kgp portion comprising ABM3; vii) at least a portion of a RgpA K2 adhesin domain; and viii) at least a portion of a RgpA catalytic domain, wherein these domains are positioned from the N-terminus to the C-terminus of the polypeptide in the following order: Kgp catalytic domain; first Kgp portion comprising ABM1; Kgp DUF2436; first Kgp portion comprising ABM2; second Kgp portion comprising ABM1; Kgp portion comprising ABM3; Kgp K1; RgpA K2; the second Kgp moiety containing ABM2; the RgpA catalytic domain.
[0388] In some embodiments, the polypeptide or nucleic acid encoding the polypeptide of the present invention comprises: i) at least a portion of a Kgp catalytic domain; ii) at least a portion of Kgp DUF2436; iii) at least a portion of a Kgp K1 adhesin domain; iv) a first Kgp portion comprising ABM1 and a first Kgp portion comprising ABM2; v) a second Kgp portion comprising ABM1 and a second Kgp portion comprising ABM2; vi) a Kgp portion comprising ABM3; vii) at least a portion of a Kgp K2 adhesin domain; and viii) at least a portion of a RgpA catalytic domain; ix) a first RgpA portion comprising ABM1 and a first RgpA portion comprising ABM2; x) at least a portion of RgpA DUF2436, wherein these domains are positioned from the N-terminus to the C-terminus of the polypeptide in the following order: Kgp catalytic domain; first Kgp portion comprising ABM1; Kgp DUF2436; containing a first Kgp portion of ABM2; containing a second Kgp portion of ABM1; containing a Kgp portion of ABM3; Kgp K1; Kgp K2; containing a second Kgp portion of ABM2; containing a first RgpA portion of ABM1; RgpA DUF2436; containing a first RgpA portion of ABM2; RgpA catalytic domain.
[0389] In some embodiments, the polypeptide or nucleic acid encoding the polypeptide of the present invention comprises: i) at least a portion of a Kgp catalytic domain; ii) at least a portion of Kgp DUF2436; iii) at least a portion of a Kgp K1 adhesin domain; iv) a first Kgp portion comprising ABM1 and a first Kgp portion comprising ABM2; v) a second Kgp portion comprising ABM1 and a second Kgp portion comprising ABM2; vi) a Kgp portion comprising ABM3; vii) at least a portion of a RgpA K2 adhesin domain; and viii) at least a portion of a RgpA catalytic domain; ix) a first RgpA portion comprising ABM1 and a first RgpA portion comprising ABM2; x) at least a portion of RgpA DUF2436, wherein these domains are positioned from the N-terminus to the C-terminus of the polypeptide in the following order: Kgp catalytic domain; first Kgp portion comprising ABM1; Kgp DUF2436; containing a first Kgp portion of ABM2; containing a second Kgp portion of ABM1; containing a Kgp portion of ABM3; Kgp K1; RgpA K2; containing a second Kgp portion of ABM2; containing a first RgpA portion of ABM1; RgpA DUF2436; containing a first RgpA portion of ABM2; RgpA catalytic domain.
[0390] Table 19 provides examples of polypeptides or nucleic acids encoding polypeptides of the present invention. Other examples of polypeptides or nucleic acids encoding polypeptides of the present invention are the sequences provided in Table 19, wherein the N-terminal methionine is absent. The table also provides nucleic acid sequences encoding polypeptides, which also constitute a part of the present invention.
[0391] Table 19: Examples of polypeptides of the present invention or polypeptides encoded by the nucleic acids of the present invention
[0392]
[0393] In some embodiments, the polypeptide comprises a sequence according to SEQ ID NO: 1 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90% or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%) identity with it.
[0394] In some embodiments, the polypeptide comprises a sequence according to SEQ ID NO: 6 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90% or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%) identity with it.
[0395] In some embodiments, the polypeptide comprises a sequence according to SEQ ID NO: 11 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90% or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%) identity with it.
[0396] In some embodiments, the polypeptide comprises a sequence according to SEQ ID NO: 16 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90% or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%) identity with it.
[0397] In some embodiments, the polypeptide comprises a sequence according to SEQ ID NO: 367 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it. In some embodiments, the polypeptide comprises a sequence according to SEQ ID NO: 371 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it.
[0398] In some embodiments, the polypeptide comprises a sequence according to SEQ ID NO: 375 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90% or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%) identity with it.
[0399] In some embodiments, the polypeptide comprises a sequence according to SEQ ID NO: 379 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90% or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%) identity with it.
[0400] In some embodiments, the polypeptide comprises a sequence according to SEQ ID NO: 383 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90% or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%) identity with it.
[0401] In some embodiments, the polypeptide comprises a sequence according to SEQ ID NO: 397 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90% or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%) identity with it.
[0402] In some embodiments, the polypeptide comprises a sequence according to SEQ ID NO: 403 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90% or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%) identity with it.
[0403] In some embodiments, the polypeptide comprises a sequence according to SEQ ID NO: 415 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90% or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%) identity with it.
[0404] In some embodiments, the polypeptide comprises a sequence according to SEQ ID NO: 409 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90% or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%) identity with it.
[0405] The N-terminal methionine in any of the above embodiments may be omitted from the polypeptide. Therefore, in some embodiments, the polypeptide comprises a sequence according to SEQ ID NO: 254 (i.e., SEQ ID NO: 1 without the N-terminal methionine) or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it.
[0406] In some embodiments, the polypeptide comprises a sequence according to SEQ ID NO: 259 (i.e., SEQ ID NO: 6 without an N-terminal methionine) or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it.
[0407] In some embodiments, the polypeptide comprises a sequence according to SEQ ID NO: 264 (i.e., SEQ ID NO: 11 without an N-terminal methionine) or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it.
[0408] In some embodiments, the polypeptide comprises a sequence according to SEQ ID NO: 269 (i.e., SEQ ID NO: 16 without an N-terminal methionine) or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it.
[0409] In some embodiments, the polypeptide comprises a sequence according to SEQ ID NO: 368 (i.e., SEQ ID NO: 367 without an N-terminal methionine) or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it.
[0410] In some embodiments, the polypeptide comprises a sequence according to SEQ ID NO: 372 (i.e., SEQ ID NO: 371 without an N-terminal methionine) or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it.
[0411] In some embodiments, the polypeptide comprises a sequence according to SEQ ID NO: 376 (i.e., SEQ ID NO: 375 without an N-terminal methionine) or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it.
[0412] In some embodiments, the polypeptide comprises a sequence according to SEQ ID NO: 380 (i.e., SEQ ID NO: 379 without an N-terminal methionine) or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it.
[0413] In some embodiments, the polypeptide comprises a sequence according to SEQ ID NO: 384 (i.e., SEQ ID NO: 383 without an N-terminal methionine) or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it.
[0414] In some embodiments, the polypeptide comprises a sequence according to SEQ ID NO: 398 (i.e., SEQ ID NO: 397 without an N-terminal methionine) or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it.
[0415] In some embodiments, the polypeptide comprises a sequence according to SEQ ID NO: 404 (i.e., SEQ ID NO: 403 without an N-terminal methionine) or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it.
[0416] In some embodiments, the polypeptide comprises a sequence according to SEQ ID NO: 416 (i.e., SEQ ID NO: 415 without an N-terminal methionine) or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it.
[0417] In some embodiments, the polypeptide comprises a sequence according to SEQ ID NO: 410 (i.e., SEQ ID NO: 409 without an N-terminal methionine) or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it.
[0418] In some embodiments, the nucleic acid encoding the polypeptide comprises the sequence according to SEQ ID NO: 21.
[0419] In some embodiments, the nucleic acid encoding the polypeptide comprises the sequence according to SEQ ID NO: 22.
[0420] In some embodiments, the nucleic acid encoding the polypeptide comprises the sequence according to SEQ ID NO: 31.
[0421] In some embodiments, the nucleic acid encoding the polypeptide comprises the sequence according to SEQ ID NO: 32.
[0422] In some embodiments, the nucleic acid encoding the polypeptide comprises the sequence according to SEQ ID NO: 41.
[0423] In some embodiments, the nucleic acid encoding the polypeptide comprises the sequence according to SEQ ID NO: 42.
[0424] In some embodiments, the nucleic acid encoding the polypeptide comprises the sequence according to SEQ ID NO: 51.
[0425] In some embodiments, the nucleic acid encoding the polypeptide comprises the sequence according to SEQ ID NO: 52.
[0426] In some embodiments, the amino acid sequence of the polypeptide of the present invention is encoded by a codon-optimized polynucleotide sequence.
[0427] Variants of peptides
[0428] The sequence of a polypeptide, as described herein, may contain one or more mutations or modifications.
[0429] In some embodiments, the polypeptide as described herein may contain one or more conserved amino acid substitutions.
[0430] Mutations at glycosylation sites
[0431] Glycosylation can occur in eukaryotic cells but not in prokaryotic cells. As used herein, “glycosylation” refers to the addition of a sugar unit to a protein. In particular, N-linked glycosylation refers to the attachment of a glycan to the amide nitrogen of an asparagine (Asn;N) residue in a protein. The attachment process produces a glycosylated protein. This glycan can be a polysaccharide. Glycosylation can occur at any asparagine residue in a protein that is accessible and recognized by glycosylation enzymes after protein translation, and is most common at accessible asparagine residues that are part of an NXS / T motif, where the second amino acid residue following the asparagine is a serine or threonine. Non-human glycosylation patterns can render peptides undesirable reactivity when used to induce antibodies. Additionally, glycosylation of normally unglycosylated peptides (such as those described herein) can alter their immunogenicity. For example, glycosylation can mask important immunogenic epitopes within a protein. Therefore, in order to reduce or eliminate glycosylation, asparagine residues or serine / threonine residues can be modified, for example by replacing them with another amino acid.
[0432] In some embodiments, the polypeptide as described herein contains at least one mutated glycosylation site, such as at least one mutated N-linked glycosylation site and / or at least one O-linked glycosylation site. In some embodiments, one or more (e.g., all) of the N-glycosylation sites in the polypeptide as described herein are removed. Removal of N-glycosylation sites can reduce the glycosylation of the polypeptide. In some embodiments, the polypeptide as described herein has reduced glycosylation relative to the corresponding wild-type polypeptide. Reduced glycosylation relative to the corresponding wild-type polypeptide can be observed in one or all domains of the polypeptide. For example, at least a portion of the Kgp catalytic domain can have reduced glycosylation relative to the corresponding wild-type portion of the Kgp catalytic domain. In some embodiments, all domains of the polypeptide have reduced glycosylation relative to the corresponding wild-type domains. Removal of N-glycosylation sites can eliminate the N-glycosylation of the polypeptide.
[0433] In some embodiments, the modification includes substitution of one or more (e.g., all) of the N, S, and T amino acids in the NXS / T sequence motif, where X corresponds to any amino acid. In some embodiments, the N, S, or T amino acid is substituted with a conserved amino acid.
[0434] Exemplary mutated glycosylation sites within Kgp or RgpA that can be mutated are shown in Tables 20 and 21 below. Therefore, in any nucleic acid or polypeptide of the present invention disclosed herein, one or more (e.g., all) mutated sites within Kgp correspond to the positions of the wild-type sequence of SEQ ID NO: 157 specified in Table 20. In any nucleic acid or polypeptide of the present invention disclosed herein, one or more (e.g., all) mutated sites within RgpA correspond to one or more (e.g., all) positions of the wild-type sequence of SEQ ID NO: 158 specified in Table 21.
[0435] Table 20. Exemplary mutant glycosylation sites in Kgp from Porphyromonas gingivalis strain W50.
[0436]
[0437] Table 21. Exemplary mutant glycosylation sites in RgpA from Porphyromonas gingivalis strain W50.
[0438]
[0439] In some embodiments, the polypeptides described herein contain one or more (e.g., all) of the mutations shown in Table 20. In some embodiments, the polypeptides described herein contain one or more (e.g., all) of the mutations shown in Table 21. In some embodiments, the polypeptides described herein contain one or more (e.g., all) of the mutations shown in Table 20 and one or more (e.g., all) of the mutations shown in Table 21.
[0440] In some embodiments, the Kgp-based peptides described herein contain a single amino acid substitution at one or more (e.g., all) of the N-glycosylation sites corresponding to the *Porphyromonas gingivalis* Kgp peptide (e.g., SEQ ID NO: 157). In some embodiments, the Kgp-based peptides described herein contain one or more (e.g., all) amino acid substitutions at positions 284, 442, 574, 645, 691, 950, 968, 1089, 1316, and 1390 corresponding to SEQ ID NO: 157. In some embodiments, the Kgp-based peptides described herein contain one or more (e.g., all) amino acid substitutions at positions 284, 442, 574, 645, 691, 950, 968, and 1089 corresponding to SEQ ID NO: 157. In some embodiments, the Kgp-based peptides described herein contain one or more (e.g., all) amino acid substitutions at positions 284, 442, 574, 645, 691, 950, and 968 corresponding to SEQ ID NO: 157. In some embodiments, the Kgp-based peptides described herein contain one or more (e.g., all) amino acid substitutions at positions 442, 691, 950, 1089, and 968 corresponding to SEQ ID NO: 157. In some embodiments, the Kgp-based peptides described herein contain one or more (e.g., all) amino acid substitutions at positions 442, 691, 950, and 968 corresponding to SEQ ID NO: 157.
[0441] In some embodiments, the RgpA-based peptides described herein contain a single amino acid substitution at one or more (e.g., all) of the N-glycosylation sites corresponding to the native Porphyromonas gingivalis RgpA peptide (e.g., SEQ ID NO: 158). In some embodiments, the RgpA-based peptides described herein contain one or more (e.g., all) amino acid substitutions at positions corresponding to SEQ ID NO: 158, such as 363, 434 and 436, 508, 592, 597, 623, 629, 635, 671, 691, 766, 931, 947, 1298, and 1372. In some embodiments, the RgpA-based peptides described herein contain one or more (e.g., all) amino acid substitutions at positions 363, 436, 508, 592, 597, 623, 629, 635, 671, 691, 766, 931, 947, 1298, and 1372 corresponding to SEQ ID NO: 158. In some embodiments, the RgpA-based peptides described herein contain one or more (e.g., all) amino acid substitutions at positions 434, 671, 69, 766, 931, 947, 1298, and 1372 of SEQ ID NO: 158.
[0442] In some embodiments, the Kgp and RgpA-based peptides described herein contain a single amino acid substitution at one or more (e.g., all) of the N-glycosylation sites corresponding to the *Porphyromonas gingivalis* Kgp peptide (e.g., SEQ ID NO: 157) and the *Porphyromonas gingivalis* RgpA peptide (e.g., SEQ ID NO: 158). In some embodiments, the Kgp and RgpA-based peptides described herein contain a single amino acid substitution at one or more (e.g., all) of the positions corresponding to SEQ ID NO: 157 (442, 691, 950, 968, 1089, 1390) and SEQ ID NO: 158 (434). In some embodiments, the Kgp and RgpA-based peptides described herein contain a single amino acid substitution at one or more (e.g., all) of the positions corresponding to SEQ ID NO: 157 (442, 691, 950, 968, 1089, 1390) and SEQ ID NO: 158 (434). In some embodiments, the Kgp and RgpA-based peptides described herein contain a single amino acid substitution at one or more (e.g., all) positions corresponding to SEQ ID NO: 157 442, 691, 950, 968, 1089, 1316, 1390 and SEQ ID NO: 158 434. In some embodiments, the Kgp and RgpA-based peptides described herein contain a single amino acid substitution at one or more (e.g., all) positions corresponding to SEQ ID NO: 157 442, 691, 950, 968, 1089, 1316, 1390 and SEQ ID NO: 158 434, 671, 691, 766.
[0443] Table 22 provides examples of the polypeptides of the present invention.
[0444] Table 22 Examples of polypeptides of the present invention or polypeptides encoded by the nucleic acids of the present invention.
[0445]
[0446] In some embodiments, the polypeptide comprises a sequence according to SEQ ID NO: 359 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90% or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%) identity with it.
[0447] In some embodiments, the polypeptide comprises a sequence according to SEQ ID NO: 361 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90% or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%) identity with it.
[0448] In some embodiments, the polypeptide comprises a sequence according to SEQ ID NO: 363 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90% or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%) identity with it.
[0449] In some embodiments, the polypeptide comprises a sequence according to SEQ ID NO: 365 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90% or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%) identity with it.
[0450] In some embodiments, the polypeptide comprises a sequence according to SEQ ID NO: 369 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90% or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%) identity with it.
[0451] In some embodiments, the polypeptide comprises a sequence according to SEQ ID NO: 373 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90% or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%) identity with it.
[0452] In some embodiments, the polypeptide comprises a sequence according to SEQ ID NO: 377 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90% or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%) identity with it.
[0453] In some embodiments, the polypeptide comprises a sequence according to SEQ ID NO: 381 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90% or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%) identity with it.
[0454] In some embodiments, the polypeptide comprises a sequence according to SEQ ID NO: 385 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90% or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%) identity with it.
[0455] In some embodiments, the polypeptide comprises a sequence according to SEQ ID NO: 387 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90% or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%) identity with it.
[0456] In some embodiments, the polypeptide comprises a sequence according to SEQ ID NO: 389 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90% or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%) identity with it.
[0457] In some embodiments, the polypeptide comprises a sequence according to SEQ ID NO: 391 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90% or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%) identity with it.
[0458] In some embodiments, the polypeptide comprises a sequence according to SEQ ID NO: 393 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90% or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%) identity with it.
[0459] In some embodiments, the polypeptide comprises a sequence according to SEQ ID NO: 395 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90% or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%) identity with it.
[0460] In some embodiments, the polypeptide comprises a sequence according to SEQ ID NO: 399 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90% or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%) identity with it.
[0461] In some embodiments, the polypeptide comprises a sequence according to SEQ ID NO: 405 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90% or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%) identity with it.
[0462] In some embodiments, the polypeptide comprises a sequence according to SEQ ID NO: 417 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90% or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%) identity with it.
[0463] In some embodiments, the polypeptide comprises a sequence according to SEQ ID NO: 411 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90% or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%) identity with it.
[0464] In some embodiments, the polypeptide comprises a sequence according to SEQ ID NO: 360 (i.e., SEQ ID NO: 359 without an N-terminal methionine) or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it.
[0465] In some embodiments, the polypeptide comprises a sequence according to SEQ ID NO: 362 (i.e., SEQ ID NO: 361 without an N-terminal methionine) or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it.
[0466] In some embodiments, the polypeptide comprises a sequence according to SEQ ID NO: 364 (i.e., SEQ ID NO: 363 without an N-terminal methionine) or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it.
[0467] In some embodiments, the polypeptide comprises a sequence according to SEQ ID NO: 366 (i.e., SEQ ID NO: 365 without an N-terminal methionine) or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it.
[0468] In some embodiments, the polypeptide comprises a sequence according to SEQ ID NO: 370 (i.e., SEQ ID NO: 369 without an N-terminal methionine) or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it.
[0469] In some embodiments, the polypeptide comprises a sequence according to SEQ ID NO: 374 (i.e., SEQ ID NO: 373 without an N-terminal methionine) or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it.
[0470] In some embodiments, the polypeptide comprises a sequence according to SEQ ID NO: 378 (i.e., SEQ ID NO: 377 without an N-terminal methionine) or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it.
[0471] In some embodiments, the polypeptide comprises a sequence according to SEQ ID NO: 382 (i.e., SEQ ID NO: 381 without an N-terminal methionine) or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it.
[0472] In some embodiments, the polypeptide comprises a sequence according to SEQ ID NO: 386 (i.e., SEQ ID NO: 385 without an N-terminal methionine) or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it.
[0473] In some embodiments, the polypeptide comprises a sequence according to SEQ ID NO: 388 (i.e., SEQ ID NO: 387 without an N-terminal methionine) or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it.
[0474] In some embodiments, the polypeptide comprises a sequence according to SEQ ID NO: 390 (i.e., SEQ ID NO: 389 without an N-terminal methionine) or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it.
[0475] In some embodiments, the polypeptide comprises a sequence according to SEQ ID NO: 392 (i.e., SEQ ID NO: 391 without an N-terminal methionine) or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it.
[0476] In some embodiments, the polypeptide comprises a sequence according to SEQ ID NO: 394 (i.e., SEQ ID NO: 393 without an N-terminal methionine) or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it.
[0477] In some embodiments, the polypeptide comprises a sequence according to SEQ ID NO: 396 (i.e., SEQ ID NO: 395 without an N-terminal methionine) or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it.
[0478] In some embodiments, the polypeptide comprises a sequence according to SEQ ID NO: 400 (i.e., SEQ ID NO: 399 without an N-terminal methionine) or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it.
[0479] In some embodiments, the polypeptide comprises a sequence according to SEQ ID NO: 406 (i.e., SEQ ID NO: 405 without an N-terminal methionine) or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it.
[0480] In some embodiments, the polypeptide comprises a sequence according to SEQ ID NO: 418 (i.e., SEQ ID NO: 417 without an N-terminal methionine) or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it.
[0481] In some embodiments, the polypeptide comprises a sequence according to SEQ ID NO: 412 (i.e., SEQ ID NO: 411 without an N-terminal methionine) or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it.
[0482] Secretion signal peptide sequence
[0483] The polypeptides of the present invention as described herein may include a secretion signal peptide sequence. The secretion signal peptide may be cleaved during post-translational processing of the polypeptide described herein. Therefore, the mature form of the polypeptide may not include the secretion signal peptide sequence. However, the nucleotide sequence encoding the secretion signal peptide sequence may be present in the nucleic acid described herein that encodes the polypeptide described herein.
[0484] In some embodiments, the polypeptides of the present invention as described herein may comprise a viral or eukaryotic (e.g., human) secretory signal peptide (SS) sequence. Using a viral or eukaryotic secretory signal peptide sequence attached to the polypeptides described herein can provide numerous advantages for immunogenic compositions. When expressed from mRNA, particularly in eukaryotic cells, polypeptides of the present invention comprising the SS sequence can have increased extracellular expression relative to polypeptides without the SS sequence. Increased extracellular expression can promote higher immunogenicity, thereby enhancing vaccine efficacy.
[0485] Viral SS sequences can be found in publicly accessible databases (such as NCBI or UniProt databases), which include annotated viral peptide sequences and identify experimentally validated start and end positions of the SS.
[0486] In some embodiments, the SignalP algorithm can be used to predict the SS sequence and the location of the SS sequence cleavage site for a given known input peptide sequence. The SignalP algorithm (and more specifically SignalP v6.0) is described in further detail in Armenteros et al. (Nature Biotechnology. 37: 420-423. 2019), Teufel et al. (Nature Biotechnology. 40: 1023-1025. 2022), and services.healthtech.dtu.dk / services / SignalP-6.0 / , each of which is incorporated herein by reference in its entirety. The strength of the prediction is assessed based on a cumulative ranking score that considers the likelihood of typical features of the detected signal sequence (SS probability score) and the probability of cleavage at the cleavage site (cleavage probability score).
[0487] In some embodiments, the SS sequence is a viral SS sequence. In some embodiments, the viral secretion signal peptide sequence is derived from a viral sequence of a virus capable of infecting humans. The descriptions preceding "secretion signal peptide sequence" such as "influenza," "SARS-CoV-2," "varicella-zoster virus (VZV)," "measles," "rubella," "rabies," "Ebola," and "smallpox" indicate that the secretion signal peptide is derived from the virus corresponding to that name.
[0488] In some embodiments, the viral secretion signal peptide is derived from viral sequences selected from the group consisting of: influenza secretion signal peptide sequences, SARS-CoV-2 secretion signal peptide sequences, varicella-zoster virus (VZV) secretion signal peptide sequences, measles secretion signal peptide sequences, rubella secretion signal peptide sequences, mumps secretion signal peptide sequences, Ebola secretion signal peptide sequences, rabies secretion signal peptide sequences, and smallpox secretion signal peptide sequences. These specific signal peptides are derived from viral sequences in viruses that have been administered to humans as vaccines (live attenuated vaccines, inactivated vaccines, or mRNA vaccines) and have demonstrated a strong safety profile.
[0489] In some embodiments, the viral secretion signal peptide is selected from the group consisting of: influenza hemagglutinin (HA) secretion signal peptide sequence, SARS CoV-2 spike secretion signal peptide sequence, VZV gB secretion signal peptide sequence, VZV gE secretion signal peptide sequence, VZV gI secretion signal peptide sequence, VZV gK secretion signal peptide sequence, measles F-protein secretion signal peptide sequence, rubella E1 protein secretion signal peptide sequence, rubella E2 protein secretion signal peptide sequence, mumps F-protein secretion signal peptide sequence, Ebola GP protein secretion signal peptide sequence, rabies virus glycoprotein (rabies G) secretion signal peptide sequence, and smallpox 6kDa IC protein secretion signal peptide sequence.
[0490] In some embodiments, the viral secretion signal peptide comprises an HA secretion signal peptide sequence from influenza A or influenza B, preferably from influenza A.
[0491] In some embodiments, the viral secretion signal peptide comprises the signal peptide described in PCT / EP2023 / 062066, which is incorporated herein by reference in its entirety.
[0492] Table 23 below shows the amino acid sequences of exemplary viral secretion signal peptides disclosed herein. Table 23.1 below shows the amino acid sequences of exemplary viral secretion signal peptides derived from influenza A or B of this disclosure.
[0493] Table 23 Amino acid sequence of viral secretion signal peptide (SS)
[0494]
[0495] Table 23.1—Amino acid sequences of influenza A and B virus-specific viral secretion signal peptides (SS)
[0496]
[0497] In some embodiments, the secretory signal peptide has the sequence of SEQ ID NO: 67.
[0498] The secretion signal peptide sequence may be located at the N-terminus or C-terminus of the polypeptide described herein (e.g., at the N-terminus).
[0499] In some embodiments, the SS amino acid sequence is encoded by a codon-optimized polynucleotide sequence.
[0500] In some embodiments, the viral secretion signal peptide is linked to the prokaryotic antigen peptide via a linker.
[0501] Table 24 provides examples of polypeptides of the present invention that contain a secretory signal peptide. The table also provides the nucleic acid sequences encoding the polypeptides, which are also part of the present invention. The table also includes corresponding polypeptides with glycosylation sites mutated. These mutations in the polypeptides are examples of the glycosylation mutants discussed above.
[0502] Table 24: Examples of polypeptides of the present invention or polypeptides encoded by the nucleic acids of the present invention
[0503]
[0504] In some embodiments, the polypeptide comprises a sequence according to SEQ ID NO: 2 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90% or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%) identity with it.
[0505] In some embodiments, the polypeptide comprises a sequence according to SEQ ID NO: 7 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90% or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%) identity with it.
[0506] In some embodiments, the polypeptide comprises a sequence according to SEQ ID NO: 12 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90% or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%) identity with it.
[0507] In some embodiments, the polypeptide comprises a sequence according to SEQ ID NO: 17 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90% or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%) identity with it.
[0508] In some embodiments, the polypeptide comprises a sequence according to SEQ ID NO: 3 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90% or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%) identity with it.
[0509] In some embodiments, the polypeptide comprises a sequence according to SEQ ID NO: 279 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90% or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%) identity with it.
[0510] In some embodiments, the polypeptide comprises a sequence according to SEQ ID NO: 8 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90% or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%) identity with it.
[0511] In some embodiments, the polypeptide comprises a sequence according to SEQ ID NO: 13 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90% or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%) identity with it.
[0512] In some embodiments, the polypeptide comprises a sequence according to SEQ ID NO: 280 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90% or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%) identity with it.
[0513] In some embodiments, the polypeptide comprises a sequence according to SEQ ID NO: 297 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90% or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%) identity with it.
[0514] In some embodiments, the polypeptide comprises a sequence according to SEQ ID NO: 18 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90% or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%) identity with it.
[0515] In some embodiments, the polypeptide comprises a sequence according to SEQ ID NO: 73 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90% or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%) identity with it.
[0516] In some embodiments, the polypeptide comprises a sequence according to SEQ ID NO: 74 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90% or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%) identity with it.
[0517] In some embodiments, the polypeptide comprises a sequence according to SEQ ID NO: 75 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90% or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%) identity with it.
[0518] In some embodiments, the polypeptide comprises a sequence according to SEQ ID NO: 283 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90% or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%) identity with it.
[0519] In some embodiments, the polypeptide comprises a sequence according to SEQ ID NO: 76 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90% or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%) identity with it.
[0520] In some embodiments, the polypeptide comprises a sequence according to SEQ ID NO: 284 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90% or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%) identity with it.
[0521] In some embodiments, the polypeptide comprises a sequence according to SEQ ID NO: 401 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90% or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%) identity with it.
[0522] In some embodiments, the polypeptide comprises a sequence according to SEQ ID NO: 413 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90% or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%) identity with it.
[0523] In some embodiments, the polypeptide comprises a sequence according to SEQ ID NO: 77 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90% or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%) identity with it.
[0524] In some embodiments, the polypeptide comprises a sequence according to SEQ ID NO: 285 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90% or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%) identity with it.
[0525] In some embodiments, the polypeptide comprises a sequence according to SEQ ID NO: 407 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90% or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%) identity with it.
[0526] The N-terminal methionine in any of the above embodiments may be omitted from the polypeptide. Therefore, in some embodiments, the polypeptide comprises a sequence according to SEQ ID NO: 255 (i.e., SEQ ID NO: 2 without the N-terminal methionine) or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it.
[0527] In some embodiments, the polypeptide comprises a sequence according to SEQ ID NO: 260 (i.e., SEQ ID NO: 7 without an N-terminal methionine) or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it.
[0528] In some embodiments, the polypeptide comprises a sequence according to SEQ ID NO: 265 (i.e., SEQ ID NO: 12 without an N-terminal methionine) or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it.
[0529] In some embodiments, the polypeptide comprises a sequence according to SEQ ID NO: 270 (i.e., SEQ ID NO: 17 without an N-terminal methionine) or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it.
[0530] In some embodiments, the polypeptide comprises a sequence according to SEQ ID NO: 256 (i.e., SEQ ID NO: 3 without an N-terminal methionine) or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it.
[0531] In some embodiments, the polypeptide comprises a sequence according to SEQ ID NO: 281 (i.e., SEQ ID NO: 279 without an N-terminal methionine) or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it.
[0532] In some embodiments, the polypeptide comprises a sequence according to SEQ ID NO: 261 (i.e., SEQ ID NO: 8 without an N-terminal methionine) or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it.
[0533] In some embodiments, the polypeptide comprises a sequence according to SEQ ID NO: 266 (i.e., SEQ ID NO: 13 without an N-terminal methionine) or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it.
[0534] In some embodiments, the polypeptide comprises a sequence according to SEQ ID NO: 299 (i.e., SEQ ID NO: 297 without an N-terminal methionine) or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it. In some embodiments, the polypeptide comprises a sequence according to SEQ ID NO: 282 (i.e., SEQ ID NO: 280 without an N-terminal methionine) or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it.
[0535] In some embodiments, the polypeptide comprises a sequence according to SEQ ID NO: 271 (i.e., SEQ ID NO: 18 without an N-terminal methionine) or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it.
[0536] In some embodiments, the polypeptide comprises a sequence according to SEQ ID NO: 274 (i.e., SEQ ID NO: 73 without an N-terminal methionine) or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it.
[0537] In some embodiments, the polypeptide comprises a sequence according to SEQ ID NO: 275 (i.e., SEQ ID NO: 74 without an N-terminal methionine) or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%) identity with it.
[0538] In some embodiments, the polypeptide comprises a sequence according to SEQ ID NO: 276 (i.e., SEQ ID NO: 75 without an N-terminal methionine) or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it.
[0539] In some embodiments, the polypeptide comprises a sequence according to SEQ ID NO: 286 (i.e., SEQ ID NO: 283 without an N-terminal methionine) or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it.
[0540] In some embodiments, the polypeptide comprises a sequence according to SEQ ID NO: 277 (i.e., SEQ ID NO: 76 without an N-terminal methionine) or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it.
[0541] In some embodiments, the polypeptide comprises a sequence according to SEQ ID NO: 287 (i.e., SEQ ID NO: 284 without an N-terminal methionine) or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it.
[0542] In some embodiments, the polypeptide comprises a sequence according to SEQ ID NO: 402 (i.e., SEQ ID NO: 401 without an N-terminal methionine) or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it.
[0543] In some embodiments, the polypeptide comprises a sequence according to SEQ ID NO: 414 (i.e., SEQ ID NO: 413 without an N-terminal methionine) or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it.
[0544] In some embodiments, the polypeptide comprises a sequence according to SEQ ID NO: 278 (i.e., SEQ ID NO: 77 without an N-terminal methionine) or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it.
[0545] In some embodiments, the polypeptide comprises a sequence according to SEQ ID NO: 288 (i.e., SEQ ID NO: 285 without an N-terminal methionine) or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it.
[0546] In some embodiments, the polypeptide comprises a sequence according to SEQ ID NO: 408 (i.e., SEQ ID NO: 407 without an N-terminal methionine) or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it. In some embodiments, the nucleic acid encoding the polypeptide comprises a sequence according to SEQ ID NO: 23. In some embodiments, the nucleic acid encoding the polypeptide comprises a sequence according to SEQ ID NO: 24.
[0547] In some embodiments, the nucleic acid encoding the polypeptide comprises the sequence according to SEQ ID NO: 33. In some embodiments, the nucleic acid encoding the polypeptide comprises the sequence according to SEQ ID NO: 34.
[0548] In some embodiments, the nucleic acid encoding the polypeptide comprises the sequence according to SEQ ID NO: 43. In some embodiments, the nucleic acid encoding the polypeptide comprises the sequence according to SEQ ID NO: 44.
[0549] In some embodiments, the nucleic acid encoding the polypeptide comprises the sequence according to SEQ ID NO: 53. In some embodiments, the nucleic acid encoding the polypeptide comprises the sequence according to SEQ ID NO: 54.
[0550] In some embodiments, the nucleic acid encoding the polypeptide comprises the sequence according to SEQ ID NO: 25. In some embodiments, the nucleic acid encoding the polypeptide comprises the sequence according to SEQ ID NO: 26.
[0551] In some embodiments, the nucleic acid encoding the polypeptide comprises the sequence according to SEQ ID NO: 289.
[0552] In some embodiments, the nucleic acid encoding the polypeptide comprises the sequence according to SEQ ID NO: 35. In some embodiments, the nucleic acid encoding the polypeptide comprises the sequence according to SEQ ID NO: 36.
[0553] In some embodiments, the nucleic acid encoding the polypeptide comprises the sequence according to SEQ ID NO: 45. In some embodiments, the nucleic acid encoding the polypeptide comprises the sequence according to SEQ ID NO: 46.
[0554] In some embodiments, the nucleic acid encoding the polypeptide comprises the sequence according to SEQ ID NO: 290.
[0555] In some embodiments, the nucleic acid encoding the polypeptide comprises the sequence according to SEQ ID NO: 298.
[0556] In some embodiments, the nucleic acid encoding the polypeptide comprises the sequence according to SEQ ID NO: 55. In some embodiments, the nucleic acid encoding the polypeptide comprises the sequence according to SEQ ID NO: 56.
[0557] In some embodiments, the nucleic acid encoding the polypeptide comprises the sequence according to SEQ ID NO: 78. In some embodiments, the nucleic acid encoding the polypeptide comprises the sequence according to SEQ ID NO: 79.
[0558] In some embodiments, the nucleic acid encoding the polypeptide comprises the sequence according to SEQ ID NO: 80. In some embodiments, the nucleic acid encoding the polypeptide comprises the sequence according to SEQ ID NO: 81.
[0559] In some embodiments, the nucleic acid encoding the polypeptide comprises the sequence according to SEQ ID NO: 82. In some embodiments, the nucleic acid encoding the polypeptide comprises the sequence according to SEQ ID NO: 83.
[0560] In some embodiments, the nucleic acid encoding the polypeptide comprises the sequence according to SEQ ID NO: 291. In some embodiments, the nucleic acid encoding the polypeptide comprises the sequence according to SEQ ID NO: 292.
[0561] In some embodiments, the nucleic acid encoding the polypeptide comprises the sequence according to SEQ ID NO: 84. In some embodiments, the nucleic acid encoding the polypeptide comprises the sequence according to SEQ ID NO: 85.
[0562] In some embodiments, the nucleic acid encoding the polypeptide comprises the sequence according to SEQ ID NO: 293. In some embodiments, the nucleic acid encoding the polypeptide comprises the sequence according to SEQ ID NO: 294.
[0563] In some embodiments, the nucleic acid encoding the polypeptide comprises the sequence according to SEQ ID NO: 86. In some embodiments, the nucleic acid encoding the polypeptide comprises the sequence according to SEQ ID NO: 87.
[0564] In some embodiments, the nucleic acid encoding the polypeptide comprises the sequence according to SEQ ID NO: 295. In some embodiments, the nucleic acid encoding the polypeptide comprises the sequence according to SEQ ID NO: 296.
[0565] In some embodiments, the amino acid sequence of the polypeptide of the present invention is encoded by a codon-optimized polynucleotide sequence.
[0566] Heterogeneous transmembrane domain (TMB)
[0567] The polypeptides of the present invention as described herein may include a heterologous transmembrane domain. Including a TMB may be advantageous because this will allow the antigen to be localized to the cell membrane. This can reduce the localization of the antigen within the cell and further promote higher immunogenicity compared to antigens without a TMB sequence. Polypeptides containing a heterologous transmembrane domain may also include a secretion signal peptide sequence. In some embodiments, the nucleic acid encoding the polypeptide containing the heterologous transmembrane domain, as described herein, further includes a nucleotide sequence encoding a secretion signal peptide sequence.
[0568] Transmembrane membrane proteins (TMBs) can be derived from any known TMB in the art, including but not limited to TMBs derived from eukaryotic transmembrane proteins (e.g., mammalian transmembrane proteins, such as human transmembrane proteins), prokaryotic transmembrane proteins, and viral transmembrane proteins. TMBs can be further identified by computer prediction algorithms, for example, in the TMHMM prediction methods described below: Krogh et al. (J Mol Biol. [Journal of Molecular Biology] 305(3): 567-580. 2001) and services.healthtech.dtu.dk / services / TMHMM-2.0 / , each of which is incorporated herein by reference in its entirety. Some characteristics of TMBs are further described in detail in Albers et al. (Chapter 2 - cell membrane structures and functions. [Basic Neurochemistry] eighth edition. [Basic Neurochemistry] 8th ... TMB is typically, but not exclusively, composed primarily of nonpolar (hydrophobic) amino acid residues and can cross the lipid bilayer once or multiple times. Methods for determining the hydrophobicity of amino acids are well known to those skilled in the art. See Simm et al. (2016), Biol Res., 49(1):31; Wimlet and White (1996), Nat Struct Biol., 3(10): 842-848; blanco.biomol.uci.edu / hydrophobicity_scales.htm; and www.cgl.ucsf.edu / chimera / docs / UsersGuide / midas / hydrophob.html.
[0569] In some embodiments, the TMB: (a) comprises or consists of 15 to 50 amino acid residues, preferably 15 to 30 amino acid residues, more preferably 18 to 25 amino acid residues; and / or (b) comprises at least 50% hydrophobic amino acid residues, which are preferably selected from the group consisting of alanine, isoleucine, leucine, valine, phenylalanine, tryptophan, and tyrosine; and / or (c) comprises at least one α-helix.
[0570] Transmembrane domains (TMBs) typically contain α-helices, each containing 18-21 amino acids, sufficient to span the lipid bilayer. Therefore, in some embodiments, the transmembrane domain comprises one or more α-helices.
[0571] In some embodiments, the transmembrane domain is derived from an integrated membrane protein, which, as further defined below and by Albers et al., is a membrane protein (also called an intrinsic membrane protein) that is permanently attached to the lipid membrane. In some embodiments, the transmembrane domain is derived from an integrated polytopic protein. An integrated polytopic protein is a protein that spans the entire membrane. In some embodiments, the transmembrane domain is derived from a single-pass (transmembrane-crossing) protein, more particularly a bitopic membrane protein, such as type I or type II. A single-pass protein crosses the membrane only once (i.e., a bitopic membrane protein), while a bitopic protein shuttles in and out, crossing several times. Single-pass proteins can be classified as type I (whose position causes the carboxyl terminus to face the cytoplasm) or type II (whose amino terminus faces the cytoplasm). In some embodiments, the transmembrane domain is derived from an integrated monotopic protein. A complete monotopic protein is a protein that binds to the membrane from only one side and does not completely span the lipid bilayer.
[0572] In some embodiments, the heterogeneous transmembrane domains are derived from non-human sequences.
[0573] In some embodiments, the heterologous transmembrane domain is derived from a viral sequence. The phrases preceding the phrase "transmembrane domain sequence" such as "influenza," "SARS-CoV-2," "varicella-zoster virus (VZV)," "measles," "rubella," "rabies," "Ebola," and "smallpox" indicate that the transmembrane domain sequence is derived from the virus corresponding to that name.
[0574] In some embodiments, the heterologous transmembrane domain is derived from viral transmembrane domain sequences selected from the group consisting of: influenza transmembrane domain sequences, SARS-CoV-2 transmembrane domain sequences, varicella-zoster virus (VZV) transmembrane domain sequences, measles transmembrane domain sequences, rubella transmembrane domain sequences, mumps transmembrane domain sequences, rabies transmembrane domain sequences, and Ebola transmembrane domain sequences. These specific transmembrane domains are derived from viral sequences in viruses administered to humans as vaccines (live attenuated vaccines, inactivated vaccines, or mRNA vaccines) that have demonstrated a robust safety profile.
[0575] In some embodiments, the heterologous transmembrane domain is selected from the group consisting of: influenza hemagglutinin (HA) transmembrane domain sequence, SARS CoV-2 spike transmembrane domain sequence, VZV gB transmembrane domain sequence, VZV gE transmembrane domain sequence, VZV gI transmembrane domain sequence, VZV gK transmembrane domain sequence, measles F-protein transmembrane domain sequence, rubella E1 protein transmembrane domain sequence, rubella E2 protein transmembrane domain sequence, mumps F-protein transmembrane domain sequence, rabies virus glycoprotein (rabies G) transmembrane domain sequence, and Ebola GP protein transmembrane domain sequence.
[0576] In some embodiments, the heterologous transmembrane domain comprises an HA transmembrane domain sequence derived from influenza A or influenza B, preferably from influenza A.
[0577] Table 25 below shows exemplary viral transmembrane domain amino acid sequences disclosed herein.
[0578] Table 25: Amino acid sequence of viral transmembrane domain (TMB) signaling domain
[0579]
[0580] In some embodiments, the TMB sequence has the sequence GGSILAIYSTVASSLVLVVSLGAISFGG (SEQ ID NO: 70).
[0581] In some embodiments, the heterologous TMB sequence is located at the N-terminus or C-terminus (e.g., the C-terminus) of the peptide described herein.
[0582] In some embodiments, the TMB amino acid sequence is encoded by a codon-optimized polynucleotide sequence.
[0583] In some embodiments, TMB is linked to the polypeptide described herein via a connector.
[0584] Table 26 provides examples of polypeptides of the present invention that contain TMB. The table also provides the nucleic acid sequences encoding the polypeptides, which are also part of the present invention. The table also includes corresponding polypeptides with glycosylation sites mutated. These mutations in the polypeptides are examples of the glycosylation mutants discussed above.
[0585] Table 26: Examples of polypeptides of the present invention or polypeptides encoded by the nucleic acids of the present invention
[0586]
[0587] In some embodiments, the polypeptide comprises a sequence according to SEQ ID NO: 4 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90% or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%) identity with it.
[0588] In some embodiments, the polypeptide comprises a sequence according to SEQ ID NO: 9 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90% or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%) identity with it.
[0589] In some embodiments, the polypeptide comprises a sequence according to SEQ ID NO: 14 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90% or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%) identity with it.
[0590] In some embodiments, the polypeptide comprises a sequence according to SEQ ID NO: 19 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90% or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%) identity with it.
[0591] In some embodiments, the polypeptide comprises a sequence according to SEQ ID NO: 5 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90% or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%) identity with it.
[0592] In some embodiments, the polypeptide comprises a sequence according to SEQ ID NO: 10 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90% or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%) identity with it.
[0593] In some embodiments, the polypeptide comprises a sequence according to SEQ ID NO: 15 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90% or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%) identity with it.
[0594] In some embodiments, the polypeptide comprises a sequence according to SEQ ID NO: 20 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90% or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%) identity with it.
[0595] The N-terminal methionine in any of the above embodiments may be omitted from the polypeptide. Therefore, in some embodiments, the polypeptide comprises a sequence according to SEQ ID NO: 257 (i.e., SEQ ID NO: 4 without the N-terminal methionine) or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it.
[0596] In some embodiments, the polypeptide comprises a sequence according to SEQ ID NO: 262 (i.e., SEQ ID NO: 9 without an N-terminal methionine) or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it.
[0597] In some embodiments, the polypeptide comprises a sequence according to SEQ ID NO: 267 (i.e., SEQ ID NO: 14 without an N-terminal methionine) or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it.
[0598] In some embodiments, the polypeptide comprises a sequence according to SEQ ID NO: 272 (i.e., SEQ ID NO: 19 without an N-terminal methionine) or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it.
[0599] In some embodiments, the polypeptide comprises a sequence according to SEQ ID NO: 258 (i.e., SEQ ID NO: 5 without an N-terminal methionine) or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it.
[0600] In some embodiments, the polypeptide comprises a sequence according to SEQ ID NO: 263 (i.e., SEQ ID NO: 10 without an N-terminal methionine) or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it.
[0601] In some embodiments, the polypeptide comprises a sequence according to SEQ ID NO: 268 (i.e., SEQ ID NO: 15 without an N-terminal methionine) or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it.
[0602] In some embodiments, the polypeptide comprises a sequence according to SEQ ID NO: 273 (i.e., SEQ ID NO: 20 without an N-terminal methionine) or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it.
[0603] In some embodiments, the nucleic acid encoding the polypeptide comprises the sequence according to SEQ ID NO: 27. In some embodiments, the nucleic acid encoding the polypeptide comprises the sequence according to SEQ ID NO: 28.
[0604] In some embodiments, the nucleic acid encoding the polypeptide comprises the sequence according to SEQ ID NO: 37. In some embodiments, the nucleic acid encoding the polypeptide comprises the sequence according to SEQ ID NO: 38.
[0605] In some embodiments, the nucleic acid encoding the polypeptide comprises the sequence according to SEQ ID NO: 47. In some embodiments, the nucleic acid encoding the polypeptide comprises the sequence according to SEQ ID NO: 48.
[0606] In some embodiments, the nucleic acid encoding the polypeptide comprises the sequence according to SEQ ID NO: 57. In some embodiments, the nucleic acid encoding the polypeptide comprises the sequence according to SEQ ID NO: 58.
[0607] In some embodiments, the nucleic acid encoding the polypeptide comprises the sequence according to SEQ ID NO: 29. In some embodiments, the nucleic acid encoding the polypeptide comprises the sequence according to SEQ ID NO: 30.
[0608] In some embodiments, the nucleic acid encoding the polypeptide comprises the sequence according to SEQ ID NO: 39. In some embodiments, the nucleic acid encoding the polypeptide comprises the sequence according to SEQ ID NO: 40.
[0609] In some embodiments, the nucleic acid encoding the polypeptide comprises the sequence according to SEQ ID NO: 49. In some embodiments, the nucleic acid encoding the polypeptide comprises the sequence according to SEQ ID NO: 50.
[0610] In some embodiments, the nucleic acid encoding the polypeptide comprises the sequence according to SEQ ID NO: 59. In some embodiments, the nucleic acid encoding the polypeptide comprises the sequence according to SEQ ID NO: 60.
[0611] In some embodiments, the amino acid sequence of the polypeptide of the present invention is encoded by a codon-optimized polynucleotide sequence.
[0612] connector
[0613] In some embodiments disclosed herein, the secretion signal peptide (SS) sequence or transmembrane domain (TMB) is directly fused to the polypeptide described herein (i.e., there is no linker, such as an amino acid linker, connecting the SS sequence or TMB to the polypeptide described herein). In some embodiments, the Kgp or RgpA domains of the polypeptide described herein are directly fused to each other (i.e., there is no linker, such as an amino acid linker, connecting the SS sequence or TMB to the polypeptide described herein).
[0614] In other embodiments, the SS sequence and TMB disclosed herein are optionally attached to the polypeptide described herein via a linker. In some embodiments, the linker is an amino acid linker. In some embodiments, the amino acid linker is 1 to 10 amino acids in length (e.g., the amino acid linker has a length of 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acids). In other embodiments, the Kgp or RgpA domains of the polypeptide described herein are linked to each other via linkers. In some embodiments, the linker is an amino acid linker. In some embodiments, the amino acid linker is 1 to 10 amino acids in length (e.g., the amino acid linker has a length of 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acids).
[0615] Exemplary examples of connectors include glycine polymer (Gly)n, where n is an integer of at least 1, 2, 3, 4, 5, 6, 7, or 8; glycine-serine polymer (GlySer)n, where n is an integer of at least one, two, three, four, five, six, seven, or eight; glycine-alanine polymer; alanine-serine polymer; and other flexible connectors known in the art.
[0616] Glycine and glycine-serine polymers are relatively unstructured and flexible, thus capable of acting as neutral linkers between the SS sequence and / or TMB and the peptides described herein. In some embodiments, the linker is SGS or GSG. In some embodiments, the linker is GGS and / or GG.
[0617] Other exemplary linkers include, but are not limited to, the following amino acid sequences: GGG; DGGGS (SEQ ID NO: 241); TGEKP (SEQ ID NO: 242) (Liu et al., Proc. Natl. Acad. Sci. [Proceedings of the National Academy of Sciences] 94:5525-5530. 1997); GGRR (SEQ ID NO: 243); (GGGGS)n (SEQ ID NO: 244), where n = 1, 2, 3, 4, or 5 (Kim et al., Proc. Natl. Acad. Sci. [Proceedings of the National Academy of Sciences] 93: 1156-1160. 1996); EGKSSGSGSESKVD (SEQ ID NO: 245) (Chaudhary et al., Proc. Natl. Acad. Sci. [Proceedings of the National Academy of Sciences] 87: 1066-1070. 1990); KESGSVSSEQLAQFRSLD (SEQ ID NO: 246) (Bird et al. Science [Science]. 242:423-426. 1988), GGRRGGGS (SEQ ID NO: 247); LRQRDGERP (SEQ ID NO: 248); LRQKDGGGSERP (SEQ ID NO: 249); and GSTGSGSGKPGSGEGSTKG (SEQ ID NO: 250) (Cooper et al. Blood [Blood]. 101(4): 1637-1644. 2003). Preferred linkers are shorter, for example, consisting of 2, 3, 4 or 5 amino acids.
[0618] Other examples of connectors are provided in Chen et al. (Adv Drug Deliv Rev. 65(10): 1357-1369. 2013), which is incorporated herein by reference.
[0619] Composition
[0620] This invention provides a composition comprising one or more nucleic acids disclosed herein. This invention also provides a composition comprising one or more polypeptides disclosed herein. The compositions of this invention can be pharmaceutical compositions, such as those comprising pharmaceutically acceptable carriers, excipients, or diluents. In some embodiments, the compositions of this invention are immunogenic compositions. "Immunogenic composition" means a composition comprising nucleic acids or proteins that, when administered to a subject, elicits an immune response, such as an antigen-specific immune response. The immune response can be a humoral (antibody) immune response or a cell-mediated immune response. The compositions of this invention can be vaccine compositions. Immunogenic compositions (e.g., vaccine compositions) can elicit immunity (e.g., an antibody response) against *Porphyromonas gingivalis* infection. Antibody responses can include antibodies that bind to the surface of *Porphyromonas gingivalis* bacteria or their outer membrane vesicles (OMVs) and neutralize gingival protease activity associated with *Porphyromonas gingivalis* pathogenicity. These antibodies can cross-react with a range of *Porphyromonas gingivalis* strains.
[0621] As used herein, "protective immunity" or "protective immune response" refers to a subject exhibiting immunity or initiating an immune response against an infectious pathogen (e.g., *Porphyromonas gingivalis*) that prevents or improves the infection or reduces at least one of its symptoms. Specifically, protective immunity or a protective immune response is induced by administering the compositions of the present invention, characterized by the elimination or reduction of one or more symptoms of *Porphyromonas gingivalis* infection (e.g., periodontitis). As used herein, the term "immune response" refers to both humoral immune responses and cell-mediated immune responses. In some embodiments, treatment with the compositions of the present invention described herein provides protective immunity against *Porphyromonas gingivalis* infection.
[0622] Nucleic acid composition
[0623] In one aspect, the present invention provides a composition comprising a nucleic acid as described herein, the nucleic acid comprising a nucleotide sequence encoding a gingival protease-based polypeptide as described herein. For example, in one embodiment, the composition comprises a nucleic acid as described herein, the nucleic acid comprising a nucleotide sequence encoding a Kgp-based polypeptide. In another embodiment, the composition comprises a nucleic acid as described herein, the nucleic acid comprising a nucleotide sequence encoding an RgpA-based polypeptide. In yet another embodiment, the composition comprises a nucleic acid as described herein, the nucleic acid comprising a nucleotide sequence encoding both Kgp-based and RgpA-based polypeptides.
[0624] In another aspect, the present invention provides a composition comprising (a) a nucleic acid as described herein, the nucleic acid comprising a nucleotide sequence encoding a Kgp-based polypeptide as described herein; and (b) a nucleic acid as described herein, the nucleic acid comprising a nucleotide sequence encoding an RgpA-based polypeptide as described herein. Exemplary combinations are described in Table 27, and polypeptides comprising sequences having at least 70% (e.g., 90% or 95%) identity with the sequences mentioned in that table may be used as combinations of Kgp-based polypeptides and RgpA-based polypeptides.
[0625] The specific Kgp-based and Rgp-based polypeptide sequences used in the combinations specified in Table 27 can be modified as described elsewhere herein. For example, the DUF2436 domain can be replaced with a truncated DUF2436 domain or a DUF2436 domain having at least 70% (e.g., at least 90% or 95%) identity with the DUF2436 domain.
[0626] Table 27: Examples of combinations of Kgp-based and Rgp-based peptides
[0627]
[0628] In one specific embodiment, the present invention provides a composition comprising:
[0629] (a) A first nucleic acid encoding a polypeptide comprising: i) at least a portion of a Kgp catalytic domain; ii) at least a portion of KgpDUF2436; iii) at least a portion of a Kgp K1 adhesin domain; iv) a first Kgp portion comprising ABM1 and a first Kgp portion comprising ABM2; v) a second Kgp portion comprising ABM1 and a second Kgp portion comprising ABM2; and vi) a Kgp portion comprising ABM3; wherein these domains are positioned from the N-terminus to the C-terminus of the polypeptide in the following order: Kgp catalytic domain; first Kgp portion comprising ABM1; Kgp DUF2436; first Kgp portion comprising ABM2; second Kgp portion comprising ABM1; Kgp portion comprising ABM3; Kgp K1; second Kgp portion comprising ABM2;
[0630] (b) A second nucleic acid encoding a polypeptide comprising: i) at least a portion of an RgpA catalytic domain; ii) at least a portion of RgpA DUF2436; iii) at least a portion of an RgpA K1 adhesin domain; iv) a first RgpA portion comprising ABM1 and a first RgpA portion comprising ABM2; v) a second RgpA portion comprising ABM1 and a second RgpA portion comprising ABM2; vi) an RgpA portion comprising ABM3; vii) at least a portion of an RgpA K2 adhesin domain; wherein these domains are positioned from the N-terminus to the C-terminus of the polypeptide in the following order: RgpA catalytic domain; first RgpA portion comprising ABM1; RgpA DUF2436; first RgpA portion comprising ABM2; second RgpA portion comprising ABM1; RgpA portion comprising ABM3; RgpA K1; RgpA K2; second RgpA portion comprising ABM2.
[0631] In one specific embodiment, the present invention provides a composition comprising:
[0632] (a) A first nucleic acid encoding a polypeptide comprising: i) at least a portion of a Kgp catalytic domain, wherein the at least portion of the Kgp catalytic domain comprises a full-length Kgp catalytic domain; ii) at least a portion of Kgp DUF2436; iii) at least a portion of a Kgp K1 adhesin domain, wherein the at least portion of Kgp K1 adhesin comprises a full-length Kgp K1 adhesin domain; iv) a first Kgp portion comprising ABM1 and a first Kgp portion comprising ABM2; v) a second Kgp portion comprising ABM1 and a second Kgp portion comprising ABM2; and vi) a Kgp portion comprising ABM3; wherein these domains are positioned from the N-terminus to the C-terminus of the polypeptide in the following order: Kgp catalytic domain; first Kgp portion comprising ABM1; Kgp DUF2436; first Kgp portion comprising ABM2; second Kgp portion comprising ABM1; Kgp portion comprising ABM3; Kgp K1; contains the second Kgp portion of ABM2;
[0633] (b) A second nucleic acid encoding a polypeptide comprising: i) at least a portion of an RgpA catalytic domain; ii) at least a portion of RgpA DUF2436; iii) at least a portion of an RgpA K1 adhesin domain; iv) a first RgpA portion comprising ABM1 and a first RgpA portion comprising ABM2; v) a second RgpA portion comprising ABM1 and a second RgpA portion comprising ABM2; vi) an RgpA portion comprising ABM3; vii) at least a portion of an RgpA K2 adhesin domain; wherein these domains are positioned from the N-terminus to the C-terminus of the polypeptide in the following order: RgpA catalytic domain; first RgpA portion comprising ABM1; RgpA DUF2436; first RgpA portion comprising ABM2; second RgpA portion comprising ABM1; RgpA portion comprising ABM3; RgpA K1; RgpA K2; second RgpA portion comprising ABM2.
[0634] In one specific embodiment, the present invention provides a composition comprising:
[0635] (a) A first nucleic acid encoding a polypeptide comprising: i) at least a portion of a Kgp catalytic domain, wherein the at least portion of the Kgp catalytic domain comprises a full-length Kgp catalytic domain; ii) at least a portion of Kgp DUF2436; iii) at least a portion of a Kgp K1 adhesin domain, wherein the at least portion of Kgp K1 adhesin comprises a full-length Kgp K1 adhesin domain; iv) a first Kgp portion comprising ABM1 and a first Kgp portion comprising ABM2; v) a second Kgp portion comprising ABM1 and a second Kgp portion comprising ABM2; and vi) a Kgp portion comprising ABM3; wherein these domains are positioned from the N-terminus to the C-terminus of the polypeptide in the following order: Kgp catalytic domain; first Kgp portion comprising ABM1; Kgp DUF2436; first Kgp portion comprising ABM2; second Kgp portion comprising ABM1; Kgp portion comprising ABM3; Kgp K1; comprising a second Kgp portion of ABM2; wherein the glycosylation sites corresponding to glycosylation sites N691-T693 in the WT Kgp sequence (SEQ ID NO: 157) are mutated by substitution with T693A; and wherein the glycosylation sites corresponding to glycosylation sites N950-T952 in the WT Kgp sequence (SEQ ID NO: 157) are mutated by substitution with T952A; and
[0636] (b) A second nucleic acid encoding a polypeptide comprising: i) at least a portion of an RgpA catalytic domain; ii) at least a portion of RgpA DUF2436; iii) at least a portion of an RgpA K1 adhesin domain; iv) a first RgpA portion comprising ABM1 and a first RgpA portion comprising ABM2; v) a second RgpA portion comprising ABM1 and a second RgpA portion comprising ABM2; vi) an RgpA portion comprising ABM3; vii) at least a portion of an RgpA K2 adhesin domain; wherein these domains are positioned from the N-terminus to the C-terminus of the polypeptide in the following order: RgpA catalytic domain; first RgpA portion comprising ABM1; RgpA DUF2436; first RgpA portion comprising ABM2; second RgpA portion comprising ABM1; RgpA portion comprising ABM3; RgpA K1; RgpA K2; second RgpA portion comprising ABM2.
[0637] In one specific embodiment, the present invention provides a composition comprising:
[0638] (a) A first nucleic acid encoding a Kgp-based polypeptide comprising the sequence according to SEQ ID NO: 279 or having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it; and
[0639] (b) A second nucleic acid encoding an RgpA-based polypeptide comprising the sequence according to SEQ ID NO: 73 or having at least 70% (e.g., at least 75%, 80%, 85%, 90% or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%) identity with it.
[0640] The compositions of the present invention may comprise combinations of nucleic acids as described herein (e.g., they may be formulated in the same composition). Combinations of nucleic acids as described herein may alternatively be in two or more separate compositions (e.g., as a combination of compositions for simultaneous, individual or sequential administration (e.g., in therapeutic uses as described herein)).
[0641] The compositions of this disclosure, comprising one or more nucleic acids disclosed herein, may also include one or more additional components, such as small molecule immune enhancers (e.g., TLR agonists). The compositions of this disclosure may also include a delivery system for the nucleic acid (e.g., RNA) described herein, such as liposomes, oil-in-water emulsions, or microparticles. In some embodiments, the composition comprises lipid nanoparticles (LNPs). In some embodiments, the composition comprises nucleic acid molecules of the present invention encapsulated within LNPs.
[0642] polypeptide composition
[0643] In one aspect, the present invention provides a composition comprising a gingivase-based polypeptide as described herein.
[0644] In one aspect, the present invention provides a composition comprising a gingival protease-based polypeptide as described herein. For example, in one embodiment, the composition comprises a Kgp-based polypeptide. In another embodiment, the composition comprises an RgpA-based polypeptide. In yet another embodiment, the composition comprises polypeptides based on both Kgp and RgpA.
[0645] In another aspect, the present invention provides a composition comprising (a) a Kgp-based polypeptide as described herein; and (b) an RgpA-based polypeptide as described herein. Exemplary combinations are described in Table 27, and polypeptides comprising sequences having at least 70% (e.g., 90% or 95%) identity with the sequences mentioned in that table may be used as a combination of a Kgp-based polypeptide and an RgpA-based polypeptide.
[0646] In one specific embodiment, the present invention provides a composition comprising:
[0647] (a) A first polypeptide comprising: i) at least a portion of a Kgp catalytic domain; ii) at least a portion of KgpDUF2436; iii) at least a portion of a Kgp K1 adhesin domain; iv) a first Kgp moiety comprising ABM1 and a first Kgp moiety comprising ABM2; v) a second Kgp moiety comprising ABM1 and a second Kgp moiety comprising ABM2; and vi) a Kgp moiety comprising ABM3; wherein these domains are positioned from the N-terminus to the C-terminus of the polypeptide in the following order: Kgp catalytic domain; first Kgp moiety comprising ABM1; Kgp DUF2436; first Kgp moiety comprising ABM2; second Kgp moiety comprising ABM1; Kgp moiety comprising ABM3; Kgp K1; second Kgp moiety comprising ABM2;
[0648] (b) A second polypeptide comprising: i) at least a portion of an RgpA catalytic domain; ii) at least a portion of RgpADUF2436; iii) at least a portion of an RgpA K1 adhesin domain; iv) a first RgpA moiety comprising ABM1 and a first RgpA moiety comprising ABM2; v) a second RgpA moiety comprising ABM1 and a second RgpA moiety comprising ABM2; vi) an RgpA moiety comprising ABM3; vii) at least a portion of an RgpA K2 adhesin domain; wherein these domains are positioned from the N-terminus to the C-terminus of the polypeptide in the following order: RgpA catalytic domain; first RgpA moiety comprising ABM1; RgpA DUF2436; first RgpA moiety comprising ABM2; second RgpA moiety comprising ABM1; RgpA moiety comprising ABM3; RgpA K1; RgpA K2; second RgpA moiety comprising ABM2.
[0649] In one specific embodiment, the present invention provides a composition comprising:
[0650] (a) A first polypeptide comprising: i) at least a portion of a Kgp catalytic domain, wherein the at least portion of the Kgp catalytic domain comprises a full-length Kgp catalytic domain; ii) at least a portion of Kgp DUF2436; iii) at least a portion of a Kgp K1 adhesin domain, wherein the at least portion of Kgp K1 adhesin comprises a full-length Kgp K1 adhesin domain; iv) a first Kgp portion comprising ABM1 and a first Kgp portion comprising ABM2; v) a second Kgp portion comprising ABM1 and a second Kgp portion comprising ABM2; and vi) a Kgp portion comprising ABM3; wherein these domains are positioned from the N-terminus to the C-terminus of the polypeptide in the following order: Kgp catalytic domain; first Kgp portion comprising ABM1; Kgp DUF2436; first Kgp portion comprising ABM2; second Kgp portion comprising ABM1; Kgp portion comprising ABM3; Kgp K1; contains the second Kgp portion of ABM2;
[0651] (b) A second polypeptide comprising: i) at least a portion of an RgpA catalytic domain; ii) at least a portion of RgpADUF2436; iii) at least a portion of an RgpA K1 adhesin domain; iv) a first RgpA moiety comprising ABM1 and a first RgpA moiety comprising ABM2; v) a second RgpA moiety comprising ABM1 and a second RgpA moiety comprising ABM2; vi) an RgpA moiety comprising ABM3; vii) at least a portion of an RgpA K2 adhesin domain; wherein these domains are positioned from the N-terminus to the C-terminus of the polypeptide in the following order: RgpA catalytic domain; first RgpA moiety comprising ABM1; RgpA DUF2436; first RgpA moiety comprising ABM2; second RgpA moiety comprising ABM1; RgpA moiety comprising ABM3; RgpA K1; RgpA K2; second RgpA moiety comprising ABM2.
[0652] In one specific embodiment, the present invention provides a composition comprising:
[0653] (a) A first polypeptide comprising: i) at least a portion of a Kgp catalytic domain, wherein the at least portion of the Kgp catalytic domain comprises a full-length Kgp catalytic domain; ii) at least a portion of Kgp DUF2436; iii) at least a portion of a Kgp K1 adhesin domain, wherein the at least portion of Kgp K1 adhesin comprises a full-length Kgp K1 adhesin domain; iv) a first Kgp portion comprising ABM1 and a first Kgp portion comprising ABM2; v) a second Kgp portion comprising ABM1 and a second Kgp portion comprising ABM2; and vi) a Kgp portion comprising ABM3; wherein these domains are positioned from the N-terminus to the C-terminus of the polypeptide in the following order: Kgp catalytic domain; first Kgp portion comprising ABM1; Kgp DUF2436; first Kgp portion comprising ABM2; second Kgp portion comprising ABM1; Kgp portion comprising ABM3; Kgp K1; comprising a second Kgp portion of ABM2; wherein the glycosylation sites corresponding to glycosylation sites N691-T693 in the WT Kgp sequence (SEQ ID NO: 157) are mutated by substitution with T693A; and wherein the glycosylation sites corresponding to glycosylation sites N950-T952 in the WT Kgp sequence (SEQ ID NO: 157) are mutated by substitution with T952A; and
[0654] (b) A second polypeptide comprising: i) at least a portion of an RgpA catalytic domain; ii) at least a portion of RgpADUF2436; iii) at least a portion of an RgpA K1 adhesin domain; iv) a first RgpA moiety comprising ABM1 and a first RgpA moiety comprising ABM2; v) a second RgpA moiety comprising ABM1 and a second RgpA moiety comprising ABM2; vi) an RgpA moiety comprising ABM3; vii) at least a portion of an RgpA K2 adhesin domain; wherein these domains are positioned from the N-terminus to the C-terminus of the polypeptide in the following order: RgpA catalytic domain; first RgpA moiety comprising ABM1; RgpA DUF2436; first RgpA moiety comprising ABM2; second RgpA moiety comprising ABM1; RgpA moiety comprising ABM3; RgpA K1; RgpA K2; second RgpA moiety comprising ABM2.
[0655] In one specific embodiment, the present invention provides a composition comprising:
[0656] (a) A first polypeptide comprising a sequence according to SEQ ID NO: 279 or a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity with it; and
[0657] (b) A second polypeptide comprising the sequence according to SEQ ID NO: 73 or having at least 70% (e.g., at least 75%, 80%, 85%, 90% or 95%; or, for example, at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%) identity with it.
[0658] The specific Kgp-based and Rgp-based polypeptide sequences used in the combinations specified in Table 27 can be modified as described elsewhere herein. For example, the DUF2436 domain can be replaced with a truncated DUF2436 domain or a DUF2436 domain having at least 70% (e.g., at least 90% or 95%) identity with the DUF2436 domain.
[0659] The compositions of the present invention may comprise combinations of polypeptides as described herein (e.g., they may be formulated in the same composition). Combinations of polypeptides as described herein may alternatively be in two or more separate compositions (e.g., as a combination of compositions for simultaneous, individual or sequential administration (e.g., in therapeutic uses as described herein)).
[0660] Compositions of this disclosure comprising one or more polypeptides disclosed herein may contain adjuvants. As used herein, “adjuvant” means a substance or carrier that enhances an immune response to an antigen. Adjuvants may include, but are not limited to, suspensions of minerals (e.g., alum, aluminum hydroxide, or phosphate) to which antigens are adsorbed; water-in-oil or oil-in-water emulsions of antigen solutions emulsified in mineral oil or water (e.g., Freund's incomplete adjuvant). Sometimes, killed mycobacteria (e.g., Freund's complete adjuvant) are included to further enhance antigenicity. Immunostimulatory oligonucleotides (e.g., CpG motifs) may also be used as adjuvants (e.g., see U.S. Patent Nos. 6,194,388; 6,207,646; 6,214,806; 6,218,371; 6,239,116; 6,339,068; 6,406,705; and 6,429,199). Adjuvants may also include biomolecules such as Toll-like receptor (TLR) agonists (e.g., SPA14, as described in WO 2022090359) and co-stimulatory molecules. In some embodiments, the adjuvant is AFO3 (oil-in-water squalene emulsion adjuvant).
[0661] In some embodiments, the adjuvant is selected from the group consisting of: aluminum-based adjuvants (e.g., AlOOH), squalene-based oil-in-water emulsion adjuvants (e.g., AF03, AS03, MF59), and liposome-based adjuvants containing saponins and TLR4 agonists (e.g., SPA14, AS01).
[0662] LNP
[0663] In some embodiments, the compositions of the present invention (e.g., compositions comprising the nucleic acids of the present invention) further comprise lipid nanoparticles (LNPs). In some embodiments, the nucleic acids of the present invention are encapsulated in LNPs.
[0664] The LNP disclosed herein may include four types of lipids: (i) ionizable lipids (e.g., cationic lipids); (ii) PEGylated lipids; (iii) cholesterol-based lipids; and (iv) accessory lipids.
[0665] A. Ionizable lipids
[0666] Ionizable lipids can promote mRNA encapsulation and can be cationic lipids. Cationic lipids provide a positively charged environment at low pH to promote the effective encapsulation of negatively charged mRNA drugs.
[0667] In some embodiments, the cationic lipid is OF-02:
[0668]
[0669] Formula (I)
[0670] OF-02 is a non-degradable structural analogue of OF-Deg-Lin. OF-Deg-Lin contains a degradable ester bond to connect the diketopiperazine core and the biunsaturated tail, while OF-02 contains a non-degradable 1,2-amino-ol bond to connect the same diketopiperazine core and biunsaturated tail (Fenton et al., Adv Mater. [Advanced Materials] (2016) 28:2939; U.S. Patent 10,201,618). The exemplary LNP formulation (lipid A) described herein contains OF-2.
[0671] In some embodiments, the cationic lipid is cKK-E10 (Dong et al., PNAS [Proceedings of the National Academy of Sciences] (2014) 111(11):3955-60; US Patent 9,512,073):
[0672]
[0673] cKK-E10
[0674] Equation (II)
[0675] The exemplary LNP formulation (lipid B) described herein contains cKK-E10.
[0676] In some embodiments, the cationic lipid is GL-HEPES-E3-E10-DS-3-E18-1 (2-(4-(2-((3-(bis((Z)-2-hydroxyoctadecyl-9-en-1-yl)amino)propyl)dithioalkyl)ethyl)piperazin-1-yl)ethyl 4-(bis(2-hydroxydecyl)amino)butyrate) (WO 2022 / 221688), which is a HEPES-based disulfide cationic lipid with a piperazine core, having Formula III:
[0677]
[0678] Equation (III)
[0679] The exemplary LNP formulation (lipid C) described herein contains GL-HEPES-E3-E10-DS-3-E18-1. Lipid C has the same composition as lipid A or lipid B, except that it is a cationic lipid.
[0680] In some embodiments, the cationic lipid is GL-HEPES-E3-E12-DS-4-E10(2-(4-(2-((3-(bis(2-hydroxydecyl)amino)butyl)dithioalkyl)ethyl)piperazine-1-yl)ethyl 4-(bis(2-hydroxydodecyl)amino)butyrate) (WO 2022 / 221688), which is a HEPES-based disulfide cationic lipid with a piperazine core, having Formula IV:
[0681]
[0682] Formula (IV)
[0683] The exemplary LNP formulation (lipid D) described herein contains GL-HEPES-E3-E12-DS-4-E10. Lipid D has the same composition as lipid A or lipid B, except that it is a different cationic lipid.
[0684] In some embodiments, the cationic lipid is GL-HEPES-E3-E12-DS-3-E14(2-(4-(2-((3-(bis(2-hydroxytetradecyl)amino)propyl)dithioalkyl)ethyl)piperazin-1-yl)ethyl 4-(bis(2-hydroxydodecyl)amino)butyrate) (WO 2022 / 221688), which is a HEPES-based disulfide cationic lipid with a piperazine core, having formula V:
[0685]
[0686] Formula (V)
[0687] The exemplary LNP formulation (lipid E) described herein contains GL-HEPES-E3-E12-DS-3-E14. Lipid E has the same composition as lipid A or lipid B, except that it is a cationic lipid.
[0688] The cationic lipids GL-HEPES-E3-E10-DS-3-E18-1 (III), GL-HEPES-E3-E12-DS-4-E10 (IV), and GL-HEPES-E3-E12-DS-3-E14 (V) can be synthesized according to the general procedure listed in Scheme 1:
[0689] Scheme 1: General synthetic schemes for lipids of formulas (III), (IV) and (V)
[0690]
[0691] In some embodiments, the cationic lipid is MC3, which has formula VI:
[0692]
[0693] Formula (VI)
[0694] In some embodiments, the cationic lipid is SM-102 (9-heptadecyl 8-{(2-hydroxyethyl)[6-oxo-6-(undecyloxy)hexyl]amino}octanoate), having formula VII:
[0695]
[0696] Equation (VII)
[0697] In some embodiments, the cationic lipid is ALC-0315 [(4-hydroxybutyl)azanidinediyl]bis(hexane-6,1-diyl)bis(2-hexyldecanoate), having formula VIII:
[0698]
[0699] Formula (VIII)
[0700] In some embodiments, the cationic lipid is cOrn-EE1, which has formula IX:
[0701]
[0702] Formula (IX)
[0703] In some embodiments, the cationic lipid may be selected from the group consisting of: cKK-E10; OF-02; [(6Z,9Z,28Z,31Z)-heptadecane-6,9,28,31-tetraen-19-yl] 4-(dimethylamino)butyrate (D-Lin-MC3-DMA); 2,2-dilinoleyl-4-dimethylaminoethyl-[1,3]-dioxolane (DLin-KC2-DMA); 1,2-dilinoleyloxy-N,N-dimethyl-3-aminopropane (DLin-DMA); di((Z)-non-2-en-1-yl)9-((4-(dimethylamino)butyryl)oxy)heptadecanedioate (L319); 8-{(2-hydroxyethyl)[6-oxo-6-(undecyloxy)hexyl]amino}octanoic acid 9-heptadecanedioate (SM-102); [(4-hydroxybutyl)azanediyl]di(hexane-6,1-diyl)bis( 2-Hexyldecanoate (ALC-0315); [3-(dimethylamino)-2-[(Z)-octadec-9-enoyl]oxypropyl](Z)-octadec-9-enoate (DODAP); 2,5-bis(3-aminopropylamino)-N-[2-[di(heptadecyl)amino]-2-oxoethyl]pentanamide (DOGS); [(3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-[(2R)-6-methylheptane-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecano-1H-cyclopentadien[a]phenanthrene-3-yl]N-[2-(dimethylamino)ethyl]carbamate (DC-Chol); tetra(8-methylnonyl) 3,3′,3″,3′′′-(((methylazanediyl)bis(propane-3,1-diyl))bis(azanetriyl))tetrapropionate (306Oi10); (2-(dioctylammonyl)ethyl)decyl phosphate (9A1P9); 5,5-di((Z)-heptadec-8-en-1-yl)-1-(3-(pyrrolidone-1-yl)propyl)-2,5-dihydro-1H-imidazol-2-carboxylic acid ethyl ester (A2-Iso5-2DC18); bis(2-(dodecyldithio)ethyl)3,3'-((3-methyl -9-oxo-10-oxa-13,14-dithia-3,6-diazatrolhizo)azanediyl)dipropionate (BAME-O16B); 1,1′-((2-(4-(2-((2-(bis(2-hydroxydodecyl)amino)ethyl)(2-hydroxydodecyl)amino)ethyl)piperazin-1-yl)ethyl)azanediyl)bis(dodecane-2-ol) (C12-200); 3,6-bis(4-(bis(2-hydroxydodecyl)amino)butyl)piperazin-2,5-dione (cKK-E12);Hexa(octane-3-yl)9,9′,9″,9′′′,9″″,9′′′″-((((benzene-1,3,5-tricarbonyl)tri(azanediyl))tri(propane-3,1-diyl))tri(azanetriyl))hexanonanoate (FTT5); (((3,6-dioxopiperazine-2,5-diyl)bis(butane-4,1-diyl))bis(azanetriyl))tetra(ethane-2,1-diyl)(9Z,9′Z,9″Z,9′′′Z,12Z,12′Z,12″Z,12′′′Z)-tetra(octadec-9,12-dienoate) (OF-Deg-Lin); TT3; N; 1 N 3 N 5 - Tris(3-(bis(dodecylamino)propyl)phenyl-1,3,5-tricarboxamide; N1-[2-((1S)-1-[(3-aminopropyl)amino]-4-[bis(3-aminopropyl)amino]butylcarboxymethylamino)ethyl]-3,4-bis[oleyloxy]-benzamide (MVL5); 8-((2-hydroxyethyl)(8-(nonoxy)-8-oxooctyl)amino)octanoic acid heptadecanyl-9-yl ester (lipid 5); GL-HEPES-E3-E10-DS-3-E18-1; GL-HEPES-E3-E12-DS-4-E10; GL-HEPES-E3-E12-DS-3-E14; and combinations thereof.
[0704] In some embodiments, the cationic lipid is IM-001, which has the formula X (EP23306049.0):
[0705]
[0706] Formula (X)
[0707] The exemplary LNP formulation (lipid G) described herein contains IM-001. Lipid G has the same composition as lipid A or lipid B, except that it is a cationic lipid.
[0708] The cationic lipid IM-001 (X) can be synthesized according to the general procedure described in Scheme 2:
[0709] Scheme 2: General synthetic scheme for lipids of formula (X)
[0710]
[0711] Option 2 can be carried out as described in Example 2.
[0712] In some embodiments, the cationic lipid is IS-001, having the formula XI (EP23306049.0):
[0713]
[0714] Formula (XI)
[0715] The exemplary LNP formulation (lipid H) described herein contains IS-001. Lipid H has the same composition as lipid A or lipid B, except that it is a cationic lipid.
[0716] The cationic lipid IS-001 (XI) can be synthesized according to the general procedure described in Scheme 3:
[0717] Scheme 3: General synthesis scheme for lipids of formula (XI)
[0718]
[0719] Option 3 can be performed as described in Example 3.
[0720] In some embodiments, the cationic lipids are biodegradable.
[0721] In some embodiments, the cationic lipids are not biodegradable.
[0722] In some embodiments, the cationic lipid is cleavable.
[0723] In some embodiments, the cationic lipids are not cleavable.
[0724] Cationic lipids are described in further detail in Dong et al. (PNAS. 111(11):3955-60. 2014), Fenton et al. (Adv. Mater. 28:2939. 2016), U.S. Patent Nos. 9,512,073 and 10,201,618, which are incorporated herein by reference.
[0725] B. PEGylated lipids
[0726] PEGylated lipid components provide control over the particle size and stability of nanoparticles. The addition of such components can prevent complex aggregation and provides a means to increase the cycle life of lipid-nucleic acid drug compositions and enhance their delivery to target tissues (Klibanov et al., FEBS Letters [Federation of European Biochemical Societies Letters] 268(1):235-7. 1990). These components can be selected for rapid in vivo exchange of drug compositions (see, for example, U.S. Patent No. 5,885,613).
[0727] The PEGylated lipids under consideration include, but are not limited to, polyethylene glycol (PEG) chains up to 5 kDa in length, covalently linked to C6-C6 bonds. 20(For example, C8, C) 10 C 12 C 14 C 16 Or C 18 Lipids with one or more alkyl chains of length 1000, such as derivatized ceramides (e.g., N-octanoyl-sphingosine-1-[succinyl(methoxypolyethylene glycol)] (C8 PEG ceramide)). In some embodiments, the PEGylated lipids are 1,2-dimyristoyl-racemic-glycerol-3-methoxy polyethylene glycol (DMG-PEG); 1,2-distearyl-sn-glycerol-3-phosphorylethanolamine-polyethylene glycol (DSPE-PEG); 1,2-dilauryl-sn-glycerol-3-phosphorylethanolamine-polyethylene glycol (DLPE-PEG); or 1,2-distearyl-racemic-glycerol-polyethylene glycol (DSG-PEG); PEG-DAG; PEG-PE; PEG-S-DAG; PEG-S-DMG; PEG-cer; PEG-dialkoxypropylcarbamate; 2-[(polyethylene glycol)-2000]-N,N-bistetradecylacetamide (ALC-0159); and combinations thereof.
[0728] In some embodiments, the PEG has a high molecular weight, for example, 2000-2400 g / mol. In some embodiments, the PEG is PEG2000 (or PEG-2K). In some embodiments, the PEGylated lipids described herein are DMG-PEG2000, DSPE-PEG2000, DLPE-PEG2000, DSG-PEG2000, C8 PEG2000, or ALC-0159 (2-[(polyethylene glycol)-2000]-N,N-bistetradecylacetamide). In some embodiments, the PEGylated lipids described herein are DMG-PEG2000.
[0729] C. Cholesterol-based lipids
[0730] The cholesterol component provides stability to the lipid bilayer structure within the nanoparticles. In some embodiments, the LNP comprises one or more cholesterol-based lipids. Suitable cholesterol-based lipids include, for example: DC-Choi (N,N-dimethyl-N-ethylformamidocholesterol), 1,4-bis(3-N-oleenylaminopropyl)piperazine (Gao et al., BiochemBiophys Res Comm. (1991) 179:280; Wolf et al., BioTechniques (1997) 23:139; U.S. Patent 5,744,335), and imidazole cholesterol ester (“ICE”; WO 2011 / 068810), sitosterol (22,23-dihydrostigmasterol), β-stigmasterol, sitosterol, fucosterol, stigmasterol (stigmasterane-5,22-dien-3-ol), ergosterol; 3β-hydroxy-5,24-cholestadiene; lanosterol (8,24-lanosterdien-3β-ol); 7-dehydrocholesterol (Δ5,7-cholesterol); dihydrolanosterol (24,25-dihydrolanosterol); yeast sterol (5α-cholest-8,24-dien-3β-ol); cholesterol Lathosterol (5α-cholesterol-7-en-3β-ol); diosgenin ((3β,25R)-spirost-5-en-3-ol); campesterol (campesterol-5-en-3β-ol); campestanol (5α-campestanol-3β-ol); 24-methylene cholesterol (5,24(28)-cholestadien-24-methylen-3β-ol); cholesterol margarate (cholesterol-5-en-3β-yl margarate); cholesterol oleate; cholesterol stearate; and other modified forms of cholesterol. In some embodiments, the cholesterol-based lipids used in the LNP are cholesterol.
[0731] D. Helper lipids
[0732] The assisting lipid enhances the structural stability of the LNP and facilitates its escape from the endosome. It improves the uptake and release of the mRNA drug payload. In some embodiments, the assisting lipid is a zwitterionic lipid with fusion-promoting properties that enhance the uptake and release of the drug payload. Examples of accessory lipids are 1,2-dioleoyl-SN-glycerol-3-phosphoethanolamine (DOPE); 1,2-distearyl-sn-glycerol-3-phosphocholine (DSPC); 1,2-dioleoyl-sn-glycerol-3-phosphate-L-serine (DOPS); 1,2-ditransoleoyl-sn-glycerol-3-phosphoethanolamine (DEPE); and 1,2-dioleoyl-sn-glycerol-3-phosphocholine (DPOC), dipalmitoylphosphatidylcholine (DPPC), DMPC, 1,2-dilauroyl-sn-glycerol-3-phosphocholine (DLPC), 1,2-distearylphosphatidylethanolamine (DSPE), and 1,2-dilauroyl-sn-glycerol-3-phosphoethanolamine (DLPE).
[0733] Other exemplary cofactor lipids are dioleoylphosphatidylcholine (DOPC), dioleoylphosphatidylglycerol (DOPG), dipalmitoylphosphatidylglycerol (DPPG), palmitoyloleoylphosphatidylcholine (POPC), palmitoyloleoylphosphatidylethanolamine (POPE), dioleoylphosphatidylethanolamine 4-(N-maleiminomethyl)-cyclohexane-1-carboxylate (DOPE-mal), dipalmitoylphosphatidylethanolamine (DPPE), dimyristoylphosphatidylethanolamine (DMPE), phosphatidylserine, sphingolipids, sphingomyelin, ceramides, cerebrosides, gangliosides, 16-O-monomethylPE, 16-O-dimethylPE, 18-1-transPE, 1-stearoyl-2-oleoylphosphatidylethanolamine (SOPE), or combinations thereof. In some embodiments, the cofactor lipid is DOPE. In some embodiments, the cofactor lipid is DSPC.
[0734] In various embodiments, the LNP of the present invention comprises (i) a cationic lipid selected from the following: OF-02, cKK-E10, GL-HEPES-E3-E10-DS-3-E18-1, GL-HEPES-E3-E12-DS-4-E10, GL-HEPES-E3-E12-DS-3-E14, IM-001 or IS-001; (ii) DMG-PEG2000; (iii) cholesterol; and (iv) DOPE.
[0735] In other embodiments, the LNP of the present invention comprises (i) SM-102; (ii) DMG-PEG2000; (iii) cholesterol; and (iv) DSPC.
[0736] In some other embodiments, the LNP of the present invention comprises (i) ALC-0315; (ii) ALC-0159; (iii) cholesterol; and (iv) DSPC.
[0737] E. Molar ratio of lipid components
[0738] The molar ratios of the above components are important for the effectiveness of LNP in delivering mRNA. The molar ratio of cationic lipids, PEGylated lipids, cholesterol-based lipids, and cofactor lipids is A : B : C : D, where A + B + C + D = 100%. In some embodiments, the molar ratio of cationic lipids to total lipids (i.e., A) in the LNP is 35%-55%, such as 35%-50% (e.g., 38%-42%, such as 40% or 45%-50%). In some embodiments, the molar ratio of the PEGylated lipid component to total lipids (i.e., B) is 0.25%-2.75% (e.g., 1%-2%, such as 1.5%). In some embodiments, the molar ratio of cholesterol-based lipids to total lipids (i.e., C) is 20%-50% (e.g., 27%-30%, such as 28.5% or 38%-43%). In some embodiments, the molar ratio of the auxiliary lipids to the total lipids (i.e., D) is 5%-35% (e.g., 28%-32%, such as 30% or 8%-12%, such as 10%). In some embodiments, the (PEGylated lipids + cholesterol) component has the same molar amount as the auxiliary lipids. In some embodiments, the molar ratio of the cationic lipids to the auxiliary lipids contained in the LNP is greater than 1.
[0739] In some embodiments, the LNP disclosed herein includes:
[0740] Cationic lipids with a molar ratio of 35% to 55% or 40% to 50% (e.g., cationic lipids with molar ratios of 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 51%, 52%, 53%, 54% or 55%).
[0741] A polyethylene glycol (PEG) conjugated (PEGylated) lipid in a molar ratio of 0.25% to 2.75% or 1.00% to 2.00% (e.g., PEGylated lipids in molar ratios of 0.25%, 0.50%, 0.75%, 1.00%, 1.25%, 1.50%, 1.75%, 2.00%, 2.25%, 2.50%, or 2.75%).
[0742] Cholesterol-based lipids with molar ratios of 20% to 50%, 25% to 45%, or 28.5% to 43% (e.g., cholesterol-based lipids with molar ratios of 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, or 50%); and
[0743] The auxiliary lipids are in the molar ratio of 5% to 35%, 8% to 30%, or 10% to 30% (e.g., auxiliary lipids in the molar ratio of 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, or 35%).
[0744] All molar ratios are relative to the total lipid content of the LNP.
[0745] In some embodiments, the LNP comprises: 40% cationic lipids; 1.5% PEGylated lipids; 28.5% cholesterol-based lipids; and 30% auxiliary lipids.
[0746] In some embodiments, the LNP disclosed herein comprises: cationic lipids in a molar ratio of 45% to 50%; PEGylated lipids in a molar ratio of 1.5% to 1.7%; cholesterol-based lipids in a molar ratio of 38% to 43%; and auxiliary lipids in a molar ratio of 9% to 10%.
[0747] In some embodiments, the PEGylated lipid is dimyristic PEG2000 (DMG-PEG2000).
[0748] In various embodiments, the cholesterol-based lipid is cholesterol.
[0749] In some embodiments, the auxiliary lipid is 1,2-dioleoyl-SN-glycerol-3-phosphate ethanolamine (DOPE).
[0750] In some embodiments, the LNP comprises: OF-02 in a molar ratio of 35% to 55%; DMG-PEG2000 in a molar ratio of 0.25% to 2.75%; cholesterol in a molar ratio of 20% to 50%; and DOPE in a molar ratio of 5% to 35%.
[0751] In some embodiments, the LNP comprises: cKK-E10 in a molar ratio of 35% to 55%; DMG-PEG2000 in a molar ratio of 0.25% to 2.75%; cholesterol in a molar ratio of 20% to 50%; and DOPE in a molar ratio of 5% to 35%.
[0752] In some embodiments, the LNP comprises: GL-HEPES-E3-E10-DS-3-E18-1 in a molar ratio of 35% to 55%; DMG-PEG2000 in a molar ratio of 0.25% to 2.75%; cholesterol in a molar ratio of 20% to 50%; and DOPE in a molar ratio of 5% to 35%.
[0753] In some embodiments, the LNP comprises: GL-HEPES-E3-E12-DS-4-E10 in a molar ratio of 35% to 55%; DMG-PEG2000 in a molar ratio of 0.25% to 2.75%; cholesterol in a molar ratio of 20% to 50%; and DOPE in a molar ratio of 5% to 35%.
[0754] In some embodiments, the LNP comprises: GL-HEPES-E3-E12-DS-3-E14 in a molar ratio of 35% to 55%; DMG-PEG2000 in a molar ratio of 0.25% to 2.75%; cholesterol in a molar ratio of 20% to 50%; and DOPE in a molar ratio of 5% to 35%.
[0755] In some embodiments, the LNP comprises: SM-102 in a molar ratio of 35% to 55%; DMG-PEG2000 in a molar ratio of 0.25% to 2.75%; cholesterol in a molar ratio of 20% to 50%; and DSPC in a molar ratio of 5% to 35%.
[0756] In some embodiments, the LNP comprises: ALC-0315 in a molar ratio of 35% to 55%; ALC-0159 in a molar ratio of 0.25% to 2.75%; cholesterol in a molar ratio of 20% to 50%; and DSPC in a molar ratio of 5% to 35%.
[0757] In some embodiments, the LNP comprises: 40% OF-02 in a molar ratio; 1.5% DMG-PEG2000 in a molar ratio; 28.5% cholesterol in a molar ratio; and 30% DOPE in a molar ratio. This LNP formulation is designated herein as "Lipid A".
[0758] In some embodiments, the LNP comprises: 40% cKK-E10 in a molar ratio; 1.5% DMG-PEG2000 in a molar ratio; 28.5% cholesterol in a molar ratio; and 30% DOPE in a molar ratio. This LNP formulation is designated herein as "Lipid B".
[0759] In some embodiments, the LNP comprises: 40% GL-HEPES-E3-E10-DS-3-E18-1 in a molar ratio; 1.5% DMG-PEG2000 in a molar ratio; 28.5% cholesterol in a molar ratio; and 30% DOPE in a molar ratio. This LNP formulation is designated herein as "Lipid C".
[0760] In some embodiments, the LNP comprises: 40% GL-HEPES-E3-E12-DS-4-E10 in a molar ratio; 1.5% DMG-PEG2000 in a molar ratio; 28.5% cholesterol in a molar ratio; and 30% DOPE in a molar ratio. This LNP formulation is designated herein as "Lipid D".
[0761] In some embodiments, the LNP comprises: 40% GL-HEPES-E3-E12-DS-3-E14 in a molar ratio; 1.5% DMG-PEG2000 in a molar ratio; 28.5% cholesterol in a molar ratio; and 30% DOPE in a molar ratio. This LNP formulation is designated herein as "Lipid E".
[0762] In some embodiments, the LNP comprises 50% DLin-MC3-DMA (MC3); 1.5% DMG-PEG2000; 38.5% cholesterol; and 10% DSPC. This LNP formulation is designated herein as "Lipid F". In some embodiments, the LNP comprises: 50% 9-heptadecyl 8-{(2-hydroxyethyl)[6-oxo-6-(undecyloxy)hexyl]amino}octanoate (SM-102); 10% 1,2-distearate-sn-glycerol-3-phosphorylcholine (DSPC); 38.5% cholesterol; and 1.5% 1,2-dimyristoyl-racemic-glycerol-3-methoxy polyethylene glycol-2000 (DMG-PEG2000).
[0763] In some embodiments, the LNP comprises: 46.3% (4-hydroxybutyl)azanidinediyl]bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315); 9.4% 1,2-distearate-sn-glycerol-3-phosphorylcholine (DSPC); 42.7% cholesterol; and 1.6% 2-[(polyethylene glycol)-2000]-N,N-bistetradecylacetamide (ALC-0159).
[0764] In some embodiments, the LNP comprises: 47.4% molar of [(4-hydroxybutyl)azanidinediyl]bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315); 10% molar of 1,2-distearate-sn-glycerol-3-phosphorylcholine (DSPC); 40.9% molar of cholesterol; and 1.7% molar of 2-[(polyethylene glycol)-2000]-N,N-bistetradecylacetamide (ALC-0159).
[0765] In some embodiments, the LNP comprises: 40% IM-001; 1.5% DMG-PEG2000; 28.5% cholesterol; and 30% DOPE. This LNP formulation is designated herein as "Lipid G".
[0766] In some embodiments, the LNP comprises: 40% IS-001 in a molar ratio; 1.5% DMG-PEG2000 in a molar ratio; 28.5% cholesterol in a molar ratio; and 30% DOPE in a molar ratio. This LNP formulation is designated herein as "Lipid H".
[0767] In some embodiments, LNP formulations are defined as “lipid A”, “lipid B”, or “lipid D”. In some embodiments, LNP formulations are defined as “lipid G” or “lipid H”.
[0768] To calculate the actual amount of each lipid to be incorporated into the LNP formulation, the molar amount of the cationic lipid is first determined based on the desired N / P ratio, where N is the number of nitrogen atoms in the cationic lipid and P is the number of phosphate groups in the mRNA to be transported by LNP. Next, the molar amount of each other lipid is calculated based on the molar amount of the cationic lipid and the selected molar ratio. These molar amounts are then converted to weight using the molecular weight of each lipid.
[0769] F. Nucleic acid in LNP
[0770] The LNP compositions described herein may contain the nucleic acids (e.g., mRNA) of the present invention.
[0771] If desired, the LNP can be multivalent. In some embodiments, the LNP may carry nucleic acids, such as mRNA, encoding more than one polypeptide of the present invention, such as two, three, four, five, six, seven, or eight polypeptides. For example, the LNP may carry multiple nucleic acids of the present invention (e.g., mRNA), each encoding a different polypeptide of the present invention; or carry polycistronic mRNA that can be translated into more than one polypeptide of the present invention (e.g., each antigen-coding sequence is separated by a nucleotide linker encoding a self-cleaving peptide such as peptide 2A). An LNP carrying different nucleic acids (e.g., mRNA) typically contains (encapsulates) multiple copies of each nucleic acid. For example, an LNP carrying or encapsulating two different nucleic acids typically carries multiple copies of each of the two different nucleic acids.
[0772] In some embodiments, a single LNP formulation may contain multiple (e.g., two, three, four, five, six, seven, eight, nine, ten or more) LNPs, each carrying a different nucleic acid (e.g., mRNA).
[0773] When the nucleic acid is mRNA, the mRNA can be unmodified (i.e., containing only natural ribonucleotides A, U, C, and / or G linked by phosphodiester bonds) or chemically modified (e.g., including nucleotide analogs such...
Claims
1. A nucleic acid comprising a nucleotide sequence encoding a polypeptide, wherein the polypeptide comprises: i) At least a portion of the catalytic domain of the Lys-specific protease (Kgp) of Porphyromonas gingivalis; ii) At least a portion of the unknown functional domain 2436 (DUF2436) of Porphyromonas gingivalis Kgp; iii) At least a portion of the Kgp K1 adhesin domain of Porphyromonas gingivalis; iv) The Kgp portion of *Porphyromonas gingivalis* containing adhesin-binding motif 1 (ABM1) and the Kgp portion of *Porphyromonas gingivalis* containing adhesin-binding motif 2 (ABM2); v) The Kgp fraction of *Porphyromonas second gingivalis* containing ABM1 and the Kgp fraction of *Porphyromonas second gingivalis* containing ABM2; and vi) The Kgp portion of Porphyromonas gingivalis containing the adhesin-binding motif 3 (ABM3).
2. The nucleic acid as described in claim 1, wherein: (a) The first Kgp portion containing ABM1 contains a sequence according to SEQ ID NO: 120 or a sequence having at least 70% (e.g., at least 90% or 95%) identity with it; (b) The first Kgp portion containing ABM2 contains a sequence according to SEQ ID NO: 130 or a sequence having at least 70% (e.g., at least 90% or 95%) identity with it; (c) The second Kgp portion containing ABM1 contains a sequence according to SEQ ID NO: 120 or a sequence having at least 70% (e.g., at least 90% or 95%) identity with it; and / or (d) The second Kgp portion containing ABM2 contains a sequence according to SEQ ID NO: 130 or a sequence having at least 70% (e.g., at least 90% or 95%) identity with it.
3. The nucleic acid according to claim 1 or claim 2, wherein: (a) The first Kgp portion containing ABM1 contains a sequence according to SEQ ID NO: 89 or a sequence having at least 70% (e.g., at least 90% or 95%) identity with it; (b) The first Kgp portion containing ABM2 contains a sequence according to SEQ ID NO: 91 or a sequence having at least 70% (e.g., at least 90% or 95%) identity with it; (c) The second Kgp portion containing ABM1 contains a sequence according to SEQ ID NO: 92 or a sequence having at least 70% (e.g., at least 90% or 95%) identity with it; and / or (d) The second Kgp portion containing ABM2 contains a sequence according to SEQ ID NO: 95 or a sequence having at least 70% (e.g., at least 90% or 95%) identity with it.
4. The nucleic acid according to any one of claims 1-3, wherein at least a portion of Kgp DUF2436 is full-length Kgp DUF2436, wherein optionally the full-length Kgp DUF2436 comprises a sequence according to SEQ ID NO: 90 or a sequence having at least 70% (e.g., at least 90% or 95%) identity with it.
5. The nucleic acid according to any of the preceding claims, wherein at least a portion of the Kgp catalytic domain is: (a) A full-length Kgp catalytic domain, wherein optionally the full-length Kgp catalytic domain comprises the sequence according to SEQ ID NO: 64 or a sequence having at least 70% (e.g., at least 90% or 95%) identity with it; or (b) A truncated Kgp catalytic domain, wherein optionally the truncated Kgp catalytic domain comprises a Lys gingival protease active site peptide (KAS peptide), for example, wherein: (i) The KAS peptide comprises the Kas2 peptide according to SEQ ID NO: 61 or a sequence having at least 70% (e.g., at least 90% or 95%) identity with it; or (ii) The KAS peptide comprises an extended Kas2 peptide according to SEQ ID NO: 88 or a sequence having at least 70% (e.g., at least 90% or 95%) identity with it.
6. The nucleic acid of any of the preceding claims, wherein the polypeptide further comprises at least a portion of an Arg-specific protease A (RgpA) or Arg-specific protease B (RgpB) catalytic domain of *Porphyromonas gingivalis*, wherein optionally the at least a portion of the RgpA or RgpB catalytic domain is a truncated RgpA or RgpB catalytic domain, for example, wherein the truncated RgpA or RgpB catalytic domain comprises an Arg gingival protease active site peptide (RAS peptide), such as: (i) The RAS peptide comprises the Ras2 peptide according to SEQ ID NO: 166 or a sequence having at least 70% (e.g., at least 90% or 95%) identity with it; or (ii) The RAS peptide comprises an extended Ras2 peptide according to SEQ ID NO: 97 or a sequence having at least 70% (e.g., at least 90% or 95%) identity with it.
7. The nucleic acid of any of the preceding claims, wherein the polypeptide further comprises at least a portion of the *Porphyromonas gingivalis* Kgp K2 adhesin domain, wherein optionally the at least a portion of the Kgp K2 adhesin domain is a full-length K2 adhesin domain, for example wherein the full-length Kgp K2 adhesin domain comprises the sequence according to SEQ ID NO: 96 or a sequence having at least 70% (e.g., at least 90% or 95%) identity with it.
8. The nucleic acid of claim 6, wherein the polypeptide further comprises at least a portion of the RgpA K2 adhesin domain of Porphyromonas gingivalis, wherein optionally the at least a portion of the RgpA K2 adhesin domain is a full-length K2 adhesin domain, for example, wherein the full-length RgpA K2 adhesin domain comprises the sequence according to SEQ ID NO: 104 or a sequence having at least 70% (e.g., at least 90% or 95%) identity with it.
9. The nucleic acid of any one of claims 6-8, wherein the polypeptide comprises at least a portion of RgpA DUF2436, wherein optionally the RgpA DUF2436 is full-length RgpA DUF2436, for example, wherein the full-length RgpA DUF2436 comprises the sequence according to SEQ ID NO: 100 or a sequence having at least 70% (e.g., at least 90% or 95%) identity with it.
10. The nucleic acid as claimed in any of the preceding claims, wherein: (a) At least a portion of the Kgp K1 adhesin domain is a full-length Kgp K1 adhesin domain, wherein optionally the full-length Kgp K1 adhesin domain and the Kgp portion containing ABM3 together comprise a sequence according to SEQ ID NO: 93 or a sequence having at least 70% (e.g., at least 90% or 95%) identity with it; or (b) At least a portion of the Kgp K1 adhesin domain is a truncated Kgp K1 adhesin domain, wherein optionally the truncated Kgp K1 adhesin domain and the Kgp portion containing ABM3 together contain a sequence according to SEQ ID NO: 94 or a sequence having at least 70% (e.g., at least 90% or 95%) identity with it.
11. A nucleic acid comprising a nucleotide sequence encoding a polypeptide, wherein the polypeptide comprises: i) At least a portion of the catalytic domain of *Porphyromonas gingivalis* Arg-specific protease A (RgpA) or Arg-specific protease B (RgpB), for example, at least a portion of the catalytic domain of *Porphyromonas gingivalis* Arg-specific protease A (RgpA). ii) At least a portion of Porphyromonas gingivalis RgpA DUF2436; iii) At least a portion of the adhesin domain of Porphyromonas gingivalis RgpA K1; iv) The RgpA portion of *Porphyromonas gingivalis* containing ABM1 and the RgpA portion of *Porphyromonas gingivalis* containing ABM2; v) The RgpA portion of *Porphyromonas second gingivalis* containing ABM1 and the RgpA portion of *Porphyromonas second gingivalis* containing ABM2; and vi) The RgpA portion of Porphyromonas gingivalis containing ABM3.
12. The nucleic acid of claim 11, wherein: (a) The first RgpA portion containing ABM1 contains a sequence according to SEQ ID NO: 120 or a sequence having at least 70% (e.g., at least 90% or 95%) identity with it; (b) The first RgpA portion containing ABM2 contains a sequence according to SEQ ID NO: 130 or a sequence having at least 70% (e.g., at least 90% or 95%) identity with it; (c) The second RgpA portion containing ABM1 contains a sequence according to SEQ ID NO: 120 or a sequence having at least 70% (e.g., at least 90% or 95%) identity with it; and / or (d) The second RgpA portion containing ABM2 contains a sequence according to SEQ ID NO: 130 or a sequence having at least 70% (e.g., at least 90% or 95%) identity with it.
13. The nucleic acid according to claim 11 or claim 12, wherein: (a) The first RgpA portion containing ABM1 contains a sequence according to SEQ ID NO: 99 or a sequence having at least 70% (e.g., at least 90% or 95%) identity with it; (b) The first RgpA portion containing ABM2 contains a sequence according to SEQ ID NO: 101 or a sequence having at least 70% (e.g., at least 90% or 95%) identity with it; (c) The second RgpA portion containing ABM1 contains a sequence according to SEQ ID NO: 102 or a sequence having at least 70% (e.g., at least 90% or 95%) identity with it; and / or (d) The second RgpA portion containing ABM2 contains a sequence according to SEQ ID NO: 105 or a sequence having at least 70% (e.g., at least 90% or 95%) identity with it.
14. The nucleic acid of any one of claims 11-13, wherein at least a portion of RgpA DUF2436 is full-length RgpA DUF2436, wherein optionally the full-length RgpA DUF2436 comprises a sequence according to SEQ ID NO: 100 or a sequence having at least 70% (e.g., at least 90% or 95%) identity with it.
15. The nucleic acid according to any one of claims 11-14, wherein at least a portion of the RgpA catalytic domain is: (a) A full-length RgpA catalytic domain, wherein optionally the full-length RgpA catalytic domain comprises the sequence according to SEQ ID NO:98 or a sequence having at least 70% (e.g., at least 90% or 95%) identity with it; or (b) A truncated Kgp catalytic domain, wherein optionally the truncated RgpA catalytic domain comprises an Arg gingival protease active site peptide (RAS peptide), for example, wherein: (i) The RAS peptide comprises the Ras2 peptide according to SEQ ID NO: 166 or a sequence having at least 70% (e.g., at least 90% or 95%) identity with it; or (ii) The RAS peptide comprises an extended Ras2 peptide according to SEQ ID NO: 97 or a sequence having at least 70% (e.g., at least 90% or 95%) identity with it.
16. The nucleic acid of any one of claims 11-15, wherein at least a portion of the RgpA K1 adhesin domain is a truncated RgpA K1 adhesin domain, wherein optionally the truncated RgpA K1 adhesin domain and the RgpA portion comprising ABM3 together comprise a sequence according to SEQ ID NO: 103 or a sequence having at least 70% (e.g., at least 90% or 95%) identity with it.
17. The nucleic acid of any one of claims 11-16, wherein the polypeptide comprises at least a portion of the RgpA K2 adhesin domain of Porphyromonas gingivalis, wherein optionally the at least a portion of the RgpA K2 adhesin domain is a full-length K2 adhesin domain, for example, wherein the full-length Kgp K2 adhesin domain comprises the sequence according to SEQ ID NO: 104 or a sequence having at least 70% (e.g., at least 90% or 95%) identity with it.
18. The nucleic acid as claimed in any of the preceding claims, wherein the polypeptide further comprises a secretion signal peptide sequence.
19. The nucleic acid of claim 18, wherein the secretion signal peptide comprises the secretion signal peptide sequence of the HA protein of influenza A virus, optionally wherein the secretion signal peptide sequence comprises the sequence according to SEQ ID NO:
67.
20. The nucleic acid according to any one of claims 1-19, wherein the polypeptide comprises a sequence according to any one of SEQ ID NO: 1-20, 73-77, 279, 280, 283-285, 297, 359, 361, 363, 365, 367, 369, 371, 373, 375, 377, 379, 381, 383, 385, 387, 389, 391, 393, 395, 397, 399, 401, 403, 405, 407, 409 or 411; or a sequence having at least 70% (e.g., at least 90% or 95%) identity with it.
21. The nucleic acid as claimed in any of the preceding claims, wherein the nucleic acid is messenger RNA (mRNA), optionally wherein (i) The mRNA contains at least one 5' untranslated portion (5' UTR), at least one 3' untranslated portion (3' UTR) and / or at least one poly(A) sequence; (ii) The mRNA is unmodified or contains at least one chemical modification, optionally wherein the mRNA contains at least one chemical modification, for example, wherein the chemical modification contains N1-methylpseudouridine; and / or (iii) The mRNA is a self-replicating mRNA or a non-replicating mRNA, such as a non-replicating mRNA.
22. A polypeptide as defined in any one of claims 1-20.
23. A composition comprising a nucleic acid as described in any one of claims 1-21 or a polypeptide as described in claim 22, preferably wherein the composition is an immunogenic composition.
24. A composition comprising: (a) A first nucleic acid encoding a polypeptide, the polypeptide comprising: i) At least a portion of the Kgp catalytic domain, optionally wherein the at least a portion of the Kgp catalytic domain comprises the full-length Kgp catalytic domain; ii) At least a portion of Kgp DUF2436; iii) At least a portion of the Kgp K1 adhesin domain, optionally wherein the at least a portion of the Kgp K1 adhesin comprises the full-length Kgp K1 adhesin domain. iv) Contains the first Kgp portion of ABM1 and the first Kgp portion of ABM2; v) The second Kgp portion containing ABM1 and the second Kgp portion containing ABM2; and vi) Contains the Kgp portion of ABM3; These domains are located from the N-terminus to the C-terminus of the polypeptide in the following order: Kgp catalytic domain; first Kgp moiety containing ABM1; Kgp DUF2436; first Kgp moiety containing ABM2; second Kgp moiety containing ABM1; Kgp moiety containing ABM3; Kgp K1; second Kgp moiety containing ABM2; Optionally, the glycosylation sites corresponding to glycosylation sites N691-T693 in the WT Kgp sequence (SEQ ID NO: 157) are mutated by substitution with T693A; and the glycosylation sites corresponding to glycosylation sites N950-T952 in the WT Kgp sequence (SEQ ID NO: 157) are mutated by substitution with T952A; and (b) A second nucleic acid encoding a polypeptide, the polypeptide comprising: i) At least a portion of the RgpA catalytic domain; ii) At least a portion of RgpA DUF2436; iii) At least a portion of the RgpA K1 adhesin domain; iv) Containing the first RgpA portion of ABM1 and the first RgpA portion of ABM2; v) Contains the second RgpA portion of ABM1 and the second RgpA portion of ABM2; vi) Contains the RgpA portion of ABM3; vii) At least a portion of the RgpA K2 adhesin domain; These domains are located from the N-terminus to the C-terminus of the polypeptide in the following order: RgpA catalytic domain; first RgpA moiety containing ABM1; RgpA DUF2436; first RgpA moiety containing ABM2; second RgpA moiety containing ABM1; RgpA moiety containing ABM3; RgpA K1; RgpA K2; second RgpA moiety containing ABM2.
25. The composition of claim 23 or claim 24, wherein the composition comprises: i) A first nucleic acid encoding a polypeptide comprising the sequence according to SEQ ID NO: 279 or a sequence having at least 70% (e.g., at least 90% or 95%) identity with it; and ii) A second nucleic acid encoding a polypeptide comprising the sequence according to SEQ ID NO: 73 or a sequence having at least 70% (e.g., at least 90% or 95%) identity with it.
26. A composition comprising: (a) A first polypeptide, the first polypeptide comprising: i) At least a portion of the Kgp catalytic domain, optionally wherein the at least a portion of the Kgp catalytic domain comprises the full-length Kgp catalytic domain; ii) At least a portion of Kgp DUF2436; iii) At least a portion of the Kgp K1 adhesin domain, optionally wherein the at least a portion of the Kgp K1 adhesin comprises the full-length Kgp K1 adhesin domain. iv) Contains the first Kgp portion of ABM1 and the first Kgp portion of ABM2; v) The second Kgp portion containing ABM1 and the second Kgp portion containing ABM2; and vi) Contains the Kgp portion of ABM3; These domains are located from the N-terminus to the C-terminus of the polypeptide in the following order: Kgp catalytic domain; first Kgp moiety containing ABM1; Kgp DUF2436; first Kgp moiety containing ABM2; second Kgp moiety containing ABM1; Kgp moiety containing ABM3; Kgp K1; second Kgp moiety containing ABM2; Optionally, the glycosylation sites corresponding to glycosylation sites N691-T693 in the WT Kgp sequence (SEQ ID NO: 157) are mutated by substitution with T693A; and the glycosylation sites corresponding to glycosylation sites N950-T952 in the WT Kgp sequence (SEQ ID NO: 157) are mutated by substitution with T952A; and (b) A second polypeptide comprising: i) At least a portion of the RgpA catalytic domain; ii) At least a portion of RgpA DUF2436; iii) At least a portion of the RgpA K1 adhesin domain; iv) Containing the first RgpA portion of ABM1 and the first RgpA portion of ABM2; v) Contains the second RgpA portion of ABM1 and the second RgpA portion of ABM2; vi) Contains the RgpA portion of ABM3; vii) At least a portion of the RgpA K2 adhesin domain; These domains are located from the N-terminus to the C-terminus of the polypeptide in the following order: RgpA catalytic domain; first RgpA moiety containing ABM1; RgpA DUF2436; first RgpA moiety containing ABM2; second RgpA moiety containing ABM1; RgpA moiety containing ABM3; RgpA K1; RgpA K2; second RgpA moiety containing ABM2.
27. The composition of claim 23 or claim 26, wherein the composition comprises: i) A first polypeptide comprising the sequence according to SEQ ID NO: 279 or a sequence having at least 70% (e.g., at least 90% or 95%) identity with it; and ii) A second polypeptide comprising the sequence according to SEQ ID NO: 73 or a sequence having at least 70% (e.g., at least 90% or 95%) identity with it.
28. The nucleic acid as described in any one of claims 1-21, the polypeptide as described in claim 22, or the composition as described in any one of claims 23-27, as a pharmaceutical.
29. The nucleic acid of any one of claims 1-21, the polypeptide of any one of claims 22, or the composition of any one of claims 23-27, for use in the treatment or prevention of Porphyromonas gingivalis infection, such as periodontitis.
30. A vaccine comprising a nucleic acid as described in any one of claims 1-21, a polypeptide as described in claim 22, or a composition as described in any one of claims 23-27.
Citation Information
Patent Citations
Alkenyl substituted 2,5-piperazinediones, compositions, and uses thereof
US10201618B2
Delivery of mRNA for the augmentation of proteins and enzymes in human genetic diseases
US20110244026A1
Lipid nanoparticle compositions and methods for mRNA delivery
US20140206753A1
Pulmonary delivery of mRNA to non-lung target cells
US20150157565A1
Quantitative assessment for cap efficiency of messenger RNA
US20160032356A1
